{
  "letters": 708755,
  "pages": 199,
  "meta": {
    "end_of_period": {
      "year": 2022,
      "month": 12
    },
    "company_name": "Atreca, Inc.",
    "major_industry": "Healthcare",
    "mentions_recent_mergers_and_acquisitions": {
      "value": true,
      "elements": [
        {
          "type": "merger_acquisition",
          "page": 11,
          "title": "Atreca Product Development and Collaboration Overview",
          "data": [
            {
              "key": "Product",
              "value": "MAM01/ATRC-501"
            },
            {
              "key": "Collaboration",
              "value": "Gates MRI Licensing Agreement"
            },
            {
              "key": "Grant Awarded",
              "value": "$1.2 million"
            },
            {
              "key": "Development Focus",
              "value": "Malaria Prevention"
            },
            {
              "key": "Collaboration Duration",
              "value": "Three years"
            },
            {
              "key": "First Joint Program Announcement",
              "value": "February 2023"
            },
            {
              "key": "Collaborator",
              "value": "Xencor"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 34,
          "title": "Table of Contents - Strategic Transactions Overview",
          "data": [
            {
              "key": "Transaction Objectives",
              "value": "Enter into strategic transactions to support the research, development, and commercialization of current and potential future product candidates."
            },
            {
              "key": "Transaction Types",
              "value": "Collaborations, acquisitions of companies, asset purchases, joint ventures, and in-/out-licensing agreements."
            },
            {
              "key": "Example Agreement",
              "value": "Collaboration and license agreement with Xencor in July 2020."
            },
            {
              "key": "Risks",
              "value": "Includes exposure to unknown liabilities, business disruption, potential incurrence of substantial debt or dilutive equity issuances, higher-than-expected costs, integration challenges, and possible disputes or litigation."
            },
            {
              "key": "Potential Impact",
              "value": "Failure of such transactions could limit ability to capitalize on market potential, affect cash position, increase expenses, and distract management."
            },
            {
              "key": "Future Strategy",
              "value": "Plans to evaluate and possibly enter into additional collaborations, including with biotechnology or biopharmaceutical companies or hospitals."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 154,
          "title": "Corporate Transaction and Change in Control – Stock Award Adjustments",
          "data": [
            {
              "key": "Corporate Transaction Timing",
              "value": "Actions must be completed at or prior to the effective time of the Corporate Transaction"
            },
            {
              "key": "Notice Requirement",
              "value": "The Board may require Participants to complete and deliver a notice of exercise before the effective date"
            },
            {
              "key": "Reacquisition/Repurchase Rights",
              "value": "The Company may arrange for the lapse of any reacquisition or repurchase rights held with respect to the Stock Award"
            },
            {
              "key": "Cancellation of Stock Award",
              "value": "Unvested or unexercised Stock Awards may be cancelled in exchange for cash consideration as determined by the Board"
            },
            {
              "key": "Cash Payment Calculation",
              "value": "Payment equals the excess of the per share amount (or property value) payable to Common Stock holders over the exercise price, multiplied by the number of shares subject to the Stock Award"
            },
            {
              "key": "Escrow/Holdback Provisions",
              "value": "Any escrow, holdback, earnout, or similar provisions in the definitive agreement for the Corporate Transaction apply equally to Stock Award holders"
            },
            {
              "key": "Flexibility in Action",
              "value": "The Board may take different actions with respect to vested and unvested portions and need not treat all Stock Awards uniformly"
            },
            {
              "key": "Change in Control",
              "value": "A Stock Award may be subject to additional acceleration of vesting and exercisability upon or after a Change in Control if provided in the Stock Award Agreement or another agreement"
            },
            {
              "key": "Plan Suspension/Termination",
              "value": "The Board may suspend or terminate the Plan at any time, during which no new Stock Awards may be granted"
            },
            {
              "key": "Governing Law",
              "value": "The Plan is governed by the law of the State of Delaware"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 156,
          "title": "Change in Control Provisions – Merger and Related Transactions",
          "data": [
            {
              "key": "merger_consolidation_condition",
              "value": "Consummation of a merger, consolidation or similar transaction involving the Company."
            },
            {
              "key": "ownership_condition",
              "value": "Immediately after the transaction, stockholders of the Company prior to the transaction must not own more than 50% of the combined outstanding voting power of the surviving entity or its parent in substantially the same proportions."
            },
            {
              "key": "sale_of_assets_condition",
              "value": "A sale, lease, exclusive license or other disposition of all or substantially all of the Company's consolidated assets qualifies, except when such transaction is to an entity controlled by the Company’s stockholders in similar proportions."
            },
            {
              "key": "board_change_condition",
              "value": "If members of the Incumbent Board cease to constitute a majority of the Board, it triggers a change in control, with an exception for new board members approved by a majority of the remaining Incumbent Board."
            },
            {
              "key": "exclusions",
              "value": "Transactions effected exclusively to change the Company's domicile and transactions defined in individual agreements are excluded from change in control."
            },
            {
              "key": "409A_compliance",
              "value": "For Section 409A compliance, a transaction is not deemed a change in control unless it is also a change in ownership or effective control as per Treasury Regulations Section 1.409A-3(i)(5). The Board may amend the definition to conform to these regulations."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_leadership_changes": {
      "value": true,
      "elements": [
        {
          "type": "leadership_change",
          "page": 113,
          "title": "Executive Employment Agreement",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "10.22#"
            },
            {
              "key": "Description",
              "value": "Executive Employment Agreement, dated as of January 9, 2023, by and between the Registrant and Philippe Bishop"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 113,
          "title": "Atreca, Inc. 2023 Inducement Plan",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "10.23#"
            },
            {
              "key": "Description",
              "value": "Atreca, Inc. 2023 Inducement Plan"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 113,
          "title": "Form of Stock Option Grant Notice and Option Agreement for Atreca, Inc. 2023 Inducement Plan",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "10.24#"
            },
            {
              "key": "Description",
              "value": "Form of Stock Option Grant Notice and Option Agreement for Atreca, Inc. 2023 Inducement Plan"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 113,
          "title": "Form of RSU Grant Notice and Award Agreement for Atreca, Inc. 2023 Inducement Plan",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "10.25#"
            },
            {
              "key": "Description",
              "value": "Form of RSU Grant Notice and Award Agreement for Atreca, Inc. 2023 Inducement Plan"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 113,
          "title": "Letter from OUM & Co. LLP to the Securities and Exchange Commission",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "16.1"
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "File Number",
              "value": "001-38935"
            },
            {
              "key": "Date",
              "value": "7/20/21"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 113,
          "title": "Consent of WithumSmith+Brown PC, independent registered public accounting firm",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "23.1"
            },
            {
              "key": "Description",
              "value": "Consent of WithumSmith+Brown PC, independent registered public accounting firm"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 113,
          "title": "Power of Attorney (included in signature pages)",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "24.1"
            },
            {
              "key": "Description",
              "value": "Power of Attorney (included in signature pages)."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 113,
          "title": "Certification of Chief Executive Officer",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "31.1"
            },
            {
              "key": "Description",
              "value": "Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 113,
          "title": "Certification of Chief Financial Officer",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "31.2"
            },
            {
              "key": "Description",
              "value": "Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 113,
          "title": "Certification of Principal Executive Officer and Principal Financial Officer",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "32.1*"
            },
            {
              "key": "Description",
              "value": "Certification of Principal Executive Officer and Principal Financial Officer, as required by Rule 13a- 14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 113,
          "title": "Inline XBRL Instance Document",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "101.INS"
            },
            {
              "key": "Description",
              "value": "Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 113,
          "title": "Inline XBRL Taxonomy Extension Schema Document",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "101.SCH"
            },
            {
              "key": "Description",
              "value": "Inline XBRL Taxonomy Extension Schema Document"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 113,
          "title": "Inline XBRL Taxonomy Extension Calculation Linkbase Document",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "101.CAL"
            },
            {
              "key": "Description",
              "value": "Inline XBRL Taxonomy Extension Calculation Linkbase Document"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 113,
          "title": "Inline XBRL Taxonomy Extension Definition Linkbase Document",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "101.DEF"
            },
            {
              "key": "Description",
              "value": "Inline XBRL Taxonomy Extension Definition Linkbase Document"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 113,
          "title": "Inline XBRL Taxonomy Extension Label Linkbase Document",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "101.LAB 101.PRE"
            },
            {
              "key": "Description",
              "value": "Inline XBRL Taxonomy Extension Label Linkbase Document Inline XBRL Taxonomy Extension Presentation"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 115,
          "title": "Table of Contents SIGNATURES",
          "data": [
            {
              "key": "Document",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "Filing Requirement",
              "value": "Section 13 or 15(d) of the Securities Exchange Act of 1934"
            },
            {
              "key": "Company",
              "value": "ATRECA, INC."
            },
            {
              "key": "Signatory Name",
              "value": "JOHN A. ORWIN"
            },
            {
              "key": "Title",
              "value": "President and Chief Executive Officer (Principal Executive Officer)"
            },
            {
              "key": "Date",
              "value": "March 29, 2023"
            },
            {
              "key": "Location",
              "value": "San Carlos, California"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 116,
          "title": "Corporate Leadership Signatures",
          "data": [
            {
              "key": "Power of Attorney",
              "value": "Each person whose signature appears below appoints John A. Orwin, Herbert Cross, and Courtney Phillips as attorneys-in-fact with substitution power to sign amendments to the Annual Report on Form 10-K and file related documents with the SEC."
            },
            {
              "key": "John A. Orwin",
              "value": "Director, President and Chief Executive Officer (Principal Executive Officer); signed on March 29, 2023"
            },
            {
              "key": "Herbert Cross",
              "value": "Chief Financial Officer (Principal Financial and Accounting Officer); signed on March 29, 2023"
            },
            {
              "key": "Brian Atwood",
              "value": "Chairman of the Board of Directors; signed on March 29, 2023"
            },
            {
              "key": "Kristine M. Ball",
              "value": "Director; signed on March 29, 2023"
            },
            {
              "key": "Franklin Berger",
              "value": "Director; signed on March 29, 2023"
            },
            {
              "key": "David Lacey",
              "value": "Director; signed on March 29, 2023"
            },
            {
              "key": "William H. Robinson, M.D., Ph. D.",
              "value": "Director; signed on March 29, 2023"
            },
            {
              "key": "Stacey Ma, Ph.D.",
              "value": "Director; signed on March 29, 2023"
            },
            {
              "key": "Stephen Brady",
              "value": "Director; signed on March 29, 2023"
            },
            {
              "key": "Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM",
              "value": "Director; signed on March 29, 2023"
            },
            {
              "key": "Tito A. Serafini",
              "value": "Director and Chief Strategy Officer; signed on March 29, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 128,
          "title": "Executive Employment Agreement Execution",
          "data": [
            {
              "key": "Company",
              "value": "ATRECA, INC."
            },
            {
              "key": "Executive 1 Name",
              "value": "John Orwin"
            },
            {
              "key": "Executive 1 Title",
              "value": "President & Chief Executive Officer"
            },
            {
              "key": "Executive 1 Date",
              "value": "August 17, 2022"
            },
            {
              "key": "Executive 2 Name",
              "value": "Stephen Gould"
            },
            {
              "key": "Executive 2 Title",
              "value": "Chief Scientific Officer"
            },
            {
              "key": "Executive 2 Date",
              "value": "August 17, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 137,
          "title": "Outside Activities During Employment",
          "data": [
            {
              "key": "Non-Company Business",
              "value": "Executive will not during employment undertake or engage in any other employment except with prior written consent of the CEO."
            },
            {
              "key": "No Adverse Interests",
              "value": "Executive agrees not to acquire any position, investment, or interest known to be adverse to the Company."
            },
            {
              "key": "Dispute Resolution",
              "value": "Disputes related to Executive’s employment will be resolved through arbitration as stipulated in the Federal Arbitration Act."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_layoffs": {
      "value": true,
      "elements": [
        {
          "type": "layoff",
          "page": 39,
          "title": "Competitive Landscape, Intellectual Property, and Workforce Reduction",
          "data": [
            {
              "key": "Competitors",
              "value": "Companies in biotechnology, biopharmaceuticals, and antibody/immuno-oncology such as Adaptive Biotechnologies Corporation, Neurimmune Holding AG, OncoResponse, Inc., Immunome, Inc., Vir Biotechnology, Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Genentech, Inc., and Merck & Co., Inc."
            },
            {
              "key": "Key Management",
              "value": "John A. Orwin (President and CEO), Tito A. Serafini (Chief Strategy Officer and Founder)"
            },
            {
              "key": "Workforce Reduction",
              "value": "Completed in June 2022; full-time employee count decreased from 105 (as of June 30, 2022) to 90 (as of December 31, 2022)"
            },
            {
              "key": "Competitive Concerns",
              "value": "Intense competition in developing therapeutic antibodies and treatments; risk of competitors having more funding, clinical experience, and resources."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 99,
          "title": "Non-executive Severance Plan and Corporate Reorganization",
          "data": [
            {
              "key": "Severance Plan Details",
              "value": "Under the Non-executive Severance Plan approved in December 2022, a non-individually negotiated employee is entitled to severance pay and benefits upon a Company-initiated reduction-in-force (Covered Termination), except in cases of death or disability, up to June 30, 2024."
            },
            {
              "key": "Workforce Reduction and Charges",
              "value": "On June 1, 2022, the Company implemented a corporate reorganization that involved a workforce reduction. As a result, severance and employee benefits charges of $0.7 million were recorded to operating expenses in the quarter ending June 30, 2022."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_executive_compensation": {
      "value": true,
      "elements": [
        {
          "type": "executive_compensation",
          "page": 79,
          "title": "Black-Scholes Option-Pricing Model and Emerging Growth Company Disclosures",
          "data": [
            {
              "key": "Option-Pricing Model",
              "value": "The Black-Scholes option-pricing model is used for determining the fair value of stock-based awards using highly subjective assumptions."
            },
            {
              "key": "Expected Term",
              "value": "Represents the period that stock-based awards are expected to be outstanding; determined using the simplified method as the average of time-to-vesting and the contractual life of the awards."
            },
            {
              "key": "Expected Volatility",
              "value": "Estimated based on the average volatility of comparable publicly traded biotechnology companies over a period equal to the expected term, due to the lack of trading history."
            },
            {
              "key": "Risk-Free Interest Rate",
              "value": "Based on the U.S. Treasury zero coupon issues in effect at the time of the grant for periods corresponding with the expected term of the options."
            },
            {
              "key": "Expected Dividend",
              "value": "Expected dividend yield is zero since the company has never paid and does not plan to pay dividends on its common stock."
            },
            {
              "key": "Emerging Growth Company Status",
              "value": "The company qualifies as an emerging growth company under the JOBS Act, opting to use an extended transition period for adopting new or revised accounting standards."
            },
            {
              "key": "Recent Accounting Pronouncements",
              "value": "The company has early adopted relevant accounting standards updates (e.g., ASC 606 and ASC 718) and may use the extended transition period for future updates."
            },
            {
              "key": "Market Risk Disclosures",
              "value": "Note that the quantitative and qualitative disclosures about market risk are not required as the company qualifies as a smaller reporting company."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 101,
          "title": "Stock Options and RSU Activity Disclosure",
          "data": [
            {
              "key": "Total Options Outstanding",
              "value": "6373534"
            },
            {
              "key": "Weighted-Average Exercise Price (Outstanding)",
              "value": "3.56"
            },
            {
              "key": "Total Exercisable Shares",
              "value": "4178167"
            },
            {
              "key": "Weighted-Average Exercise Price (Exercisable)",
              "value": "4.02"
            },
            {
              "key": "Fair Value of Options Granted (2022)",
              "value": "1.26"
            },
            {
              "key": "Fair Value of Options Granted (2021)",
              "value": "6.66"
            },
            {
              "key": "Intrinsic Value of Options Exercised (2022)",
              "value": "8000"
            },
            {
              "key": "Intrinsic Value of Options Exercised (2021)",
              "value": "519000"
            },
            {
              "key": "Option Pricing - Expected Life (years)",
              "value": "5.98"
            },
            {
              "key": "Option Pricing - Volatility",
              "value": "90.3%"
            },
            {
              "key": "Option Pricing - Risk-Free Interest Rate",
              "value": "0.9%"
            },
            {
              "key": "RSUs Granted",
              "value": "884820"
            },
            {
              "key": "RSUs Cancelled (2020 Period)",
              "value": "-17090"
            },
            {
              "key": "Invested Balances, December 31, 2021",
              "value": "867730"
            },
            {
              "key": "RSUs Vested (2022)",
              "value": "-384390"
            },
            {
              "key": "RSUs Cancelled (2022)",
              "value": "-152900"
            },
            {
              "key": "Invested Balances, December 31, 2022",
              "value": "330440"
            },
            {
              "key": "Unvested Balances, December 31, 2022",
              "value": "102"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 102,
          "title": "Employee Stock Purchase Plan & Stock-Based Compensation Expense",
          "data": [
            {
              "key": "ESPP Adoption and Approval Dates",
              "value": "Adopted on June 2, 2019 and approved on June 7, 2019"
            },
            {
              "key": "ESPP Expense",
              "value": "$0.8 million for years ended December 31, 2022 and 2021"
            },
            {
              "key": "Total Stock-Based Compensation Expense",
              "value": "$16.9 million for options and ESPP in both 2022 and 2021"
            },
            {
              "key": "Research and Development Expense Allocation",
              "value": "2022: 7,910 (in thousands); 2021: 8,571 (in thousands)"
            },
            {
              "key": "General and Administrative Expense Allocation",
              "value": "2022: 8,981 (in thousands); 2021: 8,305 (in thousands)"
            },
            {
              "key": "Unrecognized Compensation - Stock Options",
              "value": "$12.2 million with a remaining weighted-average service period of 1.8 years (non-vested)"
            },
            {
              "key": "Unrecognized Compensation - RSUs",
              "value": "$1.3 million with a remaining weighted-average service period of 0.7 years (non-vested)"
            },
            {
              "key": "401(k) Matching Contributions",
              "value": "$0.6 million for each of the years ended December 31, 2022 and 2021"
            },
            {
              "key": "Black-Scholes Model - Expected Life",
              "value": "0.5 - 2.0 years (for both 2022 and 2021)"
            },
            {
              "key": "Black-Scholes Model - Volatility",
              "value": "2022: 79.0 - 96.7%; 2021: 91.1 - 107.6%"
            },
            {
              "key": "Black-Scholes Model - Risk-Free Interest Rate",
              "value": "2022: 0.6 - 3.5%; 2021: 0.1 - 0.2%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 109,
          "title": "Table of Contents - Proxy Statement Sections",
          "data": [
            {
              "key": "Item 10. Directors, Executive Officers and Corporate Governance",
              "value": "The required information is referenced to be included in the 2023 Proxy Statement filed with the SEC within 120 days after the fiscal year ended December 31, 2022. It also mentions the Code of Business Conduct and Ethics available on the company website and the oversight by the nominating and corporate governance committee."
            },
            {
              "key": "Item 11. Executive Compensation",
              "value": "Details on executive compensation will be provided in the 2023 Proxy Statement, to be filed with the SEC no later than 120 days after the end of the fiscal year ended December 31, 2022, and are incorporated by reference."
            },
            {
              "key": "Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters",
              "value": "This item’s information is to be included in the 2023 Proxy Statement and is incorporated by reference."
            },
            {
              "key": "Item 13. Certain Relationships and Related Transactions, and Director Independence",
              "value": "The required information will be incorporated by reference in the 2023 Proxy Statement."
            },
            {
              "key": "Item 14. Principal Accountant Fees and Services",
              "value": "Information will be provided in the 2023 Proxy Statement, incorporated by reference."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 111,
          "title": "Exhibit and Filing Information (Incorporated by Reference)",
          "data": [
            {
              "key": "Table Title",
              "value": "Exhibit and Filing Information"
            },
            {
              "key": "Summary",
              "value": "This table presents a list of exhibits and filings for Atreca, Inc., including various corporate documents, agreements, and plans. The filings span from May 2019 to July 2020 and cover corporate governance (e.g. certificate of incorporation, bylaws), stock-related matters (e.g. warrant forms, stock certificates) and various agreements and plans. Notably, several entries pertain to compensation policies such as the Non-Employee Director Compensation Policy and Performance Bonus Plan."
            },
            {
              "key": "Exhibits Count",
              "value": "14 items"
            },
            {
              "key": "Highlighted Compensation Documents",
              "value": "Atreca, Inc. Non-Employee Director Compensation Policy; Atreca, Inc. Performance Bonus Plan"
            },
            {
              "key": "File Note",
              "value": "Number - 112 - Filed Herewith"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 112,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "10.10f",
              "value": "Letter Agreement, dated as of August 21, 2015, by and between the Registrant and the Bill & Melinda Gates Foundation; Form: S-1/A; Filing Number: 333-231770; Date: 06/10/19"
            },
            {
              "key": "10.11t",
              "value": "Exclusive (Equity) Agreement, dated as of May 24, 2018, by and between the Registrant and The Board of Trustees of the Leland Stanford Junior University; Form: S-1/A; Filing Number: 333-231770; Date: 06/10/19"
            },
            {
              "key": "10.12",
              "value": "Amendment to the Exclusive (Equity) Agreement, dated as of May 24, 2018, by and between the Registrant and The Board of Trustees of the Leland Stanford Junior; Form: S-1/A; Filing Number: 333-231770; Date: 06/10/19"
            },
            {
              "key": "10.13",
              "value": "University) Amendment No. 2 to Exclusive (Equity) Agreement, dated as of July 2, 2020, by and between the Registrant and the Board of Trustees of the Leland; Form: 10-K; Filing Number: 001-38935; Date: 03/03/22"
            },
            {
              "key": "10.14",
              "value": "Stanford Junior University Collaboration and License Agreement, dated as of July 2, 2020, by and between the Registrant and Xencor, Inc.; Form: 10-Q; Filing Number: 001-38935; Date: 08/12/20"
            },
            {
              "key": "10.16",
              "value": "Amended and Restated Executive Employment Agreement, dated as of November 11, 2020, by and between the Registrant and John Orwin; Form: 10-Q; Filing Number: 001-38935; Date: 11/12/20"
            },
            {
              "key": "10.17",
              "value": "Amended and Restated Executive Employment Agreement, dated as of November 11, 2020, by and between the Registrant and Herbert Cross; Form: 10-Q; Filing Number: 001-38935; Date: 11/12/20"
            },
            {
              "key": "10.18",
              "value": "Amended and Restated Executive Employment Agreement, dated as of November 11, 2020, by and between the Registrant and Tito Serafini; Form: 10-Q; Filing Number: 001-38935; Date: 11/12/20"
            },
            {
              "key": "10.19",
              "value": "Amended and Restated Executive Employment Agreement, dated as of November 11, 2020, by and between the Registrant and Courtney Phillips; Form: 10-Q; Filing Number: 001-38935; Date: 11/12/20"
            },
            {
              "key": "10.20",
              "value": "License Agreement, dated as of October 18, 2021, by and between the Registrant and the Bill & Melinda Gates Medical Research Institute; Form: 10-K; Filing Number: 001-38935; Date: 03/03/22"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 114,
          "title": "Table of Contents",
          "data": [
            {
              "key": "management_contract_or_compensatory_plan",
              "value": "Indicates management contract or compensatory plan."
            },
            {
              "key": "exhibit_confidentiality_note",
              "value": "Portions of this exhibit (indicated by asterisks) have been omitted because they are not material and are treated as private and confidential."
            },
            {
              "key": "exhibit_certification",
              "value": "The certifications attached as Exhibit 32.1 accompany this Form 10-K pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended."
            },
            {
              "key": "form_10K_summary",
              "value": "None."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 117,
          "title": "Exhibit 10.21 ATRECA, INC. EXECUTIVE EMPLOYMENT AGREEMENT for STEPHEN GOULD",
          "data": [
            {
              "key": "Agreement Type",
              "value": "Executive Employment Agreement"
            },
            {
              "key": "Effective Date",
              "value": "June 15, 2022"
            },
            {
              "key": "Executive Name",
              "value": "Stephen Gould"
            },
            {
              "key": "Company",
              "value": "Atreca, Inc."
            },
            {
              "key": "Position",
              "value": "Chief Scientific Officer"
            },
            {
              "key": "Office Location",
              "value": "San Carlos, California"
            },
            {
              "key": "Reporting To",
              "value": "Chief Executive Officer"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 118,
          "title": "Executive Compensation Details: Salary, Bonus, and Sign-On/Retention Payment",
          "data": [
            {
              "key": "Base Salary",
              "value": "Executive receives a base salary of $400,000 per year, subject to standard payroll deductions."
            },
            {
              "key": "Annual Bonus",
              "value": "Eligible for an annual discretionary bonus of up to 40% of the Base Salary, determined at the discretion of the Board, Compensation Committee, or CEO; bonus payment to be made no later than March 15 of the calendar year following the bonus year."
            },
            {
              "key": "Sign-On/Retention Payment",
              "value": "Eligible for a one-time bonus of $80,000 (less applicable withholdings), which is advanced within 30 days after employment start and earned upon continuous employment through the one-year anniversary, with repayment required if employment terminates before then."
            },
            {
              "key": "Additional Compensation Details",
              "value": "Standard Company Benefits and expense reimbursements for reasonable travel, entertainment, and other expenses are provided as described."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 119,
          "title": "Executive Stock Option and Termination Provisions",
          "data": [
            {
              "key": "Option Grant",
              "value": "Executive shall be granted an option to purchase 200,000 shares of the Company’s Common Stock at an exercise price equal to the fair market value determined on the date of grant by the Board or the Compensation Committee."
            },
            {
              "key": "Vesting Schedule",
              "value": "The option is subject to a four-year vesting period: 25% of the shares vest on the one-year anniversary of the Executive's employment start date, and the remaining shares vest in 36 equal monthly installments contingent on continued employment."
            },
            {
              "key": "At-Will Employment",
              "value": "The Executive’s employment is at-will, allowing for termination by either party at any time, with or without cause or advance notice."
            },
            {
              "key": "Termination Without Severance",
              "value": "In cases of resignation without Good Reason, termination for Cause, or termination due to death or disability, the Executive forfeits any unvested equity awards and further compensation, and is not entitled to severance benefits."
            },
            {
              "key": "Termination With Severance",
              "value": "If terminated without Cause (other than death or disability) or if the Executive resigns for Good Reason (Qualifying Termination), and if such termination qualifies as a Separation from Service under applicable regulations, then severance benefits may be provided subject to compliance with agreement conditions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 120,
          "title": "Executive Severance Benefits Clause",
          "data": [
            {
              "key": "Qualifying Termination (Non-Change in Control)",
              "value": "In event of Qualifying Termination outside 30-day pre-close or 12-month post-close window of a Change in Control, Executive receives nine months of Base Salary as Cash Severance and nine months of COBRA premium cost as COBRA Severance."
            },
            {
              "key": "Payment Terms (Non-Change in Control)",
              "value": "Payments are made in a lump sum within 60 days following the Separation from Service, upon execution of the Separation Agreement."
            },
            {
              "key": "Qualifying Termination (Change in Control)",
              "value": "If termination occurs within 30-day pre-close or within 12-month post-close of a Change in Control, Executive is eligible for: 12 months of Base Salary (CIC Cash Severance), 12 months of target Annual Bonus (Annual Bonus Severance), and 12 months of COBRA premium cost (CIC COBRA Severance)."
            },
            {
              "key": "Accelerated Vesting",
              "value": "Time-based and performance-based Equity Awards vest immediately; 100% vesting on last day of employment for time-based awards and accelerated performance vesting as if 100% performance goals were met."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 121,
          "title": "Severance Benefits, Equity Awards Vesting, and Clawback Provisions",
          "data": [
            {
              "key": "Equity Awards Vesting",
              "value": "Performance criteria applicable to awards result in immediate vesting and exercisability of shares as of the Executive’s last day of employment."
            },
            {
              "key": "Severance Benefits Conditions",
              "value": "Receipt of Severance Benefits is contingent upon the Executive signing (and not revoking) a separation agreement and release of claims in a form acceptable to the Company within 60 days after separation."
            },
            {
              "key": "Resignation Requirement",
              "value": "Executive must resign from all positions (employee, advisor, officer, director) within the Company or its affiliates as a condition for receiving benefits."
            },
            {
              "key": "Company Property Return",
              "value": "Executive must return all Company documents and property within five days after separation."
            },
            {
              "key": "Clawback Provisions",
              "value": "Severance Benefits are subject to clawback per applicable regulatory requirements and may include additional recovery measures, including re-acquisition rights upon termination for Cause."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 122,
          "title": "Executive Termination, Good Reason, and Section 409A Provisions",
          "data": [
            {
              "key": "Termination Rights",
              "value": "Company reserves the right to terminate Executive's employment at any time."
            },
            {
              "key": "Change in Control",
              "value": "Defined as per the 2019 Equity Incentive Plan, subject to amendments or restatements."
            },
            {
              "key": "Good Reason",
              "value": "Executive may resign for Good Reason if there is a material reduction in Base Salary (at least 10%), a material reduction in duties, or relocation increasing commute by over 50 miles, without prior written consent."
            },
            {
              "key": "Resignation Process",
              "value": "Executive must provide written notice within 30 days of the triggering event and allow a 30-day cure period; if not cured, resignation is required within 15 days after the cure period."
            },
            {
              "key": "Section 409A Compliance",
              "value": "Severance benefits and installment payments are structured to comply with Section 409A of the Internal Revenue Code, treating each installment as separate to avoid adverse tax consequences."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 123,
          "title": "Deferred Compensation and Parachute Payment Provisions",
          "data": [
            {
              "key": "Section 409A Deferral Conditions",
              "value": "Payments deferred under Section 409A are not provided to the Executive until the earliest of: (i) expiration of a six-month period following the Executive’s separation from service, (ii) the Executive’s death, or (iii) an earlier permitted date under Section 409A without adverse tax consequences."
            },
            {
              "key": "Lump Sum Payment Timing",
              "value": "On the first business day after the applicable period under Section 409A(a)(2)(B)(i) expires, all deferred payments are to be paid in a lump sum, with any remaining amounts handled as provided in the agreement."
            },
            {
              "key": "Interest and Short-Term Deferral",
              "value": "No interest accrues on deferred amounts. If a payment qualifies as a 'short-term deferral' under Section 409A, it is treated as such even if it qualifies for an exemption under another provision."
            },
            {
              "key": "Expense Reimbursement and In-Kind Benefits",
              "value": "Expenses or in-kind benefits subject to Section 409A are limited to the calendar year in which they are incurred, and do not affect benefits in other years, with strict cutoffs to prevent liquidation or exchange for another benefit."
            },
            {
              "key": "Parachute Payment Provisions",
              "value": "For payments considered as 'parachute payments' under Section 280G, the agreement requires the Company to determine whether a full payment or a reduced payment (designed to avoid excise tax under Section 4999) would yield a greater after-tax benefit for the Executive. If the reduced payment option is chosen, no additional payments will be made, and reductions will be applied pro rata if multiple reduction methods yield the same benefit."
            },
            {
              "key": "Tax Considerations",
              "value": "Calculations for determining the best payment method take into account all applicable federal, state, and local income and employment taxes as well as the excise tax, computed at the highest applicable marginal rate."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 124,
          "title": "Executive Agreement - Tax Calculations and Confidentiality Obligations",
          "data": [
            {
              "key": "Tax Calculation Determination",
              "value": "Calculations are to be made in writing by the Company’s independent public accountants, whose determination is conclusive and binding on both the Executive and the Company. The accountants may use reasonable assumptions concerning taxes and interpretations of Sections 280G and 4999 of the Code."
            },
            {
              "key": "Cost Responsibility",
              "value": "The Company bears all costs incurred by the accountants for calculations and any associated costs for executive tax planning under Sections 280G and 4999."
            },
            {
              "key": "Confidential Information Agreement",
              "value": "As a condition of employment, the Executive must sign the Company’s standard Employee Confidential Information and Inventions Assignment Agreement."
            },
            {
              "key": "Third-Party Agreements",
              "value": "The Executive represents that there is no conflict with any prior employment or consulting agreements, and that confidential information from previous roles will not be used in connection with the Company."
            },
            {
              "key": "Employment Contingencies",
              "value": "The Executive’s employment and this Agreement are contingent on a satisfactory reference check, proof of the right to work in the United States, and, if required, a background check."
            },
            {
              "key": "Outside Business Restrictions",
              "value": "The Executive is restricted from engaging in other employment, occupation, or business enterprise without the prior written consent of the CEO, except where acting as a passive investor."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 127,
          "title": "Contract Provisions: Successors, Tax Withholding, and Choice of Law",
          "data": [
            {
              "key": "Successors and Assigns",
              "value": "This Agreement is intended to bind and inure to the benefit of the Executive and the Company, including their respective successors, assigns, heirs, executors, and administrators. However, the Executive may not assign any of his duties or rights under the Agreement without the written consent of the Company."
            },
            {
              "key": "Tax Withholding and Indemnification",
              "value": "All payments and awards made under this Agreement will be subject to applicable tax withholdings in compliance with relevant laws. The Executive acknowledges that the Company has made no guarantees regarding the tax treatment of these payments or awards and has had the opportunity to consult tax and financial advisors."
            },
            {
              "key": "Choice of Law",
              "value": "The construction, validity, and interpretation of the Agreement will be governed by the laws of the State of California, without regard to conflicts of law principles."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 129,
          "title": "Exhibit 10.22 ATRECA, INC. EXECUTIVE EMPLOYMENT AGREEMENT for Philippe Bishop",
          "data": [
            {
              "key": "Effective Date",
              "value": "January 9, 2023"
            },
            {
              "key": "Company",
              "value": "Atreca, Inc."
            },
            {
              "key": "Executive",
              "value": "Philippe Bishop"
            },
            {
              "key": "Position",
              "value": "Chief Medical Officer"
            },
            {
              "key": "Primary Office Location",
              "value": "San Carlos, California"
            },
            {
              "key": "Document Type",
              "value": "Executive Employment Agreement"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 130,
          "title": "Compensation – Salary, Bonus, Benefits, Expenses, and Equity",
          "data": [
            {
              "key": "Base Salary",
              "value": "$475,000.00 per year"
            },
            {
              "key": "Bonus Eligibility",
              "value": "Eligible for an annual discretionary bonus of up to 40% of Base Salary"
            },
            {
              "key": "Bonus Determination",
              "value": "Bonus amount determined solely at the discretion of the Board, Compensation Committee, or CEO based on performance objectives"
            },
            {
              "key": "Bonus Payment Date",
              "value": "Paid no later than March 15 in the calendar year following the bonus year"
            },
            {
              "key": "Equity Offer",
              "value": "Grant of a nonstatutory stock option to purchase 350,000 shares of Class A Common Stock at the closing sales price per share on the date of grant"
            },
            {
              "key": "Benefits",
              "value": "Participation in all eligible Company employee benefit programs"
            },
            {
              "key": "Expense Reimbursement",
              "value": "Reimbursement for reasonable business-related expenses per Company policy"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 131,
          "title": "Executive Stock Option Vesting and Termination Provisions",
          "data": [
            {
              "key": "Vesting Period",
              "value": "Four (4)-year vesting period with 25% vesting on the one-year anniversary and the remaining 75% vesting in 36 equal monthly installments contingent upon continued employment."
            },
            {
              "key": "Equity Incentive Plan",
              "value": "Granted under the Company’s 2019 Equity Incentive Plan, subject to amendment or restatement."
            },
            {
              "key": "Inducement Stock Option Agreement",
              "value": "Option subject to terms of an inducement stock option agreement approved by the Board or the Compensation Committee pursuant to Nasdaq Listing Rule 5635(c)(4)."
            },
            {
              "key": "Employment Nature",
              "value": "At-Will Employment, allowing termination by either Executive or Company at any time, with or without cause or notice."
            },
            {
              "key": "Termination Conditions - Non-Qualifying Termination",
              "value": "If terminated for Cause, resignation without Good Reason, or due to death or disability, vesting ceases, compensation ends, and no severance benefits are provided."
            },
            {
              "key": "Termination Conditions - Qualifying Termination",
              "value": "If terminated without Cause or resignation for Good Reason (Qualifying Termination) and upon separation from service per regulatory guidelines, severance benefits are provided subject to continued compliance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 132,
          "title": "Severance Benefits and Accelerated Vesting Details",
          "data": [
            {
              "key": "Qualifying Termination (Not in Connection with Change in Control)",
              "value": "Executive receives severance benefits if termination occurs outside the 30-day pre and 12-month post Change in Control window. Benefits include: (a) Cash Severance – equivalent to 9 months of Base Salary; (b) COBRA Severance – equivalent to 9 months of COBRA premium costs. Payment is made in a lump sum within 60 days following separation upon effectiveness of the Separation Agreement."
            },
            {
              "key": "Qualifying Termination (In Connection with Change in Control)",
              "value": "If termination occurs within the 30-day period prior or 12-month period following a Change in Control, benefits include: (a) CIC Cash Severance – 12 months of Base Salary; (b) Annual Bonus Severance – 12 months of the target Annual Bonus for the applicable year; (c) CIC COBRA Severance – 12 months of COBRA premium costs. These are paid in a lump sum within 60 days following separation upon the Separation Agreement's effectiveness."
            },
            {
              "key": "Accelerated Vesting",
              "value": "Additional severance benefits include accelerated vesting: Time-based Equity Awards become 100% vested immediately upon separation, and performance-based Equity Awards vest as if all performance goals were achieved at 100%."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 133,
          "title": "Severance Benefits and Clawback Provisions",
          "data": [
            {
              "key": "Awards Vesting",
              "value": "Awards shall be deemed immediately vested and exercisable as of the Executive’s last day of employment."
            },
            {
              "key": "Severance Conditions",
              "value": "The receipt of the Severance Benefits is subject to the Executive signing a separation agreement and release of claims within 60 days following the Executive’s separation from service. No benefits will be provided until the separation agreement becomes effective."
            },
            {
              "key": "Resignation Requirement",
              "value": "The Executive must resign from all positions and terminate any relationships as an employee, advisor, officer, or director with the Company and its affiliates, effective on the date of employment termination."
            },
            {
              "key": "Return of Company Property",
              "value": "As a precondition for receipt of severance benefits, the Executive agrees to return all Company documents and other Company property within 5 days after separation (or sooner if requested)."
            },
            {
              "key": "Clawback and Recovery",
              "value": "All Severance Benefits are subject to recoupment under any required clawback policy per national securities exchange standards, the Dodd-Frank Act, or other applicable law. Additional clawback provisions, including reacquisition rights in respect of previously acquired shares, may be imposed on termination for Cause."
            },
            {
              "key": "Definition of Cause",
              "value": "Cause for termination includes committing a felony or a crime involving dishonesty, participation in fraud or embezzlement against the Company, material breach of duties, persistent unsatisfactory performance after notice, intentional damage to Company property, misconduct or policy violations causing harm, breach of any written agreement with the Company, or conduct that in the CEO’s judgment demonstrates gross unfitness to serve."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 134,
          "title": "Change in Control and Good Reason Definitions in Executive Employment Agreement",
          "data": [
            {
              "key": "Termination Condition",
              "value": "Company’s ability to terminate Executive’s employment at any time."
            },
            {
              "key": "Change in Control",
              "value": "Defined by the Company’s 2019 Equity Incentive Plan."
            },
            {
              "key": "Good Reason for Resignation",
              "value": "Actions taken by the Company without consent that include: a) material reduction in salary, b) material reduction in duties, c) relocation increasing commute by over 50 miles."
            },
            {
              "key": "Written Notice Period",
              "value": "Executive must provide notice within 30 days and allow a 30-day cure period."
            },
            {
              "key": "Severance Benefits Compliance",
              "value": "Intended to comply with Section 409A of the Internal Revenue Code."
            },
            {
              "key": "Installment Payments",
              "value": "Considered as a series of separate payments for compliance with Section 409A."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 135,
          "title": "Executive Compensation Deferred Payments and Parachute Payments",
          "data": [
            {
              "key": "Section 409A(a)(2)(B)(i)",
              "value": "Payments shall not be provided to Executive prior to expiration of certain periods."
            },
            {
              "key": "Short-term deferral",
              "value": "Payments classified as such under Section 409A."
            },
            {
              "key": "Parachute Payments",
              "value": "Payments received in connection with a Change in Control that could be classified as parachute payments under Section 280G."
            },
            {
              "key": "Excise Tax",
              "value": "Excise tax imposed under Section 4999 of the Code."
            },
            {
              "key": "Payment Options",
              "value": "Full Payment or Reduced Payment based on tax implications."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 136,
          "title": "Transaction Payment Provisions and Confidential Information Obligations",
          "data": [
            {
              "key": "Transaction Payment Reduction",
              "value": "The portions of the Transaction Payment shall be reduced pro rata."
            },
            {
              "key": "Accountants Determination",
              "value": "Any determination required shall be made in writing by the Company’s independent public accountants."
            },
            {
              "key": "Tax Considerations",
              "value": "Accountants may make reasonable assumptions concerning applicable taxes."
            },
            {
              "key": "Executive Conditions",
              "value": "Executive must execute a Confidentiality Agreement and adhere to its terms."
            },
            {
              "key": "Third-Party Agreements",
              "value": "Executive warrants no conflict with prior agreements."
            },
            {
              "key": "Employment Conditions",
              "value": "Employment is contingent upon satisfactory reference and background checks."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 138,
          "title": "Arbitration Decision and Provisions",
          "data": [
            {
              "key": "Arbitration Decision",
              "value": "The arbitrator shall issue a written decision including essential findings and conclusions."
            },
            {
              "key": "Remedies Authorized",
              "value": "The arbitrator is authorized to award any or all remedies that Executive or the Company would seek in court."
            },
            {
              "key": "JAMS Fees Payment",
              "value": "The Company shall pay all JAMS arbitration fees exceeding the administration fees required of Executive in court."
            },
            {
              "key": "Injunctive Relief",
              "value": "Agreement allows obtaining injunctive relief in court to prevent irreparable harm."
            },
            {
              "key": "General Provisions",
              "value": "This section includes Notices, Severability, Waiver, Complete Agreement, and Counterparts."
            },
            {
              "key": "Notices Effective",
              "value": "Notices are effective upon personal delivery or next day after sending by overnight carrier."
            },
            {
              "key": "Severability Clause",
              "value": "Invalid provisions do not affect the rest of the Agreement."
            },
            {
              "key": "Waiver Requirements",
              "value": "Any waiver must be in writing to be effective."
            },
            {
              "key": "Complete Agreement Summary",
              "value": "The Agreement constitutes the entire agreement between Executive and the Company."
            },
            {
              "key": "Amendment Conditions",
              "value": "Agreement can only be modified in writing signed by a duly authorized officer."
            },
            {
              "key": "Execution Counterparts",
              "value": "Agreement may be executed in separate counterparts, including via electronic means."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 139,
          "title": "Contract Clauses – Delivery, Assignment, Tax Withholding, and Choice of Law",
          "data": [
            {
              "key": "Delivery",
              "value": "Provisions state that transmission by other methods is deemed valid and effective."
            },
            {
              "key": "Headings",
              "value": "Paragraph headings are for convenience and do not affect the interpretation of the agreement."
            },
            {
              "key": "Successors and Assigns",
              "value": "The Agreement binds Executive and Company along with their successors, assigns, heirs, executors, and administrators; however, the Executive cannot assign duties or rights without the Company's written consent."
            },
            {
              "key": "Tax Withholding and Indemnification",
              "value": "All payments and awards under the Agreement are subject to applicable tax withholdings. The Company makes no guarantees regarding tax treatment, and the Executive is advised to seek independent tax and financial advice."
            },
            {
              "key": "Choice of Law",
              "value": "The Agreement is governed by the laws of the State of California without regard to conflicts of law."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 140,
          "title": "Executive Employment Agreement Execution",
          "data": [
            {
              "key": "Company",
              "value": "ATRECA, INC."
            },
            {
              "key": "Executive 1 Name",
              "value": "John Orwin"
            },
            {
              "key": "Executive 1 Title",
              "value": "President & Chief Executive Officer"
            },
            {
              "key": "Executive 2 Name",
              "value": "Philippe Bishop"
            },
            {
              "key": "Executive 2 Title",
              "value": "Chief Medical Officer"
            },
            {
              "key": "Execution Date",
              "value": "January 8, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 141,
          "title": "Exhibit 10.23 ATRECA, INC. 2023 Inducement Plan",
          "data": [
            {
              "key": "Plan Overview",
              "value": "2023 Inducement Plan Adopted by the Compensation Committee of the Board of Directors, dated February 9, 2023."
            },
            {
              "key": "Eligible Award Recipients",
              "value": "Individuals who meet Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3) standards. Former employees or directors are eligible only after a bona fide period of non-employment."
            },
            {
              "key": "Types of Stock Awards",
              "value": "Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted Stock Unit Awards, Performance Stock Awards, and Other Stock Awards."
            },
            {
              "key": "Purpose",
              "value": "To provide inducement for employment, incentivize maximum effort for the Company and its Affiliates, and offer Eligible Employees an opportunity to benefit from increases in the Common Stock's value."
            },
            {
              "key": "Administration",
              "value": "The Plan is administered by the Board, with grants executed by either a majority of the Company’s Independent Directors or the Independent Compensation Committee, in compliance with the Inducement Award Rules."
            },
            {
              "key": "Authority of the Board",
              "value": "The Board determines who receives awards, timing, type, award provisions, share amounts/cash value, and Fair Market Value, subject to limitations under the Inducement Award Rules."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 142,
          "title": "Stock Award Plan Administration and Amendment Provisions",
          "data": [
            {
              "key": "Plan Interpretation and Administration",
              "value": "The Board is empowered to construe and interpret the Plan and Stock Awards, and to establish, amend, and revoke rules and regulations for their administration."
            },
            {
              "key": "Correction of Defects",
              "value": "The Board may correct any defect, omission, or inconsistency in the Plan or in any Stock Award Agreement to ensure the Plan is fully effective."
            },
            {
              "key": "Acceleration of Awards",
              "value": "The Board has the authority to accelerate the vesting or exercise time of a Stock Award, including the issuance of cash or shares of Common Stock."
            },
            {
              "key": "Plan Suspension or Termination",
              "value": "The Board can suspend or terminate the Plan, but such actions will not impair a Participant’s rights under an outstanding Stock Award without the Participant’s written consent, except as permitted."
            },
            {
              "key": "Plan Amendments Requiring Consent",
              "value": "Any amendment to the Plan that may impair a Participant’s rights requires the consent of the affected Participant, unless the amendment is deemed not materially impairing by the Board."
            },
            {
              "key": "Stock Award Agreement Modifications",
              "value": "The Board may approve standard forms and amend terms of Stock Award Agreements, including amendments to benefit Participants, subject to specified limits and necessary consents."
            },
            {
              "key": "Compliance with Legal Requirements",
              "value": "The Board may amend Stock Awards without consent to comply with Section 409A of the Code or other applicable laws and listing requirements."
            },
            {
              "key": "Foreign Participation Provisions",
              "value": "Rules and sub-plans may be adopted to allow participation by Eligible Employees who are foreign nationals or employed outside the United States, ensuring compliance with local laws."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 143,
          "title": "Delegation, Administration and Share Reserve Provisions under the Stock Award Plan",
          "data": [
            {
              "key": "Delegation to Committee",
              "value": "The Board may delegate administration of the Plan to a Committee or subcommittee, with such delegation documented in resolutions. The Board retains final authority on policy decisions."
            },
            {
              "key": "Rule 16b-3 Compliance",
              "value": "A Committee can consist solely of two or more Non-Employee Directors in accordance with Rule 16b-3."
            },
            {
              "key": "Board's Decision Effect",
              "value": "All determinations, interpretations, and constructions by the Board in good faith are final, binding, and conclusive."
            },
            {
              "key": "Cancellation and Re-Grant of Stock Awards",
              "value": "Neither the Board nor the Committee has authority to reduce exercise or strike prices, or cancel outstanding options or rights without proper stockholder approval."
            },
            {
              "key": "Share Reserve",
              "value": "The aggregate number of shares available for issuance under the Plan is capped at 1,000,000 shares, with clarifications regarding re-grants and adjustments in connection with mergers or acquisitions."
            },
            {
              "key": "Merger or Acquisition Provision",
              "value": "Shares issued in connection with a merger or acquisition will not reduce the number of shares available under the Plan."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 144,
          "title": "Stock Award Plan Provisions and Eligibility",
          "data": [
            {
              "key": "Share Availability",
              "value": "If shares issued under a Stock Award are forfeited, repurchased, or surrendered due to failure to meet vesting contingencies, they become available for future issuance under the Plan. Shares reacquired for tax withholding or as consideration for exercise/purchase will also be reissued."
            },
            {
              "key": "Award Recipients",
              "value": "Stock Awards are granted only to Eligible Employees as defined in Section 1(a) of the Plan. Awards serve as inducements or are permitted under Nasdaq Marketplace Rules."
            },
            {
              "key": "Stock Award Types",
              "value": "Nonstatutory Stock Options and Stock Appreciation Rights (SARs) are granted, subject to specific eligibility and vesting conditions. Provisions may vary, but each award conforms to core plan provisions."
            },
            {
              "key": "Approval Requirements",
              "value": "All awards must be approved by either a majority of the Company’s Independent Directors or by the Independent Compensation Committee."
            },
            {
              "key": "Terms and Conditions",
              "value": "Each Option or SAR is exercisable for up to ten years from the grant date, with an exercise price of not less than 100% of the fair market value at the time of grant (with noted exceptions for substitutions)."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 145,
          "title": "Option and Stock Appreciation Right (SAR) Terms",
          "data": [
            {
              "key": "Appreciation Right",
              "value": "Provides an appreciation right pursuant to a Corporate Transaction consistent with Section 409A of the Code; each SAR is denominated in shares of Common Stock equivalents."
            },
            {
              "key": "Purchase Price for Options",
              "value": "The purchase price for Common Stock acquired through Option exercise may be paid by a combination of methods including cash, check, bank draft, money order, a Regulation T program, a net exercise arrangement, or other acceptable legal consideration as determined by the Board."
            },
            {
              "key": "Net Exercise Arrangement",
              "value": "Under a net exercise, the Company reduces the number of shares issuable by the greatest whole number that does not exceed the aggregate exercise price, with any remaining balance paid in cash or other methods."
            },
            {
              "key": "SAR Exercise and Payment",
              "value": "To exercise a SAR, the Participant must provide written notice. The appreciation distribution is calculated as the excess of the aggregate Fair Market Value over the aggregate strike price, payable in Common Stock, cash, or a combination as determined by the Board."
            },
            {
              "key": "Transferability Restrictions",
              "value": "Options and SARs are generally non-transferable except by will or under laws of descent and distribution; additional limitations may be imposed by the Board."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 146,
          "title": "Analysis of Option and SAR Transfer and Vesting Provisions",
          "data": [
            {
              "key": "Transfer Restrictions",
              "value": "Options or SARs cannot be transferred for consideration except as allowed by the Plan and applicable laws. Transfers may occur via domestic relations orders or beneficiary designations subject to Board or authorized officer approval."
            },
            {
              "key": "Vesting Terms",
              "value": "Shares subject to Options or SARs vest in periodic installments, which may be tied to performance goals or other criteria, with specific vesting provisions per individual award."
            },
            {
              "key": "Termination and Exercise Post-Service",
              "value": "Upon termination of Continuous Service (except for Cause, death, or Disability), the Participant may exercise vested Options or SARs within a set period (e.g., three months post-termination) as defined in the Stock Award Agreement. Failure to exercise within the period results in termination."
            },
            {
              "key": "Extension Provisions",
              "value": "If the exercise of an Option or SAR post-termination is prohibited by registration requirements under the Securities Act or by insider trading policies, the exercise period may be extended only until such restrictions no longer apply, or until the award term expires."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 147,
          "title": "Termination Terms for Stock Options and SARs",
          "data": [
            {
              "key": "Termination Exercise Period",
              "value": "Period after the termination of the Participant’s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not violate the Company’s insider trading policy, or until the expiration of the term as set out in the applicable Stock Award Agreement."
            },
            {
              "key": "Disability of Participant",
              "value": "If a Participant’s Continuous Service terminates due to Disability, the Option or SAR may be exercised within the earlier of (i) 12 months following termination (or a period specified in the Stock Award Agreement) or (ii) the Option or SAR's expiration term."
            },
            {
              "key": "Death of Participant",
              "value": "If termination occurs because of the Participant’s death or if the Participant dies within a specified exercisability period, the Option or SAR may be exercised by the Participant’s estate, beneficiary, or designated person within the earlier of (i) 18 months following the date of death (or as specified in the Agreement) or (ii) the expiration of the Option or SAR."
            },
            {
              "key": "Termination for Cause",
              "value": "In the event of termination for Cause, the Option or SAR terminates immediately on termination of Continuous Service. If service is suspended pending an investigation, all rights under the Option or SAR are suspended."
            },
            {
              "key": "Non-Exempt Employees",
              "value": "For non-exempt employees under the U.S. Fair Labor Standards Act, Options or SARs are not initially exercisable for any shares until at least six months after the grant date, except under certain events (death, Disability, Corporate Transaction, Change in Control, or retirement) which may allow earlier exercise of the vested portion."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 148,
          "title": "Stock Award Provisions: Restricted Stock and Restricted Stock Unit Awards",
          "data": [
            {
              "key": "Exempt Employee Provision",
              "value": "Exempt employee in connection with the exercise, vesting or issuance of any shares under any Stock Award is exempt from the employee’s regular rate of pay."
            },
            {
              "key": "Restricted Stock Awards",
              "value": "Each Restricted Stock Award Agreement is established in a form approved by the Board, with provisions covering consideration (payment methods including cash or other legal consideration), vesting schedules, termination consequences, transferability restrictions, and dividend treatments."
            },
            {
              "key": "Restricted Stock Unit Awards",
              "value": "Each Restricted Stock Unit Award Agreement, also determined by the Board, contains terms regarding the consideration to be paid upon delivery of shares of Common Stock and may have terms differing from individual awards."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 149,
          "title": "Restricted & Performance Stock Awards Compensation",
          "data": [
            {
              "key": "Award Types",
              "value": "Restricted Stock Unit Award; Performance Stock Award; Other Stock Awards"
            },
            {
              "key": "Payment Methods",
              "value": "Shares of Common Stock, cash equivalent, combination of both, or other forms of legal consideration as determined by the Board"
            },
            {
              "key": "Vesting Conditions",
              "value": "Board may impose restrictions or conditions on vesting at the time of grant; additional restrictions may delay share delivery"
            },
            {
              "key": "Dividend Equivalents",
              "value": "May be credited and converted into additional shares, subject to the same terms as the underlying award"
            },
            {
              "key": "Forfeiture Condition",
              "value": "Unvested awards will be forfeited upon termination of continuous service, unless otherwise provided"
            },
            {
              "key": "Performance Criteria",
              "value": "Performance Stock Awards are contingent on the attainment of specified Performance Goals during a Performance Period, with measures and period determined solely by the Board or Committee"
            },
            {
              "key": "Board Discretion",
              "value": "The Board has sole discretion in determining vesting restrictions, payment forms, performance period length, Performance Goals, and potential use of cash in lieu of stock awards"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 150,
          "title": "Stock Award Plan and Grant Provisions",
          "data": [
            {
              "key": "Plan Authority",
              "value": "The Plan gives the majority of the Company’s Independent Directors or the Independent Compensation Committee sole authority to determine the recipients, timing, number of shares (or cash equivalent), and other terms of Other Stock Awards."
            },
            {
              "key": "Share Availability",
              "value": "The Company will continuously maintain a sufficient number of shares of Common Stock required to fulfill outstanding Stock Awards."
            },
            {
              "key": "Regulatory Compliance",
              "value": "The Company will obtain necessary regulatory approvals to grant Stock Awards and issue/sell shares, with relief from liability if such authority is not obtained despite reasonable efforts."
            },
            {
              "key": "Tax and Notification",
              "value": "The Company has no obligation to advise participants on the timing, tax treatment, or exercise of Stock Awards, nor to notify participants of impending expirations or terminations."
            },
            {
              "key": "Use of Proceeds",
              "value": "Proceeds from the sale of shares granted under Stock Awards will be used as general funds for the Company."
            },
            {
              "key": "Corporate Action for Grant",
              "value": "A corporate action by the Company, determined by the Board, will be deemed to complete the grant of a Stock Award regardless of when related documents are communicated to the participant."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 151,
          "title": "Stock Award Terms and Conditions",
          "data": [
            {
              "key": "Common Stock Issuance",
              "value": "Common Stock under the Stock Award and its issuance have been recorded in the Company's books."
            },
            {
              "key": "No Employment or Service Rights",
              "value": "The Plan and related agreements do not confer any right to continue serving the Company or its Affiliates, nor do they create an employment or service relationship."
            },
            {
              "key": "Change in Time Commitment",
              "value": "If a Participant’s regular time commitment decreases, the Board may reduce the number of shares or cash amount subject to the Stock Award or extend the vesting/payment schedule."
            },
            {
              "key": "Investment Assurances",
              "value": "The Company may require written assurances regarding the Participant's financial expertise and personal intent not to resell the acquired stock, unless registered under a valid registration statement."
            },
            {
              "key": "Withholding Obligations",
              "value": "The Company reserves the right to satisfy tax withholding obligations related to a Stock Award by cash payment or by withholding shares, within legal limits."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 152,
          "title": "Stock Award Agreement",
          "data": [
            {
              "key": "Cashless exercise",
              "value": "Exercise pursuant to a program developed under Regulation T."
            },
            {
              "key": "Deferrals",
              "value": "Delivery of Common Stock or cash payments may be deferred."
            },
            {
              "key": "Compliance with Section 409A",
              "value": "Plan will be interpreted to be in compliance with Section 409A of the Code."
            },
            {
              "key": "Clawback policy",
              "value": "Subject to recoupment under clawback policies as required."
            },
            {
              "key": "Withholding methods",
              "value": "Various methods for satisfying tax withholding obligations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 153,
          "title": "Stock Award and Corporate Transaction Provisions",
          "data": [
            {
              "key": "Clawback Provision",
              "value": "The Board may impose clawback, recovery or recoupment provisions in a Stock Award Agreement, including reacquisition rights for previously acquired shares. Recovery of compensation under such provisions will not trigger rights to resign for 'good reason' or 'constructive termination'."
            },
            {
              "key": "Capitalization Adjustments",
              "value": "In the event of a Capitalization Adjustment, the Board will adjust the class and maximum number of securities subject to the Plan as well as the class, number, and price per share of outstanding Stock Awards."
            },
            {
              "key": "Dissolution or Liquidation",
              "value": "Upon dissolution or liquidation of the Company, all outstanding Stock Awards (except fully vested awards not subject to forfeiture or repurchase) will terminate immediately prior to completion, with the Company retaining rights to repurchase or reacquire such shares, unless the Board decides to accelerate vesting."
            },
            {
              "key": "Corporate Transaction",
              "value": "In the event of a Corporate Transaction, the Board may have the surviving or acquiring corporation assume or substitute the Stock Award, assign repurchase rights, or accelerate vesting (potentially to a date five days prior to the effective date), contingent on the transaction's effectiveness."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 155,
          "title": "Определения ключевых терминов: Board, Capital Stock, Capitalization Adjustment, Cause, Change in Control",
          "data": [
            {
              "key": "Board",
              "value": "Определяется как Совет директоров Компании."
            },
            {
              "key": "Capital Stock",
              "value": "Означает все классы обыкновенных акций Компании, вне зависимости от количества голосов на акцию."
            },
            {
              "key": "Capitalization Adjustment",
              "value": "Любое изменение или событие, связанное с обыкновенными акциями, затрагиваемыми Планом или акциями, предоставляемыми по наградным программам, произошедшее без получения компенсации Компанией (исключение — конвертация конвертируемых ценных бумаг)."
            },
            {
              "key": "Cause",
              "value": "Определено как совершение участником преступления, мошенничества, несанкционированного использования конфиденциальной информации или иного серьёзного нарушения обязательств, что может привести к прекращению его непрерывного обслуживания."
            },
            {
              "key": "Change in Control",
              "value": "Определяет событие, когда одно или несколько лиц/сущностей становятся владельцами более 50% от общего голосующего капитала Компании (с рядом исключений, связанных с приобретением акций для финансирования и других транзакций)."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 157,
          "title": "Consultant, Continuous Service & Corporate Transaction Definitions",
          "data": [
            {
              "key": "Consultant Definition",
              "value": "A person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company's securities. Serving solely as a Director or receiving a fee for such service does not make one a Consultant, and Consultants are not eligible to receive Stock Awards under the Plan."
            },
            {
              "key": "Continuous Service",
              "value": "Continuous Service means that the Participant’s service with the Company or an Affiliate, whether as an Employee, Director, or Consultant, is not interrupted or terminated. A change in the capacity of service or the entity for which service is rendered (provided there is no interruption) does not terminate Continuous Service, except when an Entity ceases to qualify as an Affiliate."
            },
            {
              "key": "Corporate Transaction",
              "value": "A Corporate Transaction is defined as the consummation, in one or a series of related transactions, of events including a sale or disposition of substantially all consolidated assets, a sale or disposition of more than 50% of the outstanding securities, a merger, consolidation or similar transaction where the Company is not the surviving corporation, or a merger/consolidation where the Company's pre-transaction common stock is converted or exchanged into other property."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 158,
          "title": "Stock Awards Plan Definitions",
          "data": [
            {
              "key": "Director",
              "value": "A member of the Board. Directors are not eligible to receive Stock Awards under the Plan."
            },
            {
              "key": "Disability",
              "value": "With respect to a Participant, the inability to engage in any substantial gainful activity because of a medically determinable physical or mental impairment that is expected to result in death or last for a continuous period of not less than 12 months."
            },
            {
              "key": "Effective Date",
              "value": "February 9, 2023."
            },
            {
              "key": "Employee",
              "value": "Any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, does not make one an 'Employee' for purposes of the Plan."
            },
            {
              "key": "Exchange Act",
              "value": "The U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder."
            },
            {
              "key": "Exchange Act Person",
              "value": "Any natural person, Entity or 'group' (within the meaning of Section 13(d) or 14(d) of the Exchange Act) with specified exclusions such as the Company, its subsidiaries, employee benefit plans, underwriters in a public offering, entities owned by the stockholders in similar proportions, or any person/group owning more than 50% of the Company’s voting power as of the Effective Date."
            },
            {
              "key": "Fair Market Value",
              "value": "Determined as the value of the Common Stock based on the closing sales price on an established stock exchange or the last available closing price if no current quotation exists."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 159,
          "title": "Определения для плана по Нестатутарным опционным вознаграждениям и другим стоковым наградам",
          "data": [
            {
              "key": "Fair Market Value",
              "value": "В случае отсутствия рыночной цены на обыкновенные акции, справедливая рыночная стоимость определяется Советом в соответствии с разделами 409A и 422 Кодекса."
            },
            {
              "key": "Non-Employee Director",
              "value": "Директор, который не является текущим сотрудником или должностным лицом Компании или аффилированного лица, не получает прямого или косвенного вознаграждения за услуги, кроме как за исполнение обязанностей Директора, согласно требованиям раскрытия информации Regulation S-K."
            },
            {
              "key": "Nonstatutory Stock Option",
              "value": "Опцион, предоставленный согласно разделу 5 Плана, который не соответствует определению «инцентивного опционного вознаграждения» по разделу 422 Кодекса."
            },
            {
              "key": "Option",
              "value": "Нестатутарный опцион на покупку обыкновенных акций, предоставляемый согласно Плану."
            },
            {
              "key": "Option Agreement",
              "value": "Письменное соглашение между Компанией и держателем опциона, подтверждающее условия предоставления опциона, которое подчиняется условиям Плана."
            },
            {
              "key": "Optionholder",
              "value": "Лицо, которому предоставлен опцион по Плану или иное лицо, владеющее действующим опционом."
            },
            {
              "key": "Other Stock Award",
              "value": "Награда, основанная полностью или частично на обыкновенных акциях, предоставляемая согласно условиям раздела 6(d) Плана."
            },
            {
              "key": "Other Stock Award Agreement",
              "value": "Письменное соглашение между Компанией и держателем награды, подтверждающее условия ее предоставления, подчиняющееся условиям Плана."
            },
            {
              "key": "Officer",
              "value": "Лицо, являющееся должностным лицом Компании в соответствии с разделом 16 Закона о биржах."
            },
            {
              "key": "Ownership Definitions",
              "value": "Термины 'Own', 'Owned', 'Owner', 'Ownership' определяют владение или контроль за голосующими правами по ценным бумагам."
            },
            {
              "key": "Parent",
              "value": "Любая корпорация (за исключением Компании) в цепочке, где каждая компания, кроме Компании, владеет акциями с совокупной голосующей силой не менее 50% в одной из других компаний этой цепочки."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 160,
          "title": "Performance Criteria and Goals",
          "data": [
            {
              "key": "Participant Definition",
              "value": "Means a person to whom a Stock Award is granted pursuant to the Plan."
            },
            {
              "key": "Performance Criteria",
              "value": "The criteria established by the Company's Independent Directors or the Independent Compensation Committee for establishing the Performance Goals."
            },
            {
              "key": "Performance Goals",
              "value": "Goals established for a Performance Period based on Performance Criteria."
            },
            {
              "key": "Earnings Metrics",
              "value": "Earnings including earnings per share and net earnings; earnings before interest, taxes, depreciation, and amortization."
            },
            {
              "key": "Stockholder Return",
              "value": "Total stockholder return."
            },
            {
              "key": "Operational Metrics",
              "value": "Operating income; sales or revenue targets; expenses and cost reduction goals."
            },
            {
              "key": "Market Share and Customer Metrics",
              "value": "Market share; customer satisfaction; stockholders’ equity."
            },
            {
              "key": "Investor and Partner Relations",
              "value": "Investor relations; partner satisfaction."
            },
            {
              "key": "Clinical and Regulatory Achievements",
              "value": "Clinical achievements; regulatory milestones; submission of Device Master File(s)."
            },
            {
              "key": "Corporate Governance",
              "value": "Corporate governance and compliance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 161,
          "title": "Performance and Compensation Criteria",
          "data": [
            {
              "key": "Performance Period",
              "value": "Varies and is determined by Independent Directors or Compensation Committee."
            },
            {
              "key": "Exclusions from Performance Metrics",
              "value": "Nonrecurring charges, exchange rate effects, changes in accounting principles, tax rate adjustments, unusual items, dilutive effects of acquisitions, and others."
            },
            {
              "key": "Discretion of Directors",
              "value": "Directors can adjust compensation based on performance goals."
            },
            {
              "key": "Partial Achievement",
              "value": "Partial achievement may result in proportionate payment."
            },
            {
              "key": "Performance Stock Award Definition",
              "value": "Award granted under conditions of Section 6(c)(i)."
            },
            {
              "key": "Plan Definition",
              "value": "Atreca, Inc. 2023 Inducement Plan."
            },
            {
              "key": "Restricted Stock Award Definition",
              "value": "Award of Common Stock per Section 6(a)."
            },
            {
              "key": "Restricted Stock Unit Award Definition",
              "value": "Right to receive shares of Common Stock per Section 6(b)."
            },
            {
              "key": "Agreement Definitions",
              "value": "Documentation governing Restricted Stock and Restricted Stock Unit Awards."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 163,
          "title": "Stock Option Grant Details",
          "data": [
            {
              "key": "Optionholder: Date of Grant:",
              "value": "«Optionee» «GrantDate»"
            },
            {
              "key": "Vesting Commencement Date:",
              "value": "«VestingCommenceDate»"
            },
            {
              "key": "Number of Shares Subject to Option:",
              "value": "«NoofShares»"
            },
            {
              "key": "Exercise Price (Per Share):",
              "value": "«ExercisePrice»"
            },
            {
              "key": "Total Exercise Price:",
              "value": "«TotalExercisePrice»"
            },
            {
              "key": "Expiration Date:",
              "value": "«ExpirDate»"
            },
            {
              "key": "Type of Grant",
              "value": "Nonstatutory Stock Option"
            },
            {
              "key": "Exercise Schedule",
              "value": "Same as Vesting Schedule"
            },
            {
              "key": "Vesting Schedule",
              "value": "[VESTING SCHEDULE]"
            },
            {
              "key": "Payment",
              "value": "By cash, check, bank draft, wire transfer, money order, Regulation T Program, or net exercise arrangement"
            },
            {
              "key": "Additional Terms/Acknowledgements",
              "value": "Optionholder acknowledges receipt and agrees to the Stock Option Grant Notice, the Stock Option Agreement and the Plan. No modifications are allowed except as provided in the Plan."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 164,
          "title": "Stock Option Agreement Consent and Attachments",
          "data": [
            {
              "key": "Consent",
              "value": "By accepting this option, Optionholder consents to receive documents electronically and participate in the Plan via an online or electronic system."
            },
            {
              "key": "Company",
              "value": "ATRECA, INC."
            },
            {
              "key": "Attachments",
              "value": "Stock Option Agreement, 2023 Inducement Plan, Notice of Exercise"
            },
            {
              "key": "Signature Instructions",
              "value": "Optionholder to sign with Signature, Title, and Date"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 165,
          "title": "ATTACHMENT I ATRECA, INC. 2023 INDUCEMENT PLAN STOCK OPTION AGREEMENT",
          "data": [
            {
              "key": "Plan",
              "value": "2023 Inducement Plan"
            },
            {
              "key": "Company",
              "value": "Atreca, Inc."
            },
            {
              "key": "Option Type",
              "value": "Stock Option Agreement"
            },
            {
              "key": "Grant Details",
              "value": "Option granted per Stock Option Grant Notice with details on vesting, exercise price adjustments for Capitalization Adjustments, and exercise restrictions for Non-Exempt Employees."
            },
            {
              "key": "Key Provisions",
              "value": "Vesting per Stock Option Grant Notice; cessation of vesting upon termination of Continuous Service; exercise restrictions until six months of Continuous Service for Non-Exempt Employees unless qualified events occur (death/disability, corporate transaction, change in control, retirement termination)."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 166,
          "title": "Stock Option Exercise and Term Provisions",
          "data": [
            {
              "key": "Option Exercise Limitation",
              "value": "Only whole shares of Common Stock can be exercised."
            },
            {
              "key": "Securities Law Compliance",
              "value": "Shares issued upon exercise must be registered under the Securities Act or deemed exempt; exercise must comply with applicable laws and regulations including Treas. Reg. 1.401(k)-1(d)(3)."
            },
            {
              "key": "Option Term and Expiration",
              "value": "Exercise is restricted by the Date of Grant and various termination conditions (for Cause, non-Cause, Disability, or Death) with specified timeframes."
            },
            {
              "key": "Exercise Process",
              "value": "Involves delivering a Notice of Exercise, payment of the exercise price and applicable withholding taxes, and adherence to additional company procedures."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 167,
          "title": "Option Exercise and Transferability Provisions",
          "data": [
            {
              "key": "Tax Withholding Condition",
              "value": "By exercising the option, the holder agrees that the Company may require payment for any tax withholding obligation arising from the exercise or disposition of acquired shares."
            },
            {
              "key": "Lock-Up Period",
              "value": "Shares of Common Stock acquired upon exercise cannot be sold, transferred, or hedged for 180 days following the effective date of the Company registration statement, or a longer period if requested by underwriters or the Company for FINRA compliance. A repurchase option by the Company remains unaffected during this period."
            },
            {
              "key": "Transferability Restrictions",
              "value": "The option is non-transferable except by will or by laws of descent and distribution. Transfers are possible under certain conditions involving trusts, domestic relations orders, or beneficiary designations, each requiring written permission from the Board or designated representative and additional agreements."
            },
            {
              "key": "Right of Repurchase",
              "value": "The Company retains the right to repurchase shares acquired through option exercise if the holder’s Continuous Service terminates for Cause, at the exercise price paid."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 168,
          "title": "Stock Option Terms and Conditions",
          "data": [
            {
              "key": "OptionNature",
              "value": "Not an employment or service contract. Exercising the option does not obligate continuous employment or relationship with the Company or its affiliates."
            },
            {
              "key": "WithholdingObligations",
              "value": "Upon exercise, the Company is authorized to withhold sufficient shares or amounts to cover federal, state, local, and foreign tax withholding obligations."
            },
            {
              "key": "TaxConsequences",
              "value": "The Company does not guarantee minimization of tax liabilities; the option is subject to tax consequences and is exempt from Section 409A only under certain conditions."
            },
            {
              "key": "Notices",
              "value": "All notices regarding the option will be provided in writing, delivered electronically or by mail, and deemed effective upon receipt or after the prescribed mailing period."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 169,
          "title": "Stock Option Agreement Provisions",
          "data": [
            {
              "key": "Electronic Delivery Consent",
              "value": "You consent to receive documents by electronic delivery and to participate in the Plan through an online or electronic system."
            },
            {
              "key": "Governing Plan Document",
              "value": "Your option is subject to all Plan provisions, interpretations, amendments, and regulations."
            },
            {
              "key": "Recoupment of Compensation",
              "value": "Your option is subject to recoupment under The Dodd-Frank Act and any clawback policy of the Company."
            },
            {
              "key": "Effect on Other Employee Benefit Plans",
              "value": "The value of this option will not be included as compensation for calculating benefits under any employee benefit plan."
            },
            {
              "key": "Voting Rights",
              "value": "You will not have voting rights until shares are issued."
            },
            {
              "key": "Severability",
              "value": "If any part of the Agreement or Plan is declared unlawful, it does not invalidate the rest."
            },
            {
              "key": "No Advice Regarding Grant",
              "value": "The Company does not provide tax, legal, or financial advice related to the Plan."
            },
            {
              "key": "Electronics Delivery and Acceptance",
              "value": "The Company may decide to deliver documents related to the Plan by electronic means."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 170,
          "title": "Stock Option Agreement Terms",
          "data": [
            {
              "key": "Transferability of options",
              "value": "The rights and obligations of the Company under your option will be transferable to any one or more persons or entities."
            },
            {
              "key": "Advisory Review",
              "value": "You acknowledge and agree that you have reviewed your option in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option."
            },
            {
              "key": "Binding on Successors",
              "value": "All obligations of the Company under the Plan and this Stock Option Agreement will be binding on any successor to the Company."
            },
            {
              "key": "Compliance with Laws",
              "value": "This Stock Option Agreement will be subject to all applicable laws, rules, and regulations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 171,
          "title": "ATTACHMENT II 2023 INDUCEMENT PLAN For U.S. Participants",
          "data": [
            {
              "key": "Plan Type",
              "value": "Inducement Plan"
            },
            {
              "key": "Year",
              "value": "2023"
            },
            {
              "key": "Target Participants",
              "value": "U.S. Participants"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 172,
          "title": "Stock Option Exercise Form",
          "data": [
            {
              "key": "Document Header",
              "value": "ATTACHMENT III NOTICE OF EXERCISE"
            },
            {
              "key": "Company Name",
              "value": "Atreca, Inc."
            },
            {
              "key": "Company Address",
              "value": "835 INDUSTRIAL ROAD, SUITE 400 SAN CARLOS, CA 94070"
            },
            {
              "key": "Date of Exercise",
              "value": "______________ (to be completed)"
            },
            {
              "key": "Option Agreement Declaration",
              "value": "Election to purchase a specified number of Shares at a designated purchase price under stock option"
            },
            {
              "key": "Additional Obligations",
              "value": "Obligation to provide additional documents and to cover withholding obligations related to the exercise"
            },
            {
              "key": "Restrictions Post Exercise",
              "value": "No sale, transfer, short sale, or similar transactions for 180 days after the effective registration date under the Securities Act"
            },
            {
              "key": "Type of option",
              "value": "Nonstatutory"
            },
            {
              "key": "Stock option dated",
              "value": "null"
            },
            {
              "key": "Number of Shares as to which option is exercised",
              "value": "null"
            },
            {
              "key": "Certificates to be issued in name of",
              "value": "null"
            },
            {
              "key": "Total exercise price",
              "value": "null"
            },
            {
              "key": "Cash payment delivered herewith",
              "value": "null"
            },
            {
              "key": "Regulation T Program (cashless exercise)",
              "value": "null"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 174,
          "title": "Restricted Stock Unit Grant Notice",
          "data": [
            {
              "key": "Plan",
              "value": "2023 Inducement Plan"
            },
            {
              "key": "Award Type",
              "value": "Restricted Stock Unit Award"
            },
            {
              "key": "Company",
              "value": "Atreca, Inc."
            },
            {
              "key": "Purpose",
              "value": "Award as inducement for entering into employment with the Company"
            },
            {
              "key": "Vesting and Issuance",
              "value": "Vesting Schedule subject to continuous service; one share of Common Stock issued per vesting Restricted Stock Unit (subject to Capitalization Adjustment)"
            },
            {
              "key": "Additional Terms",
              "value": "Award governed by the Restricted Stock Unit Grant Notice, the Award Agreement, and the Plan, which supersede prior agreements except for specified exceptions"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 174,
          "title": "Restricted Stock Unit Grant Details",
          "data": [
            {
              "key": "Date of Grant",
              "value": ""
            },
            {
              "key": "Vesting Commencement Date",
              "value": ""
            },
            {
              "key": "Number of Restricted Stock Units",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 175,
          "title": "ATTACHMENTS: Restricted Stock Unit Award Agreement and 2023 Inducement Plan For U.S. Participants",
          "data": [
            {
              "key": "Document 1",
              "value": "Restricted Stock Unit Award Agreement"
            },
            {
              "key": "Document 2",
              "value": "2023 Inducement Plan For U.S. Participants"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 176,
          "title": "Atreca, Inc. 2023 Inducement Plan Restricted Stock Unit Award Agreement",
          "data": [
            {
              "key": "Award Type",
              "value": "Restricted Stock Unit Award"
            },
            {
              "key": "Plan",
              "value": "2023 Inducement Plan"
            },
            {
              "key": "Grant Basis",
              "value": "Award granted as material inducement for entering employment"
            },
            {
              "key": "Compliance",
              "value": "Granted in compliance with Nasdaq Listing Rule 5635(c)(4)"
            },
            {
              "key": "Vesting",
              "value": "Vesting schedule as provided in the Grant Notice; ceases upon termination of Continuous Service"
            },
            {
              "key": "Capital Adjustments",
              "value": "Number of Restricted Stock Units may be adjusted for Capitalization Adjustments per the Plan"
            },
            {
              "key": "Transfer Restrictions",
              "value": "Before issuance of Common Stock, the Award and underlying shares cannot be transferred, pledged, or sold"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 177,
          "title": "Restricted Stock Unit Award Agreement – Transfer and Issuance Terms",
          "data": [
            {
              "key": "Beneficiary Designation",
              "value": "U.S. Participants may designate a third party to receive their vested Restricted Stock Units upon death, subject to written notice to the Company."
            },
            {
              "key": "Transfer on Death",
              "value": "At death, vesting ceases and any vested but unissued shares become payable to the legal representative or designated beneficiary."
            },
            {
              "key": "Domestic Relations Orders",
              "value": "Transfers can be made pursuant to domestic relations orders (e.g., divorce or separation agreements) with proper board permissions and required agreements."
            },
            {
              "key": "Issuance Terms",
              "value": "Shares are issued on an Original Issuance Date in accordance with Treasury Regulations and company policies, with adjustments if the date is not a business day or falls outside permitted trading windows."
            },
            {
              "key": "Tax-Related Items",
              "value": "Issuance is subject to satisfaction of Tax-Related Items, with options including withholding shares or other arrangements as specified in the Award Agreement."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 178,
          "title": "Restricted Stock Unit Award Agreement Terms",
          "data": [
            {
              "key": "Delivery Date Condition",
              "value": "For U.S. Participants, shares that would be issued on the Original Issuance Date will instead be delivered on the first business day when selling is permitted, but no later than December 31 of the issuance year or, if compliant with Treasury Regulations Section 1.409A-1(b)(4), by the 15th day of the third calendar month of the following year."
            },
            {
              "key": "Dividends",
              "value": "No benefit or adjustment with respect to any cash dividend, stock dividend, or other distribution, unless the distribution results from a Capitalization Adjustment or occurs after share delivery."
            },
            {
              "key": "At-Will Employment and Award Terms",
              "value": "The Award does not constitute a service contract; continuous service is at-will, and neither the Award nor its vesting schedule guarantees continued employment or future compensation. The Company reserves the right to reorganize, which may affect vesting."
            },
            {
              "key": "Reorganization Impact",
              "value": "A reorganization (e.g., sale, spin-out, restructuring) may result in termination of Continuous Service or vesting rights under the Award."
            },
            {
              "key": "Tax Responsibility",
              "value": "The recipient is responsible for all applicable taxes (federal, state, local, and foreign) on the Award regardless of any actions taken by the Company or its Affiliate."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 179,
          "title": "Tax-Related Items in RSU Award Terms",
          "data": [
            {
              "key": "Scope",
              "value": "Covers U.S. Participants and tax obligations associated with Restricted Stock Units Award"
            },
            {
              "key": "Tax-Related Items",
              "value": "Participant's ultimate tax liability may exceed withholdings; includes obligations arising from grant, vesting, settlement, delivery or sale, and dividends"
            },
            {
              "key": "Withholding Methods",
              "value": "May include cash payments, wage withholding, share withholding (subject to fair market valuation and potential Board approval), and same day sale commitments via a FINRA Dealer"
            },
            {
              "key": "Responsibility and Indemnification",
              "value": "Participant acknowledges full responsibility for tax obligations and agrees not to claim against the Company, indemnifying the Company if insufficient tax is withheld"
            },
            {
              "key": "Jurisdictional Considerations",
              "value": "If subject to tax in multiple jurisdictions, tax withholding may be required in more than one jurisdiction"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 180,
          "title": "Tax Consequences and Award Agreement Terms",
          "data": [
            {
              "key": "Award Type",
              "value": "Restricted Stock Unit Award Agreement"
            },
            {
              "key": "Tax Consequences",
              "value": "The Company has no duty to minimize tax consequences and advises participants to consult personal tax, financial, or legal advisors."
            },
            {
              "key": "Obligation Status",
              "value": "Award is unfunded, making the holder an unsecured creditor until shares are issued."
            },
            {
              "key": "Notice Procedures",
              "value": "Notices or requests will be provided in writing (including electronically) with specific timelines for mail delivery."
            },
            {
              "key": "Additional Acknowledgements",
              "value": "Acceptance is voluntary, does not guarantee future awards, and participants release the Company from related claims."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 181,
          "title": "Restricted Stock Unit Award Agreement",
          "data": [
            {
              "key": "Award Agreement Provisions",
              "value": "Participants fully understand all provisions of the Award, and the agreement is subject to applicable laws, rules, regulations, and necessary governmental or exchange approvals."
            },
            {
              "key": "Successor Binding",
              "value": "All obligations under the Award Agreement bind any successor to the Company resulting from mergers, consolidations, or similar transactions involving most or all of its business and assets."
            },
            {
              "key": "Clawback Provisions",
              "value": "The Award, including any compensation paid or shares issued, is subject to recoupment under the Dodd–Frank Act, company clawback policies, and applicable law, without triggering a right to voluntary termination for 'good reason' or 'constructive termination.'"
            },
            {
              "key": "Governing Plan Document",
              "value": "The Award is governed by the Company’s Plan, including its interpretations, amendments, rules, and regulations, which are incorporated into the Award Agreement."
            },
            {
              "key": "Impact on Employee Benefits",
              "value": "The value of the Award is excluded from compensation calculations for other employee benefit plans, except as expressly provided by those plans."
            },
            {
              "key": "Amendment Process",
              "value": "The Award Agreement may only be amended in writing by both the participant and an authorized Company representative, or solely by the Board with proper notice, without materially adverse effects unless agreed in writing."
            },
            {
              "key": "Other Documents",
              "value": "Acknowledgment of receipt for the plan prospectus under Rule 428(b)(1), the share sale window policy, and the Insider Trading Policy."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 182,
          "title": "Restricted Stock Unit Award Agreement - Section 409A Compliance",
          "data": [
            {
              "key": "Document Type",
              "value": "Restricted Stock Unit Award Agreement"
            },
            {
              "key": "Section Reference",
              "value": "Section 409A of the Code"
            },
            {
              "key": "Compliance Intent",
              "value": "Award is intended to be exempt from Section 409A by complying with the short-term deferral rule, but will adjust to comply if determined to be deferred compensation."
            },
            {
              "key": "Issuance Adjustment",
              "value": "If determined subject to Section 409A and participant is a 'specified employee', issuance of shares will be delayed (lump sum issuance six months and one day after separation, or earlier in case of death) to avoid adverse tax consequences."
            },
            {
              "key": "Tax Responsibility",
              "value": "Participant is solely responsible for all taxes and costs under Section 409A or any other tax law."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 183,
          "title": "ATTACHMENT II 2023 INDUCEMENT PLAN For U.S. Participants",
          "data": [
            {
              "key": "Plan Name",
              "value": "2023 Inducement Plan"
            },
            {
              "key": "Target Participants",
              "value": "U.S. Participants"
            },
            {
              "key": "Document Type",
              "value": "Attachment"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 184,
          "title": "RSU Grant Details",
          "data": [
            {
              "key": "Award Type",
              "value": "Restricted Stock Unit Award"
            },
            {
              "key": "Plan",
              "value": "2023 Inducement Plan"
            },
            {
              "key": "Company",
              "value": "Atreca, Inc."
            },
            {
              "key": "Table - Date of Grant",
              "value": ""
            },
            {
              "key": "Table - Vesting Commencement Date",
              "value": ""
            },
            {
              "key": "Table - Number of Restricted Stock Units",
              "value": ""
            },
            {
              "key": "Vesting Schedule",
              "value": "[__________________], subject to Participant’s Continuous Service through each such vesting date"
            },
            {
              "key": "Issuance Schedule",
              "value": "Subject to any Capitalization Adjustment, one share of Common Stock will be issued for each Restricted Stock Unit that vests at the time set forth in Section 6 of the Award Agreement"
            },
            {
              "key": "Mandatory Sale to Cover Withholding Tax",
              "value": "As a condition to acceptance, shares will be sold to satisfy withholding tax obligations for applicable Tax-Related Items as determined under Section 9 of the Award Agreement"
            },
            {
              "key": "Additional Terms/Acknowledgements",
              "value": "Participant acknowledges receipt of, and agrees to, the Restricted Stock Unit Grant Notice, the Award Agreement, and the Plan, which supersede all prior agreements regarding this Award"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 185,
          "title": "Restricted Stock Unit Award and Inducement Plan Acknowledgment",
          "data": [
            {
              "key": "Award Details",
              "value": "Restricted Stock Unit Award – Participants acknowledge receipt of the Restricted Stock Unit Grant Notice, Award Agreement, and the Plan."
            },
            {
              "key": "Exceptions",
              "value": "Excludes equity awards previously granted, compensation recovery policies, and written employment or severance agreements with vesting acceleration provisions."
            },
            {
              "key": "Consent",
              "value": "Participant consents to electronic delivery of all documents and participation via an online system."
            },
            {
              "key": "Signatory",
              "value": "ATRECA, INC. PARTICIPANT (Signature, Title, Date)"
            },
            {
              "key": "Attachments",
              "value": "Restricted Stock Unit Award Agreement and 2023 Inducement Plan"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 186,
          "title": "Restricted Stock Unit Award Agreement",
          "data": [
            {
              "key": "Company",
              "value": "Atreca, Inc."
            },
            {
              "key": "Plan",
              "value": "2023 Inducement Plan"
            },
            {
              "key": "Award Type",
              "value": "Restricted Stock Unit Award Agreement"
            },
            {
              "key": "Grant Details",
              "value": "Award of Restricted Stock Units/shares of Common Stock as per Grant Notice; no payment required except future services"
            },
            {
              "key": "Vesting",
              "value": "Vesting occurs as per the schedule in the Grant Notice and ceases upon termination of Continuous Service"
            },
            {
              "key": "Adjustments",
              "value": "Number of shares may be adjusted for Capitalization Adjustments; fractional shares are rounded down"
            },
            {
              "key": "Compliance",
              "value": "In compliance with Nasdaq Listing Rule 5635(c)(4) and applicable securities laws"
            },
            {
              "key": "Transfer Restrictions",
              "value": "Shares cannot be transferred, pledged, sold, or disposed of before delivery"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 187,
          "title": "Restricted Stock Unit Award Agreement Terms",
          "data": [
            {
              "key": "Transfer Restrictions",
              "value": "For U.S. Participants, restrictions on transfer will lapse upon delivery of shares in respect of vested Restricted Stock Units."
            },
            {
              "key": "Beneficiary Designation",
              "value": "By delivering written notice, a third party may be designated to receive distributions in the event of the participant’s death; otherwise, the legal representative is entitled to receive the benefits."
            },
            {
              "key": "Death Provisions",
              "value": "At death, vesting ceases; however, any vested but unissued shares may be transferred to the estate via executor or administrator."
            },
            {
              "key": "Domestic Relations Orders",
              "value": "Rights to receive distributions can be transferred pursuant to domestic relations orders or marital settlement agreements upon meeting specified conditions and obtaining Board's permission."
            },
            {
              "key": "Date of Issuance",
              "value": "Shares are issued according to the 'Original Issuance Date', which is determined upon vesting and subject to Treasury Regulations, business day adjustments, and compliance with insider trading policies."
            },
            {
              "key": "Tax-Related Items",
              "value": "Issuance is contingent upon satisfying applicable Tax-Related Items, with options for withholding shares, entering into same-day sale commitments, or paying cash."
            },
            {
              "key": "Insider Trading Policy Considerations",
              "value": "Issuance may be deferred if it does not occur during an open window or if participant is restricted by the Company’s trading policy or a prior established 10b5-1 Arrangement."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 188,
          "title": "Restricted Stock Unit Award Agreement Clauses",
          "data": [
            {
              "key": "Share Delivery Conditions",
              "value": "For U.S. Participants, shares that would have been issued on the Original Issuance Date will instead be delivered on the first business day when selling is not prohibited in the open public market, but no later than December 31 of that calendar year, or per Treasury Regulations Section 1.409A-1(b)(4) if applicable."
            },
            {
              "key": "Dividends",
              "value": "No cash dividend, stock dividend, or other distribution benefit will be provided with respect to the Award, except for adjustments resulting from a Capitalization Adjustment, unless shares have already been delivered."
            },
            {
              "key": "Service Contract Status",
              "value": "The Award is expressly not a service contract; continuous service is not guaranteed, and employment can be terminated at will. The Award does not confer any promise of future employment or benefits."
            },
            {
              "key": "Vesting and Termination",
              "value": "Vesting in the Award is contingent upon continued service and may be terminated at any time, with or without cause or notice. A reorganization by the Company may also result in the termination of vesting rights and associated benefits."
            },
            {
              "key": "Tax Responsibilities",
              "value": "The Award outlines that the participant is responsible for all applicable federal, state, local, and foreign taxes, including income tax, social insurance, payroll tax, and others."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 189,
          "title": "Tax Withholding Provisions for RSU Award",
          "data": [
            {
              "key": "Plan",
              "value": "Restricted Stock Units Award for U.S. Participants"
            },
            {
              "key": "Tax Responsibility",
              "value": "Participant remains ultimately liable for all Tax-Related Items, which may exceed the amounts withheld by the Company or Employer."
            },
            {
              "key": "Withholding Methods",
              "value": "Includes a ‘same day sale’ commitment via a FINRA Dealer, and alternative methods such as wage/cash compensation withholding, share withholding (subject to Board/Compensation Committee approval), or a cash payment."
            },
            {
              "key": "Multi-Jurisdictional Consideration",
              "value": "If subject to Tax-Related Items in more than one jurisdiction, withholding or accounting may be required in each respective jurisdiction."
            },
            {
              "key": "Agent Appointment",
              "value": "Morgan Stanley (or a successor agent) is appointed to execute the sale of shares to satisfy withholding obligations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 190,
          "title": "Restricted Stock Units Vesting and Sales Provisions",
          "data": [
            {
              "key": "Restricted Stock Units",
              "value": "Shares of Common Stock vest and are issued to cover withholding obligations for Tax-Related Items and applicable fees."
            },
            {
              "key": "Agent Role",
              "value": "Authorized to sell the necessary shares—potentially in multiple transactions—and assign the average execution price to the participant’s account."
            },
            {
              "key": "Sales Limitations",
              "value": "Sales may be affected by legal or contractual restrictions, market disruptions, order execution rules, or applicable laws."
            },
            {
              "key": "Participant Liability",
              "value": "If the Agent is unable to sell shares, the participant remains responsible for timely payment of all Tax-Related Items."
            },
            {
              "key": "Section Termination",
              "value": "Terminates when all Tax-Related Items associated with the Award have been satisfied."
            },
            {
              "key": "Opt-Out Provision",
              "value": "Officers can opt out of the ‘same day sale’ commitment by providing notice five or more business days prior to a vesting date, given alternative arrangements."
            },
            {
              "key": "Successor Agent",
              "value": "The Company is authorized to appoint a successor Agent if the current Agent resigns or is replaced."
            },
            {
              "key": "Indemnification",
              "value": "Participant agrees to indemnify the Company and Employer for any shortfall in withholding of Tax-Related Items."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 191,
          "title": "Restricted Stock Unit Award Agreement – Key Terms",
          "data": [
            {
              "key": "Tax Consequences",
              "value": "The Company disclaims any duty to minimize the tax consequences of the Award. Participants are advised to consult their own tax, financial, and legal advisors regarding any adverse tax implications."
            },
            {
              "key": "Unsecured Obligation",
              "value": "The Award is unfunded. Once vested, participants are considered unsecured creditors of the Company with respect to any obligation to issue shares or other property. Voting and other stockholder rights are only granted upon issuance of shares as outlined in Section 6."
            },
            {
              "key": "Notices",
              "value": "All notices or requests under the Award will be provided in writing, either electronically or via mail, with specific effective times upon receipt or after five days for mailed notices."
            },
            {
              "key": "Additional Acknowledgements",
              "value": "By accepting the Award, participants acknowledge that receipt is voluntary, the future value of the Award is uncertain, no claim for future awards is implied, and that various terms such as transferability and agreement to execute further documentation apply."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 192,
          "title": "Restricted Stock Unit Award Agreement",
          "data": [
            {
              "key": "Award Provisions",
              "value": "Participants fully understand all provisions of the Award."
            },
            {
              "key": "Governing Law",
              "value": "Subject to all applicable laws, rules, and regulations."
            },
            {
              "key": "Binding Obligations",
              "value": "Obligations of the Company binding on any successor."
            },
            {
              "key": "Clawback Policy",
              "value": "Subject to recoupment in accordance with Dodd–Frank Act."
            },
            {
              "key": "Governing Plan Document",
              "value": "Subject to provisions of the Plan."
            },
            {
              "key": "Employee Benefits Impact",
              "value": "Value of the Award not included in calculating benefits under other plans."
            },
            {
              "key": "Severability",
              "value": "Unlawful or invalid portions do not invalidate the entire agreement."
            },
            {
              "key": "Other Documents",
              "value": "Acknowledgment of receipt of required documents."
            },
            {
              "key": "Amendment",
              "value": "Agreement may not be modified except in writing."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 193,
          "title": "COMPLIANCE WITH SECTION 409A OF THE CODE",
          "data": [
            {
              "key": "Applicable Regulation",
              "value": "For U.S. Participants regulation, ruling, or judicial decision applicable only to rights relating to that portion of the Award subject to restrictions."
            },
            {
              "key": "Section 409A Compliance",
              "value": "This Award is intended to be exempt from the application of Section 409A of the Code, complying with the 'short-term deferral' rule in Treasury Regulation Section 1.409A-1(b)(4)."
            },
            {
              "key": "Exemption Ambiguity",
              "value": "Any ambiguities in application will be interpreted accordingly, ensuring compliance with Section 409A where necessary."
            },
            {
              "key": "Deferred Compensation Adjustment",
              "value": "If the Award fails to satisfy the short-term deferral rule and is deemed deferred compensation subject to Section 409A, it will be adjusted to avoid adverse personal tax consequences."
            },
            {
              "key": "Share Issuance Timing",
              "value": "For 'specified employees' at the time of separation, share issuance will be delayed to six months and one day after separation (or earlier upon death), with installments treated as separate payments."
            },
            {
              "key": "Tax Responsibility",
              "value": "Under no circumstances will the Company reimburse taxes or other costs under Section 409A or any other tax law; all such costs are the responsibility of the participant."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_rnd_investment_numbers": {
      "value": true,
      "elements": [
        {
          "type": "rnd_investment",
          "page": 70,
          "title": "Management’s Discussion and Analysis of Financial Condition and Results of Operations",
          "data": [
            {
              "key": "Overview",
              "value": "Clinical-stage biopharmaceutical company leveraging a differentiated antibody discovery platform to develop novel therapeutics for solid tumors."
            },
            {
              "key": "Product Candidate",
              "value": "ATRC-101, a monoclonal antibody with a novel mechanism of action, currently in Phase 1b clinical trials."
            },
            {
              "key": "Clinical Development",
              "value": "Clinical progress includes initiation of Phase 1b trials as monotherapy and in combination (with pembrolizumab); trial enrollment ongoing with future Phase 2 decisions expected later in 2023."
            },
            {
              "key": "Pipeline Expansion",
              "value": "Efforts to advance additional product candidates such as APN-497444 (an ADC) and APN-346958 (a CD3 bispecific T-cell engager) as part of ongoing R&D investments; planning for one additional IND per year with next IND targeted in late 2024."
            },
            {
              "key": "Strategic Collaboration",
              "value": "Joint program with Xencor, Inc. leveraging Atreca-discovered antibody combined with Xencor’s XmAb® bispecific Fc domain for enhanced anti-tumor activity."
            },
            {
              "key": "Forward-Looking Information",
              "value": "Includes risk factors and uncertainties related to clinical outcomes and long-term development plans, as noted in the discussion and referenced risk factor sections."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 71,
          "title": "Table of Contents: Increase in IFN gamma levels & CD8+ T cells; Preclinical Pipeline and Product Candidate Updates",
          "data": [
            {
              "key": "Preclinical Pipeline Update",
              "value": "Update on oncology preclinical pipeline; announcement of next clinical candidate ATRC-301, an ADC targeting a novel epitope on EphA2."
            },
            {
              "key": "IND-Enabling Studies",
              "value": "Initiation of IND-enabling studies for ATRC-301, including a non-human primate toxicology study in September 2022."
            },
            {
              "key": "Product Candidate Discontinuation",
              "value": "In November 2022, safety signals (including bleeding) led to discontinuation of ATRC-301 development."
            },
            {
              "key": "Malaria Licensing Agreement",
              "value": "Entered a licensing agreement in October 2021 with the Bill & Melinda Gates Medical Research Institute to develop MAM01/ATRC-501 for malaria prevention."
            },
            {
              "key": "Future IND and Clinical Development",
              "value": "An IND for MAM01/ATRC-501 is expected to be filed in the first half of 2023, with clinical development anticipated in the second half of 2023."
            },
            {
              "key": "R&D Focus and Financial Overview",
              "value": "Company has focused substantially on R&D since 2010; reported net losses of $97.2M in 2022 and $109.3M in 2021, with an accumulated deficit of $456.9M and cash resources of $70.5M as of December 31, 2022."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 90,
          "title": "Notes to Financial Statements - ATRECA, INC. (Table of Contents)",
          "data": [
            {
              "key": "Xencor Collaboration Agreement",
              "value": "In July 2020, ATRECA, INC. entered into a Collaboration and License Agreement with Xencor, Inc. to research, develop and commercialize novel CD3 bispecific antibodies for oncology. The agreement established a three-year research program with joint cost and profit sharing, where each partner may lead development, regulatory, and commercialization activities."
            },
            {
              "key": "In-Licensing Agreement with Zymeworks",
              "value": "In April 2022, the Company entered into an Option and License Agreement with Zymeworks Inc. to obtain a license under certain proprietary drug conjugate patents and know-how. The research license, valued at an aggregate of $5.0 million and expensed as a research and development cost, includes options for exclusive licensing with tiered milestone payments and royalties."
            },
            {
              "key": "Research Cost Sharing and Expense Recognition",
              "value": "The Company evaluated the Xencor Agreement under ASC 606 and ASU 2018-18, recognizing its share of collaboration expenses as research and development expense. There are related payable and receivable amounts recorded under research cost-sharing provisions."
            },
            {
              "key": "Employee Retention Credit (ERC)",
              "value": "Under the CARES Act, the Company determined an eligible refundable credit of $2.9 million for 2021. The ERC was applied as a reduction to payroll expense, with amounts of $2.4 million and $0.5 million recorded within research and development and general and administrative expenses, respectively."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 93,
          "title": "ATRECA, INC. - Notes to Financial Statements",
          "data": [
            {
              "key": "Research and Development Costs",
              "value": "Costs are expensed as incurred and primarily consist of salaries and benefits, consultant fees, stock-based compensation, facility costs, legal costs and other development-related expenses. A significant portion of R&D activities is outsourced to third-party service providers for preclinical and clinical development and contract manufacturing for clinical trial materials. Payments are compared to estimated progress toward development objectives, with adjustments reflected as net prepaid or accrued expenses."
            },
            {
              "key": "Stock-Based Compensation",
              "value": "The Company grants stock options to employees at an exercise price equal to the fair value at the date of grant. The fair value of options is determined using the Black-Scholes model, while restricted stock units are valued based on the closing price of Class A common stock on the grant date. Compensation expense is recognized as the options vest using a straight-line attribution approach, with adjustments for forfeitures."
            },
            {
              "key": "Emerging Growth Company Status",
              "value": "The Company qualifies as an Emerging Growth Company (EGC) under the JOBS Act, allowing it to take advantage of exemptions from certain reporting requirements and to use an extended transition period for new or revised accounting standards until it no longer qualifies as an EGC."
            },
            {
              "key": "Income Taxes",
              "value": "The Company applies FASB ASC Topic 740 to account for income taxes, including uncertainty in tax positions and valuation allowances on deferred tax assets. Income tax returns are prepared for various jurisdictions with positions based on the Company’s interpretation of tax laws, and tax benefits are recognized only if sustained by technical merits."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_new_product_launches": {
      "value": true,
      "elements": [
        {
          "type": "product_launch",
          "page": 7,
          "title": "Table of Contents PART I Item 1. Business Overview",
          "data": [
            {
              "key": "Company Description",
              "value": "Clinical-stage biopharmaceutical company focused on discovering and developing novel antibody-based therapeutics to treat solid tumors."
            },
            {
              "key": "Core Platform",
              "value": "Utilizes a differentiated discovery platform that leverages the human immune system to identify unique antibody-target pairs from patients with active immune responses."
            },
            {
              "key": "Product Candidate: ATRC-101",
              "value": "A monoclonal antibody with a novel mechanism of action. It is in Phase 1b clinical trials as a monotherapy and in combination with pembrolizumab. Demonstrated robust anti-tumor activity in preclinical models with 69 participants enrolled as of December 31, 2022."
            },
            {
              "key": "Pipeline Expansion",
              "value": "Focus on advancing additional product candidates. Lead-stage oncology programs include APN-497444 (an ADC targeting a novel tumor glycan) and APN-346958 (a CD3 bispecific T-cell engager targeting an RNA-binding protein)."
            },
            {
              "key": "Strategic Collaboration",
              "value": "Joint program with Xencor, Inc. combining an Atreca-discovered antibody with Xencor’s XmAb® bispecific Fc domain, based on APN-346958."
            },
            {
              "key": "Discontinued Candidate",
              "value": "ATRC-301, an ADC targeting EphA2, was discontinued following non-human primate toxicology studies that revealed safety signals including bleeding."
            },
            {
              "key": "Future Plans",
              "value": "Plans include making additional IND submissions (one per year in oncology) with next IND targeted for late 2024, and potential Phase 2 development decisions for ATRC-101 in late 2023."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 8,
          "title": "Licensing Agreement and Product Development Strategy",
          "data": [
            {
              "key": "Agreement",
              "value": "Licensing agreement with the Bill & Melinda Gates Medical Research Institute to develop and commercialize MAM01/ATRC-501."
            },
            {
              "key": "Purpose",
              "value": "Prevent malaria in GAVI eligible countries."
            },
            {
              "key": "IND Filing",
              "value": "IND for MAM01/ATRC-501 expected to be filed by Gates MRI in first half of 2023."
            },
            {
              "key": "Clinical Development",
              "value": "Gates MRI expects to commence clinical development by the second half of 2023."
            },
            {
              "key": "Product Candidate",
              "value": "ATRC-101 is the first candidate identified using the discovery platform that has advanced into a clinical trial."
            },
            {
              "key": "Clinical Trials",
              "value": "ATRC-101 being advanced through clinical trials for multiple solid tumors."
            },
            {
              "key": "Discovery Strategy",
              "value": "Focus on developing a pipeline of antibody-based product candidates for oncology."
            },
            {
              "key": "Collaborations",
              "value": "Selective collaborations to enhance and expand product pipeline."
            },
            {
              "key": "Investments",
              "value": "Continued investment in discovery platform and expansion of sample repository."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 9,
          "title": "Atreca Drug Discovery Platform",
          "data": [
            {
              "key": "Overview",
              "value": "The Atreca Drug Discovery Platform aims to address limitations in oncology drug discovery by focusing on the active human anti-tumor immune response."
            },
            {
              "key": "Unique Approach",
              "value": "Utilizes samples from cancer patients to interrogate active B cell responses to identify relevant antibodies."
            },
            {
              "key": "Key Features",
              "value": "Plans to expand intellectual property portfolio to protect novel product candidates through patents."
            },
            {
              "key": "Investment in Infrastructure",
              "value": "Considerable capital and time invested in developing industrialized wet-lab facilities and bioinformatics capacity."
            },
            {
              "key": "Sample Repository",
              "value": "Established a repository of over 1,800 blood samples from over 500 cancer patients, facilitating extensive research."
            },
            {
              "key": "Antibody Generation Process",
              "value": "Employs a multi-step process that includes isolating plasmablasts, using proprietary technologies, and synthesizing recombinant proteins."
            },
            {
              "key": "Target Analysis",
              "value": "Identifies and characterizes targets for antibody candidates prior to preclinical development."
            },
            {
              "key": "Innovation",
              "value": "Focuses on over 2,000 hit antibodies with potential for drug development."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 10,
          "title": "ATRC-101 Product Launch",
          "data": [
            {
              "key": "Product Name",
              "value": "ATRC-101"
            },
            {
              "key": "Type",
              "value": "Monoclonal Antibody"
            },
            {
              "key": "Applications",
              "value": "Immunotherapeutic agent for solid tumors"
            },
            {
              "key": "Target",
              "value": "Ribonucleoprotein (RNP) complex"
            },
            {
              "key": "Clinical Trials Start Date",
              "value": "Early 2020"
            },
            {
              "key": "Patents Filed",
              "value": "Multiple U.S. provisional patent applications"
            },
            {
              "key": "Current Status",
              "value": "Well tolerated with longer progression-free survival observed"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 12,
          "title": "Table of Contents and Pipeline Update",
          "data": [
            {
              "key": "Program",
              "value": "Joint program based on APN-346958 targeting a cytotoxic T-cell binding domain (CD3)"
            },
            {
              "key": "Partner",
              "value": "Atreca and Xencor"
            },
            {
              "key": "Preclinical Results",
              "value": "XmAb bispecific antibody showed compelling anti-tumor activity with increased IFN gamma levels and expansion of CD8+ T cells in blood"
            },
            {
              "key": "Candidate Naming",
              "value": "Expected later this year"
            },
            {
              "key": "IND Submission Target",
              "value": "Planned no later than early 2025"
            },
            {
              "key": "ADC Development",
              "value": "License Agreement with Zymeworks for ZymeLink technology; ATRC-301 candidate (ADC) was initiated but later discontinued due to safety signals; ongoing evaluation includes APN-497444 as an ADC candidate"
            },
            {
              "key": "ADC Strategy",
              "value": "Utilizes antibody-drug conjugates via internalization assays and payload release to generate cytotoxicity against tumor cells"
            },
            {
              "key": "Manufacturing Strategy",
              "value": "Outsourced to third-party manufacturers (CDMOs) for cGMP production of clinical trial materials"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 194,
          "title": "2023 Inducement Plan for U.S. Participants",
          "data": [
            {
              "key": "1. Plan Overview",
              "value": "The 2023 Inducement Plan aims to attract and retain key talent through equity awards."
            },
            {
              "key": "2. Eligibility",
              "value": "Participants must be U.S. residents and meet specific performance criteria."
            },
            {
              "key": "3. Award Types",
              "value": "Includes stock options, restricted stock units, and performance shares."
            },
            {
              "key": "4. Grant Date",
              "value": "Awards will be granted at the discretion of the Board."
            },
            {
              "key": "5. Vesting Schedule",
              "value": "Standard vesting schedule applies unless otherwise specified."
            },
            {
              "key": "6. Plan Duration",
              "value": "The Plan will remain effective until 2028."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_capital_expenditures": {
      "value": true,
      "elements": [
        {
          "type": "capital_expenditure",
          "page": 87,
          "title": "Supplemental Disclosure of Cash Flow Information",
          "data": [
            {
              "key": "Category: Cash paid for interest",
              "value": "2022: (not provided), 2021: (not provided)"
            },
            {
              "key": "Category: Cash paid for income taxes",
              "value": "2022: (not provided), 2021: (not provided)"
            },
            {
              "key": "Category: Costs related to \"at-the-market\" offering included in accounts payable",
              "value": "2022: (not provided), 2021: 13"
            },
            {
              "key": "Category: Purchases of property and equipment included in accounts payable and accrued liabilities",
              "value": "2022: 13, 2021: 33"
            },
            {
              "key": "Summary",
              "value": "This table presents supplemental cash flow information and non-cash investing and financing activities for 2021-2022. It notes a decrease in property and equipment purchases from $33 in 2021 to $13 in 2022, and discloses at-the-market offering costs of $13 in 2021."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 97,
          "title": "Property and Equipment Breakdown",
          "data": [
            {
              "key": "Category - Laboratory equipment",
              "value": "2022: 13,191; 2021: 13,128"
            },
            {
              "key": "Category - Furniture and fixtures",
              "value": "2022: 1,929; 2021: 1,897"
            },
            {
              "key": "Category - Computer hardware and software",
              "value": "2022: 1,518; 2021: 1,433"
            },
            {
              "key": "Category - Leasehold improvements",
              "value": "2022: 37,908; 2021: 37,871"
            },
            {
              "key": "Category - Construction in process",
              "value": "2022: 178; 2021: —"
            },
            {
              "key": "Subtotal (before depreciation)",
              "value": "2022: 54,724; 2021: 54,329"
            },
            {
              "key": "Less accumulated depreciation and amortization",
              "value": "2022: (16,752); 2021: (11,314)"
            },
            {
              "key": "Depreciation & Amortization Expense",
              "value": "2022: $5.5 million; 2021: $4.5 million"
            },
            {
              "key": "Impairment Expense",
              "value": "2022: $0.4 million; 2021: None"
            },
            {
              "key": "Summary",
              "value": "The table compares property and equipment values between 2022 and 2021. Leasehold improvements represent the largest asset, and accumulated depreciation increased significantly from 2021 to 2022."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 97,
          "title": "Accrued Expenses Comparison 2021-2022",
          "data": [
            {
              "key": "Compensation and related benefits",
              "value": "2022: 3,789; 2021: 4,866"
            },
            {
              "key": "License fees",
              "value": "2022: 3,000; 2021: N/A"
            },
            {
              "key": "Contract research fees",
              "value": "2022: 2,201; 2021: 5,521"
            },
            {
              "key": "Professional fees",
              "value": "2022: 128; 2021: 189"
            },
            {
              "key": "Lease use",
              "value": "2022: N/A; 2021: 475"
            },
            {
              "key": "Other",
              "value": "2022: N/A; 2021: 504"
            },
            {
              "key": "Total accrued expenses",
              "value": "2022: N/A; 2021: 11,555"
            },
            {
              "key": "Summary",
              "value": "There is an overall decrease in several accrued expense categories from 2021 to 2022, notably in compensation benefits and contract research fees."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 97,
          "title": "Lease Disclosures",
          "data": [
            {
              "key": "Office Lease Terms",
              "value": "The Company leases its office facilities under non-cancellable operating lease agreements with scheduled increases through April 2033. The former office space was vacated in September 2021, with a $1.5 million expense recorded relating to remaining rent and associated charges."
            },
            {
              "key": "Lease Liability Settlement",
              "value": "The cease-use liability associated with the former office space was settled by March 2022."
            },
            {
              "key": "Presentation",
              "value": "Future lease payments are shown as the current portion of operating lease liabilities and operating lease liabilities (net of current portion) on the balance sheet."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_financial_performance_indicators": {
      "value": true,
      "elements": [
        {
          "type": "financial_performance",
          "page": 26,
          "title": "Risks Related to Our Business",
          "data": [
            {
              "key": "Company Type",
              "value": "Clinical-stage biopharmaceutical company"
            },
            {
              "key": "History of Losses",
              "value": "Yes"
            },
            {
              "key": "Accumulated Deficits",
              "value": "$456.9 million as of December 31, 2022"
            },
            {
              "key": "Net Losses 2022",
              "value": "$97.2 million"
            },
            {
              "key": "Net Losses 2021",
              "value": "$109.3 million"
            },
            {
              "key": "Revenue Generated",
              "value": "None"
            },
            {
              "key": "Product Candidates",
              "value": "ATRC-101 and others"
            },
            {
              "key": "Future Profitability Uncertainty",
              "value": "High"
            },
            {
              "key": "Need for Additional Funding",
              "value": "Yes"
            },
            {
              "key": "Going Concern Assessment",
              "value": "Substantial doubt raised by management"
            },
            {
              "key": "Funding Measures Planned",
              "value": "Equity financing in FY 2023, reduced spending in FY 2023 and 2024"
            },
            {
              "key": "Likelihood of Achieving Funding",
              "value": "Probable but uncertain"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 73,
          "title": "Operating Expenses and Other Income Comparison 2022-2021",
          "data": [
            {
              "key": "Summary",
              "value": "The table presents a comparative financial statement for the years ended December 31, 2022 and 2021. Total operating expenses decreased by 10% (from $110.3M to $98.7M), research and development expenses declined by 15% (a reduction of $11.5M), interest income increased by 295%, and net loss improved by 11% (from $109.3M to $97.2M)."
            },
            {
              "key": "Key Categories",
              "value": "Research and development, General and administrative, Asset impairment, Other income, Interest income, Loss on disposal of property and equipment, and Net Loss."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 73,
          "title": "Research and Development Expenses Comparison (December 31, 2022-2021)",
          "data": [
            {
              "key": "Summary",
              "value": "This table breaks down R&D expenses by category. Notable points include a decrease in personnel-related expenses by $6.5M due to restructuring and terminations, a reduction in laboratory supplies and equipment by $4.4M owing to lower headcount, decreased facility related costs by $3.7M due to consolidation to a single location, and a $2.1M decrease in consulting, legal and other services. These decreases were partially offset by the introduction of a $5.0M research license fee for preclinical research. The total R&D expense for 2021 was $78.349M and the 2022 total is not explicitly provided."
            },
            {
              "key": "Expense Categories",
              "value": "Personnel related (including stock-based compensation), Product and other contract services, Laboratory supplies and equipment, Consulting, legal and other services, Research license fees, Facility related, and Other."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 74,
          "title": "General and Administrative Expenses Comparison and Financial Performance Overview",
          "data": [
            {
              "key": "R&D Clinical Asset (ATRC-101) Cost Share",
              "value": "12.0% in 2022 and 12.8% in 2021 of total R&D expenses"
            },
            {
              "key": "Personnel related expenses (including stock-based compensation) 2022",
              "value": "17113 (in thousands)"
            },
            {
              "key": "Personnel related expenses (including stock-based compensation) 2021",
              "value": "17135 (in thousands)"
            },
            {
              "key": "Consulting, legal and other services 2022",
              "value": "4585 (in thousands)"
            },
            {
              "key": "Consulting, legal and other services 2021",
              "value": "3219 (in thousands)"
            },
            {
              "key": "Facility related expenses 2022",
              "value": "2823 (in thousands)"
            },
            {
              "key": "Facility related expenses 2021",
              "value": "3509 (in thousands)"
            },
            {
              "key": "Other expenses 2022",
              "value": "6945 (in thousands)"
            },
            {
              "key": "Other expenses 2021",
              "value": "8091 (in thousands)"
            },
            {
              "key": "Total general and administrative expenses 2022",
              "value": "31466 (in thousands)"
            },
            {
              "key": "General and administrative expenses change",
              "value": "Decreased by $0.5M (2%) in 2022 compared to 2021; influenced by a one-time $1.5M cease-use expense in Q3 2021, lower facility costs ($0.7M reduction), and offset by a $1.4M increase in consulting/legal services"
            },
            {
              "key": "Asset impairment expense 2022",
              "value": "$0.4M recognized (no impairment in 2021)"
            },
            {
              "key": "Other income change",
              "value": "Decreased by $0.1M in 2022 due to completion of services for a third party partner"
            },
            {
              "key": "Interest income",
              "value": "Increased to $0.8M in 2022 from $0.2M in 2021, driven by higher market interest rates offset by lower investment balance"
            },
            {
              "key": "Cash, cash equivalents and investments as of Dec 31, 2022",
              "value": "$70.5M"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 76,
          "title": "Cash Flow Summary and Operating Cash Flows",
          "data": [
            {
              "key": "Operating Cash Flow (2022)",
              "value": "-$80.7 million"
            },
            {
              "key": "Net Loss (2022)",
              "value": "-$97.2 million"
            },
            {
              "key": "Change in Operating Assets and Liabilities (2022)",
              "value": "$8.0 million"
            },
            {
              "key": "Non-cash Charges (2022)",
              "value": "$24.5 million"
            },
            {
              "key": "Investing Activities (2022)",
              "value": "$12.5 million"
            },
            {
              "key": "Financing Activities (2022)",
              "value": "$3.9 million"
            },
            {
              "key": "Net Increase/Decrease in Cash (2022)",
              "value": "-$64.3 million"
            },
            {
              "key": "Operating Lease Base Rent",
              "value": "$557,519 per month"
            },
            {
              "key": "Lease Term",
              "value": "August 2020 to April 2033"
            },
            {
              "key": "Additional Funding Concerns",
              "value": "Potential delays or cancellations in clinical and R&D programs if adequate financing is not secured"
            },
            {
              "key": "Summary",
              "value": "The cash flow table compares 2022 and 2021, showing a significant deterioration in cash position in 2022 with increased net losses and lower investing and financing inflows."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 77,
          "title": "Cash Flow Analysis and Critical Accounting Policies",
          "data": [
            {
              "key": "Prepaid Expenses Increase (2022)",
              "value": "$2.4 million"
            },
            {
              "key": "Operating Lease Liabilities Decrease (2022)",
              "value": "$3.2 million"
            },
            {
              "key": "Account Payables Decrease (2022)",
              "value": "$1.6 million"
            },
            {
              "key": "Non-Cash Charges - Depreciation & Amortization (2022)",
              "value": "$5.5 million"
            },
            {
              "key": "Non-Cash Charges - Stock-Based Compensation (2022)",
              "value": "$16.9 million"
            },
            {
              "key": "Non-Cash Charges - Right-of-Use Asset Amortization (2022)",
              "value": "$1.6 million"
            },
            {
              "key": "Operating Cash Used (2021)",
              "value": "$60.9 million"
            },
            {
              "key": "Net Loss (2021)",
              "value": "$109.3 million"
            },
            {
              "key": "Total Non-Cash Charges (2021)",
              "value": "$23.0 million"
            },
            {
              "key": "Non-Cash Charge - Depreciation & Amortization (2021)",
              "value": "$4.6 million"
            },
            {
              "key": "Non-Cash Charge - Stock-Based Compensation (2021)",
              "value": "$16.9 million"
            },
            {
              "key": "Increase in Deferred Rent (2021)",
              "value": "$16.7 million"
            },
            {
              "key": "Increase in Accrued Expenses (2021)",
              "value": "$5.4 million"
            },
            {
              "key": "Decrease in Prepaid Expenses (2021)",
              "value": "$3.0 million"
            },
            {
              "key": "Increase in Account Payables (2021)",
              "value": "$1.3 million"
            },
            {
              "key": "Decrease in Other Current Liabilities (2021)",
              "value": "$0.9 million"
            },
            {
              "key": "Investing Cash Provided (2022)",
              "value": "$12.5 million"
            },
            {
              "key": "Net Proceeds from Investment Maturities (2022)",
              "value": "$13.4 million"
            },
            {
              "key": "Purchases of Property and Equipment (2022)",
              "value": "$0.9 million"
            },
            {
              "key": "Investing Cash Provided (2021)",
              "value": "$89.2 million"
            },
            {
              "key": "Net Proceeds from Investment Maturities (2021)",
              "value": "$124.3 million"
            },
            {
              "key": "Purchases of Property and Equipment (2021)",
              "value": "$35.1 million"
            },
            {
              "key": "Financing Cash Provided (2022)",
              "value": "$3.9 million"
            },
            {
              "key": "Class A Stock Sales Proceeds (2022)",
              "value": "$3.5 million"
            },
            {
              "key": "ESPP Proceeds (2022)",
              "value": "$0.3 million"
            },
            {
              "key": "Stock Option Exercises Proceeds (2022)",
              "value": "$0.1 million"
            },
            {
              "key": "Financing Cash Provided (2021)",
              "value": "$5.4 million"
            },
            {
              "key": "Common Stock Sales Proceeds (2021)",
              "value": "$4.4 million"
            },
            {
              "key": "ESPP Proceeds (2021)",
              "value": "$0.8 million"
            },
            {
              "key": "Stock Option Exercises Proceeds (2021)",
              "value": "$0.3 million"
            },
            {
              "key": "Critical Accounting Policies and Estimates",
              "value": "Management’s discussion on estimates and assumptions affecting asset/liability valuations and revenue/expense recognition."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 78,
          "title": "Impairment of Long-Lived Assets, R&D Expenses and Stock-Based Compensation Disclosures",
          "data": [
            {
              "key": "Asset Impairment",
              "value": "In accordance with ASC 360-10, the company reviews long-lived assets for impairment. If undiscounted future cash flows are insufficient to recover the carrying amounts, the assets are written down to their estimated fair values and the loss is recognized in the Statements of Operations and Comprehensive Loss."
            },
            {
              "key": "Research and Development Expenses",
              "value": "R&D costs are expensed as incurred, including personnel costs, fees for preclinical studies, clinical trials, research services, laboratory supplies, equipment maintenance and depreciation, intellectual property licenses, and consulting costs. Expenses are estimated based on service progress and contractual agreements with third-party providers."
            },
            {
              "key": "Stock-Based Compensation",
              "value": "The company maintains a stock-based compensation plan for employees, consultants, and board members. Awards such as non-statutory options, incentive stock options, restricted stock, and restricted stock units are measured using fair value (via the Black-Scholes option pricing model) and recognized as expense over the service period."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 80,
          "title": "Financial Statements Index",
          "data": [
            {
              "key": "Summary",
              "value": "This table appears to be a table of contents or index for a financial report, showing the page numbers for various financial statements and documents covering the years 2021 and 2022. It includes Balance Sheets, Statements of Operations, Comprehensive Loss, Stockholders' Equity, Cash Flows, and Notes to Financial Statements."
            },
            {
              "key": "port of Independent Registered Public Accounting Firm",
              "value": "82"
            },
            {
              "key": "iancial Statements:",
              "value": ""
            },
            {
              "key": "Balance Sheets as of December 31, 2022 and 2021 Statements of Operations for the years ended December 31, 2022 and 2021",
              "value": "83 84"
            },
            {
              "key": "Statements of Operations and Comprehensive Loss for the years ended December 31, 2022 and 2021",
              "value": "85"
            },
            {
              "key": "Statements of Stockholders' Equity for the years ended December 31, 2022 and 2021",
              "value": "86"
            },
            {
              "key": "Statements of Cash Flows for the years ended December 31, 2022 and 2021",
              "value": "87"
            },
            {
              "key": "Notes to Financial Statements",
              "value": "89"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 81,
          "title": "Independent Auditor's Report & Opinion on the Financial Statements",
          "data": [
            {
              "key": "Document Type",
              "value": "Report of Independent Registered Public Accounting Firm"
            },
            {
              "key": "Company",
              "value": "Atreca, Inc."
            },
            {
              "key": "Audit Period",
              "value": "For the years ended December 31, 2022 and December 31, 2021"
            },
            {
              "key": "Opinion Summary",
              "value": "In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company and the results of its operations and cash flows for the periods ended December 31, 2022 and 2021, in conformity with GAAP."
            },
            {
              "key": "Change in Accounting Principle",
              "value": "Effective January 1, 2022, the Company adopted Accounting Standards Update 2016-02, Leases (Topic 842) using the modified retrospective transition method."
            },
            {
              "key": "Auditor",
              "value": "WithumSmith+Brown, PC"
            },
            {
              "key": "Audit Date",
              "value": "March 29, 2023"
            },
            {
              "key": "Regulatory & Standards",
              "value": "Audit conducted in accordance with PCAOB standards; PCAOB ID Number 100 - 82 -"
            },
            {
              "key": "Audit Responsibility",
              "value": "The Company’s management is responsible for the financial statements; the auditor’s responsibility is to express an opinion based on auditing procedures."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 82,
          "title": "Balance Sheet",
          "data": [
            {
              "key": "Summary",
              "value": "This is a balance sheet comparing two periods. Total assets decreased from $200,057 to $155,030. Notable changes include a significant decrease in cash and cash equivalents from $94,746 to $30,819, the addition of operating lease right-of-use assets of $36,056, an increase in total liabilities from $45,128 to $76,624, and a decrease in stockholders' equity from $154,929 to $78,406 mainly due to a rise in the accumulated deficit."
            },
            {
              "key": "ASSETS",
              "value": "Current Assets: Cash and cash equivalents (30819 current vs 94746 previous), Investments (39676 vs 22287), Prepaid expenses and other current assets (7531 vs 5337), Total current assets (78026 vs 122370). Non-Current Assets: Property and equipment, net (37972 vs 43015), Operating lease right-of-use assets (36056 vs 0), Long-term investments (0 vs 31042), Deposits and other (2976 vs 3630)."
            },
            {
              "key": "LIABILITIES AND STOCKHOLDERS' EQUITY",
              "value": "Current Liabilities: Accounts payable (1741 vs 3352), Accrued expenses (9681 vs 11555), Operating lease liabilities, current (3544 vs 0), Other current liabilities (1327 vs 1992), Total current liabilities (16293 vs 16899). Non-Current Liabilities: Operating lease liabilities, non-current (60331 vs 0), Deferred rent (0 vs 28229), Total liabilities (76624 vs 45128). Stockholders' Equity: Class A common stock (3 vs 3), Class B common stock (1 vs 1), Additional paid-in capital (535592 vs 514794), Accumulated other comprehensive loss (-266 vs -102), Accumulated deficit (-456924 vs -359767), Total stockholders' equity (78406 vs 154929)."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 83,
          "title": "Statement of Expenses and Losses Comparison",
          "data": [
            {
              "key": "Research and development (2022)",
              "value": "66829"
            },
            {
              "key": "Research and development (2021)",
              "value": "78349"
            },
            {
              "key": "General and administrative (2022)",
              "value": "31466"
            },
            {
              "key": "General and administrative (2021)",
              "value": "31954"
            },
            {
              "key": "Asset impairment (2022)",
              "value": "449"
            },
            {
              "key": "Asset impairment (2021)",
              "value": "0"
            },
            {
              "key": "Total expenses (2022)",
              "value": "98744"
            },
            {
              "key": "Total expenses (2021)",
              "value": "110303"
            },
            {
              "key": "Other income (2022)",
              "value": "770"
            },
            {
              "key": "Other income (2021)",
              "value": "851"
            },
            {
              "key": "Interest income (2022)",
              "value": "817"
            },
            {
              "key": "Interest income (2021)",
              "value": "207"
            },
            {
              "key": "Loss before income tax expense (2022)",
              "value": "-97157"
            },
            {
              "key": "Loss before income tax expense (2021)",
              "value": "-109325"
            },
            {
              "key": "Net loss (2022)",
              "value": "-97157"
            },
            {
              "key": "Net loss (2021)",
              "value": "-409326"
            },
            {
              "key": "Net loss per share, basic and diluted (2022)",
              "value": "-2.52"
            },
            {
              "key": "Net loss per share, basic and diluted (2021)",
              "value": "-2.95"
            },
            {
              "key": "Weighted-average shares used in computing net loss per share (2022)",
              "value": "38593894"
            },
            {
              "key": "Weighted-average shares used in computing net loss per share (2021)",
              "value": "37038195"
            },
            {
              "key": "Summary",
              "value": "This table presents a financial statement comparing expenses and losses between 2022 and 2021. Notable points include: Total expenses decreased from $110,303K in 2021 to $98,744K in 2022, primarily due to lower R&D costs. The net loss significantly improved from $(409,326K) in 2021 to $(97,157K) in 2022. The company's loss per share decreased from $(2.95) to $(2.52), while the weighted-average shares increased from 37.0M to 38.6M shares."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 84,
          "title": "Atreca, Inc. Statements of Operations and Comprehensive Loss (in thousands)",
          "data": [
            {
              "key": "Net loss 2022",
              "value": "-97157"
            },
            {
              "key": "Net loss 2021",
              "value": "-109326"
            },
            {
              "key": "Other comprehensive loss 2022 (Unrealized loss on available-for-sale debt securities)",
              "value": "-164"
            },
            {
              "key": "Other comprehensive loss 2021 (Unrealized loss on available-for-sale debt securities)",
              "value": "-160"
            },
            {
              "key": "Comprehensive loss 2022",
              "value": "-97321"
            },
            {
              "key": "Comprehensive loss 2021",
              "value": "-109486"
            },
            {
              "key": "Summary",
              "value": "This table presents a comparative financial statement showing comprehensive losses for the years 2022 and 2021. The net loss improved from $109,326 in 2021 to $97,157 in 2022. The comprehensive loss, which includes unrealized losses on available-for-sale debt securities, also showed improvement, decreasing from $109,486 in 2021 to $97,321 in 2022. The unrealized losses on available-for-sale debt securities remained relatively stable at $164 in 2022 compared to $160 in 2021."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 86,
          "title": "Cash Flows from Activities",
          "data": [
            {
              "key": "Operating - Net loss",
              "value": "-97157"
            },
            {
              "key": "Operating - Depreciation and amortization",
              "value": "5459"
            },
            {
              "key": "Operating - Operating right-of-use asset",
              "value": "1622"
            },
            {
              "key": "Operating - Stock-based compensation",
              "value": "16891"
            },
            {
              "key": "Operating - Amortization of discount on securities",
              "value": "56"
            },
            {
              "key": "Operating - Prepaid expenses and other current assets",
              "value": "-2441"
            },
            {
              "key": "Operating - Accounts payable",
              "value": "-1611"
            },
            {
              "key": "Operating - Accrued expenses",
              "value": "-1854"
            },
            {
              "key": "Operating - Other current liabilities",
              "value": "1052"
            },
            {
              "key": "Operating - Operating lease liabilities",
              "value": "-3187"
            },
            {
              "key": "Operating - Net cash used in operating activities",
              "value": "-80721"
            },
            {
              "key": "Investing - Purchase of property and equipment",
              "value": "-885"
            },
            {
              "key": "Investing - Purchase of investments",
              "value": "-62454"
            },
            {
              "key": "Investing - Proceeds from maturities of investments",
              "value": "75887"
            },
            {
              "key": "Investing - Net cash provided by investing activities",
              "value": "12548"
            },
            {
              "key": "Financing - Proceeds from ESPP",
              "value": "322"
            },
            {
              "key": "Financing - Proceeds from exercise of stock options",
              "value": "76"
            },
            {
              "key": "Financing - Proceeds from at-the-market offering",
              "value": "3509"
            },
            {
              "key": "Financing - Principal payments on capital lease",
              "value": "-4"
            },
            {
              "key": "Financing - Net cash provided by financing activities",
              "value": "3903"
            },
            {
              "key": "Cash Position - Net change in cash and equivalents",
              "value": "-64270"
            },
            {
              "key": "Cash Position - Beginning cash balance",
              "value": "96204"
            },
            {
              "key": "Summary",
              "value": "This is a cash flow statement showing operating, investing, and financing activities. The company reported a net loss of $97,157, negative operating cash flow of $80,721, positive cash flow of $12,548 from investing activities, and $3,903 from financing activities. Overall, there was a net decrease in cash of $64,270."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 89,
          "title": "Table of Contents ATRECA, INC. NOTES TO FINANCIAL STATEMENTS",
          "data": [
            {
              "key": "Revenue Recognition",
              "value": "The Company follows ASC 606 to identify performance obligations, measure transaction prices (including variable consideration), allocate prices to distinct obligations, and recognize revenue as services are performed."
            },
            {
              "key": "Key Estimates",
              "value": "Estimates include useful lives of property and equipment, impairment of long-lived assets, accrued expenses, valuation of deferred income tax assets, fair value of available-for-sale debt securities, incremental borrowing rate for lease accounting, and fair value of stock options."
            },
            {
              "key": "Other Income Composition",
              "value": "Other income is derived from services performed under service agreements and recognized as performance obligations are satisfied."
            },
            {
              "key": "Research Collaboration (Feb 2020)",
              "value": "Entered an agreement with an external partner for a research project to identify antigenic targets of select antibodies with potential oncology applications; nonrefundable upfront payment recognized over 18 months."
            },
            {
              "key": "Non-Core IP Assignment (Mar 2022)",
              "value": "Entered an agreement for the assignment of non-core intellectual property with initial consideration recognized upon assignment and potential additional consideration on commercial exploitation."
            },
            {
              "key": "Grant Agreement (Oct 2022)",
              "value": "Awarded up to $1.2 million from the Bill & Melinda Gates Foundation for the malaria program; during the year ended December 31, 2022, $20,000 of income was recognized, with remaining funds recorded as deferred revenue."
            },
            {
              "key": "Contract Liabilities",
              "value": "Contract liabilities were recorded at $1.2 million as of December 31, 2022, with variations noted for previous years."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 91,
          "title": "Notes to Financial Statements – Cash, Investments, and Leases",
          "data": [
            {
              "key": "Cash and cash equivalents",
              "value": "2022: 30,819; 2021: 94,746"
            },
            {
              "key": "Restricted cash",
              "value": "2022: 1,115; 2021: 1,458"
            },
            {
              "key": "Cash, cash equivalents and restricted cash (statements of cash flows)",
              "value": "2022: 31,934; 2021: 96,204"
            },
            {
              "key": "Summary",
              "value": "There is a significant decrease (~67% drop) in cash positions from 2021 to 2022, as shown by the decline in both cash and restricted cash balances."
            },
            {
              "key": "Investments Policy",
              "value": "Securities purchased with original maturities greater than three months are classified as investments, intended to be converted into cash for operations and available for sale."
            },
            {
              "key": "Lease Accounting",
              "value": "Lease liabilities are measured by the present value of lease payments using the Company’s incremental borrowing rate. Right-of-use assets are recognized at lease commencement; leases of 12 months or less are not recognized."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 94,
          "title": "Notes to Financial Statements – Net Loss Per Share & Recent Accounting Pronouncements",
          "data": [
            {
              "key": "Net Loss Per Share Calculation",
              "value": "Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding. Diluted loss per share excludes common stock equivalents when their inclusion is anti-dilutive."
            },
            {
              "key": "Lease Accounting Standard Adoption",
              "value": "In accordance with FASB ASU 2016-02 and subsequent amendments (collectively Topic 842), the Company adopted the new lease accounting standard on January 1, 2022 using the modified retrospective transition method. This resulted in recognizing right-of-use assets of $37.7 million and corresponding lease liabilities of $67.1 million, along with derecognizing approximately $10.9 million in deferred rent and $19.1 million in tenant improvement incentives."
            },
            {
              "key": "Credit Loss Standard Adoption",
              "value": "Under FASB ASU 2016-13 (Topic 326) and related amendments, the Company adopted the new expected loss methodology for measuring credit losses on financial instruments as of January 1, 2023. This adoption had no material impact on the financial statements."
            },
            {
              "key": "Comparability Note",
              "value": "Due to the adoption of transitional provisions under ASU 2016-02 and ASU 2018-11, the balance sheets and statements of operations for prior periods are not comparable with the period following adoption."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 95,
          "title": "Notes to Financial Statements - Fair Value of Financial Instruments",
          "data": [
            {
              "key": "Description",
              "value": "Disclosures on the fair value measurements of financial instruments, including assets and liabilities measured under FASB ASC 820. The content includes detailed tables breaking down financial assets by category and valuation level."
            },
            {
              "key": "Table 1 Title",
              "value": "Assets Fair Value Measurements"
            },
            {
              "key": "Table 1 Summary",
              "value": "Money market funds: 29,658; Certificates of deposit: 483; Corporate debt securities: 1,996; U.S. Treasury securities: 37,197; Total: 69,334 (in thousands)."
            },
            {
              "key": "Table 2 Title",
              "value": "Assets Fair Value Measurement Levels"
            },
            {
              "key": "Table 2 Summary",
              "value": "Money market funds: 90,251; Certificates of deposit: 1,672; Corporate debt securities: 6,089; U.S. Treasury securities: 45,568; Total: 143,580 (in thousands)."
            },
            {
              "key": "Valuation Methodology",
              "value": "The market approach was used with Level 1 valuation inputs for money market funds, certificates of deposit, and U.S. Treasury securities. Corporate debt securities were valued using Level 2 inputs based on quoted prices and market-observable data."
            },
            {
              "key": "Additional Information",
              "value": "Gross unrealized gains and losses for cash equivalents and investments were not material, and the remaining contractual maturity of marketable securities was less than two years."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 96,
          "title": "Notes to Financial Statements - Investment Holdings, Portfolio & Prepaids",
          "data": [
            {
              "key": "Investment Holdings (Dec 31, 2022)",
              "value": "Table 'Investment Holdings and Fair Value Summary as of December 31, 2022' shows a total amortized cost of $70,761 with unrealized losses of $266, resulting in a fair value of $70,495. The breakdown includes cash, cash equivalents and money market funds ($30,819) plus U.S. Treasury securities, corporate debt securities, and certificates of deposit with respective values and minor unrealized losses."
            },
            {
              "key": "Investment Portfolio (Dec 31, 2021)",
              "value": "Table 'Investment Portfolio and Cash Position as of December 31, 2021' details a total portfolio fair value of $148,075, comprising cash and equivalents ($94,746), short-term investments ($22,287), and long-term investments ($31,042). Minimal unrealized losses of $102 are reported, with U.S. Treasury securities constituting the largest non-cash component."
            },
            {
              "key": "Marketable Securities Impairment Assessment",
              "value": "The Company evaluated available-for-sale market funds as of December 31, 2021, noting that the decline in market value was attributable to current economic conditions. It concluded that it is not more likely than not that the securities will be sold before a recovery of the amortized cost basis, and therefore they were not considered other-than-temporarily impaired as of December 31, 2022."
            },
            {
              "key": "Prepaid Expenses and Other Current Assets",
              "value": "Table 'Vendor prepayments and deposits' compares figures for Dec 31, 2022 and 2021. Key observations include a reduction in repaid insurance (from $1,531 to $1,026) and facility maintenance fee (from $807 to $336), along with a new entry for Other receivables at $3,985 in 2022, and a total prepaid and other current assets amount of $7,531 for 2022."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 98,
          "title": "Lease payments schedule and operating leases",
          "data": [
            {
              "key": "Lease expense (2022)",
              "value": "$5.9 million"
            },
            {
              "key": "Variable lease expense (2022)",
              "value": "$3.6 million"
            },
            {
              "key": "Rent expense (2021)",
              "value": "$13.2 million"
            },
            {
              "key": "Cash paid for lease liabilities (2022)",
              "value": "$7.5 million"
            },
            {
              "key": "Total lease payments (2023-2027)",
              "value": "$89,123"
            },
            {
              "key": "Future lease payments thereafter",
              "value": "$48,771"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 103,
          "title": "Earnings Per Share Calculation",
          "data": [
            {
              "key": "Numerator",
              "value": "Net loss attributable to common stockholders for earnings per share, basic and diluted (no numeric values provided)"
            },
            {
              "key": "Denominator 2022",
              "value": "38,593,894"
            },
            {
              "key": "Denominator 2021",
              "value": "37,038,195"
            },
            {
              "key": "Basic and Diluted Net Loss per Share 2022",
              "value": "(252)"
            },
            {
              "key": "Basic and Diluted Net Loss per Share 2021",
              "value": "(2.95)"
            },
            {
              "key": "Summary",
              "value": "This table presents earnings per share calculations for 2021 and 2022. The number of shares used for computation increased from 37,038,195 in 2021 to 38,593,894 in 2022. The basic and diluted net loss per share significantly increased from $(2.95) in 2021 to $(252) in 2022, indicating a substantial deterioration in the company's per-share performance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 103,
          "title": "Equity-Based Securities Comparison 2021-2022",
          "data": [
            {
              "key": "Common Stock Options 2022",
              "value": "6,373,534"
            },
            {
              "key": "Common Stock Options 2021",
              "value": "7,162,676"
            },
            {
              "key": "Unvested Restricted Stock Units 2022",
              "value": "330,440"
            },
            {
              "key": "Unvested Restricted Stock Units 2021",
              "value": "867,730"
            },
            {
              "key": "Common Stock Warrants 2022",
              "value": "—_—"
            },
            {
              "key": "Common Stock Warrants 2021",
              "value": "49,997"
            },
            {
              "key": "Total 2022",
              "value": "6,703,974"
            },
            {
              "key": "Total 2021",
              "value": "8,080,403"
            },
            {
              "key": "Summary",
              "value": "This table presents a comparison of equity-based securities between 2022 and 2021. It shows a decrease in total outstanding securities from 8,080,403 in 2021 to 6,703,974 in 2022. The decrease is observed across all categories, with common stock options showing the largest absolute decrease. Common stock warrants were eliminated in 2022, and unvested restricted stock units decreased significantly."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 104,
          "title": "Tax Rate Reconciliation",
          "data": [
            {
              "key": "Tax computed at federal statutory rate",
              "value": "21.0 %"
            },
            {
              "key": "State income taxes, net of federal benefit",
              "value": "2.3 %"
            },
            {
              "key": "Other",
              "value": "— (1.8)%"
            },
            {
              "key": "Change in valuation allowance",
              "value": ""
            },
            {
              "key": "Credits",
              "value": ""
            },
            {
              "key": "Effective income tax rate",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 104,
          "title": "Deferred Tax Assets and Liabilities",
          "data": [
            {
              "key": "Net operating loss carryforward 2022",
              "value": "69296"
            },
            {
              "key": "Net operating loss carryforward 2021",
              "value": "63581"
            },
            {
              "key": "Tax credits 2022",
              "value": "14862"
            },
            {
              "key": "Tax credits 2021",
              "value": "15684"
            },
            {
              "key": "Lease liability 2022",
              "value": "13414"
            },
            {
              "key": "Lease liability 2021",
              "value": "null"
            },
            {
              "key": "Capitalized research and development expenses 2022",
              "value": "11175"
            },
            {
              "key": "Capitalized research and development expenses 2021",
              "value": "null"
            },
            {
              "key": "Intangibles 2022",
              "value": "1090"
            },
            {
              "key": "Intangibles 2021",
              "value": "1211"
            },
            {
              "key": "Fixed assets 2022",
              "value": "410"
            },
            {
              "key": "Fixed assets 2021",
              "value": "null"
            },
            {
              "key": "Other 2022",
              "value": "4172"
            },
            {
              "key": "Other 2021",
              "value": "7528"
            },
            {
              "key": "Total deferred tax assets 2022",
              "value": "114419"
            },
            {
              "key": "Total deferred tax assets 2021",
              "value": "8004"
            },
            {
              "key": "ROU assets 2022",
              "value": "11289"
            },
            {
              "key": "ROU assets 2021",
              "value": "null"
            },
            {
              "key": "Total deferred tax liabilities 2022",
              "value": "11289"
            },
            {
              "key": "Total deferred tax liabilities 2021",
              "value": "121"
            },
            {
              "key": "Valuation allowance 2022",
              "value": "-103130"
            },
            {
              "key": "Valuation allowance 2021",
              "value": "-87883"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 104,
          "title": "Tax Act Impact on Deferred Tax Assets",
          "data": [
            {
              "key": "Increase in deferred tax assets related to capitalized R&D",
              "value": "$11.2 million"
            },
            {
              "key": "Unrecognized tax benefit 2022",
              "value": "$4.7 million"
            },
            {
              "key": "Unrecognized tax benefit 2021",
              "value": "$5.0 million"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 105,
          "title": "NOTES TO FINANCIAL STATEMENTS - Unrecognized Tax Benefits",
          "data": [
            {
              "key": "Overview",
              "value": "Summary of changes in the Company’s unrecognized tax benefits for 2022 vs 2021; amounts are presented in thousands."
            },
            {
              "key": "Beginning of period (2022)",
              "value": "4951"
            },
            {
              "key": "Beginning of period (2021)",
              "value": "3378"
            },
            {
              "key": "Current period tax position increases (2022)",
              "value": "536"
            },
            {
              "key": "Current period tax position increases (2021)",
              "value": "1806"
            },
            {
              "key": "Prior period tax position changes (2022)",
              "value": "-747"
            },
            {
              "key": "Prior period tax position changes (2021)",
              "value": "-233"
            },
            {
              "key": "End of period (2022)",
              "value": "4740"
            },
            {
              "key": "End of period (2021)",
              "value": "4951"
            },
            {
              "key": "Additional Disclosures",
              "value": "No interest or penalties were recognized. The CARES Act, GILTI provisions and related tax credits and NOL carryforwards are discussed with no material impact to the tax provision."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 107,
          "title": "Evaluation of Disclosure Controls and Internal Control over Financial Reporting",
          "data": [
            {
              "key": "Item 9",
              "value": "Changes in and Disagreements with Accountants on Accounting and Financial Disclosure – Not applicable"
            },
            {
              "key": "Item 9A",
              "value": "Evaluation of Disclosure Controls and Procedures: Our disclosure controls and procedures (as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) are designed to ensure timely and accurate reporting. Management, including the CEO and CFO, evaluated these controls as of December 31, 2022 and concluded they are effective at a reasonable assurance level."
            },
            {
              "key": "Internal Controls over Financial Reporting",
              "value": "Management’s assessment, based on the COSO Internal Control – Integrated Framework (2013), concluded that internal controls over financial reporting were effective as of December 31, 2022. There were no material changes during the quarter ended December 31, 2022."
            },
            {
              "key": "Attestation Report",
              "value": "No attestation report from the registered public accounting firm due to an exemption provided by the JOBS Act for emerging growth companies."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 110,
          "title": "Table of Contents PART IV Item 15. Exhibits, and Financial Statement Schedules",
          "data": [
            {
              "key": "Financial Statements",
              "value": "Our financial statements are listed in “Financial Statements and Supplementary Data” under Part II, Item 8 of this Form 10-K."
            },
            {
              "key": "Financial Statement Schedules",
              "value": "All financial statement schedules have been omitted because they are not applicable, not material or the required information is shown in “Financial Statements and Supplementary Data” under Part II, Item 8 of this Form 10-K."
            },
            {
              "key": "Exhibits",
              "value": "The following exhibits, as required by Item 601 of Regulation S-K, are incorporated by reference or are filed with this Form 10-K, in each case as indicated therein."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 195,
          "title": "Exhibit 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM",
          "data": [
            {
              "key": "Consent Statement",
              "value": "We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (File Nos. 333-239654 and 333-239652) and Form S-8 (File Nos. 333-263804, 333-253577, 333-237090 and 333-232278) of Atreca, Inc. of our report dated March 29, 2023, relating to the financial statements, which appears in this Form 10-K."
            },
            {
              "key": "Auditor",
              "value": "WithumSmith+Brown, PC"
            },
            {
              "key": "Location",
              "value": "San Francisco, California"
            },
            {
              "key": "Report Date",
              "value": "March 29, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 196,
          "title": "Exhibit 31.1 CERTIFICATION",
          "data": [
            {
              "key": "Report Reviewed",
              "value": "Annual Report on Form 10-K of Atreca, Inc."
            },
            {
              "key": "Certification Statement",
              "value": "John A. Orwin certifies that the report contains no untrue statement of a material fact, that the financial statements fairly present the financial condition, results of operations, and cash flows, and that robust disclosure controls and internal controls over financial reporting are maintained."
            },
            {
              "key": "Internal Control Disclosures",
              "value": "Implemented disclosure controls and procedures, designed and evaluated internal control over financial reporting, and disclosed any changes that materially affected internal control over financial reporting."
            },
            {
              "key": "Fraud and Deficiency Reporting",
              "value": "Significant deficiencies, material weaknesses, and any fraud involving management or employees with significant roles in internal control over financial reporting have been disclosed."
            },
            {
              "key": "Date",
              "value": "March 29, 2023"
            },
            {
              "key": "Certifier",
              "value": "John A. Orwin"
            },
            {
              "key": "Title/Role",
              "value": "Chief Executive Officer (Principal Executive Officer)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 197,
          "title": "Exhibit 31.2 CERTIFICATION",
          "data": [
            {
              "key": "Certifier",
              "value": "Herbert Cross"
            },
            {
              "key": "Position",
              "value": "Chief Financial Officer (Principal Financial and Accounting Officer)"
            },
            {
              "key": "Filing",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "Company",
              "value": "Atreca, Inc."
            },
            {
              "key": "Certification Date",
              "value": "March 29, 2023"
            },
            {
              "key": "Certification Statement",
              "value": "Review and attestation that the report fairly presents the financial condition, results of operations, and cash flows, and that internal controls are maintained and evaluated in accordance with regulatory requirements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 198,
          "title": "Exhibit 32.1 CERTIFICATION",
          "data": [
            {
              "key": "Certification Basis",
              "value": "Rule 13a-14(b) of the Securities Exchange Act of 1934 and Section 1350 of Chapter 63 of Title 18, U.S. Code"
            },
            {
              "key": "Referenced Report",
              "value": "Annual Report on Form 10-K for the year ended December 31, 2022"
            },
            {
              "key": "Certification Statement",
              "value": "The Annual Report on Form 10-K fully complies with Exchange Act requirements and fairly presents the Company’s financial condition and results of operations."
            },
            {
              "key": "Certification Date",
              "value": "March 29, 2023"
            },
            {
              "key": "Signatories",
              "value": "John A. Orwin (Chief Executive Officer) and Herbert Cross (Chief Financial Officer)"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_dividend_policy_changes": {
      "value": true,
      "elements": [
        {
          "type": "dividend_policy",
          "page": 69,
          "title": "Market Information for Common Stock & Dividend Policy",
          "data": [
            {
              "key": "Stock Trading",
              "value": "Class A common stock is traded on Nasdaq under the symbol 'BCEL'"
            },
            {
              "key": "Class B Convertible",
              "value": "Class B common stock is not listed; convertible into a share of Class A common stock at holder's option"
            },
            {
              "key": "Record Holders",
              "value": "As of March 13, 2023, there were 50 record holders for Class A and 2 for Class B"
            },
            {
              "key": "Dividends Strategy",
              "value": "The company intends to retain all available funds and future earnings for business operation and expansion, and does not anticipate declaring or paying dividends in the foreseeable future"
            },
            {
              "key": "Dividend Payment Discretion",
              "value": "Any future dividend payment will be at the discretion of the board of directors based on multiple factors including financial condition and results of operations"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_share_buyback_plans": {
      "value": false,
      "elements": []
    },
    "has_capital_structure_changes": {
      "value": true,
      "elements": [
        {
          "type": "capital_structure",
          "page": 75,
          "title": "Capital Structure and Equity Financing Details",
          "data": [
            {
              "key": "Research and Development Expenditures",
              "value": "Significant R&D expenditures have contributed to operating losses since inception."
            },
            {
              "key": "Funding Strategy",
              "value": "Operations have been primarily funded through the sale of convertible preferred stock and common stock."
            },
            {
              "key": "Class A Common Stock Issuance (July 2020)",
              "value": "7,642,125 shares issued at an offering price of $16.00 per share."
            },
            {
              "key": "Class B Common Stock Issuance (July 2020)",
              "value": "781,250 shares issued at an offering price of $16.00 per share."
            },
            {
              "key": "Net Proceeds from July 2020 Offering",
              "value": "$126.1 million received after deducting underwriting discounts, commissions ($8.1 million), and other offering expenses ($0.6 million)."
            },
            {
              "key": "Sales Agreement with Cowen (August 2020)",
              "value": "Agreement to issue and sell up to $100.0 million of Class A common stock; as of December 31, 2022, 1,493,361 shares were sold under this agreement."
            },
            {
              "key": "Net Proceeds from Sales Agreement",
              "value": "$7.9 million after deducting underwriting fee ($0.3 million) and issuance costs ($0.3 million)."
            },
            {
              "key": "Accumulated Deficit",
              "value": "$456.9 million as of December 31, 2022."
            },
            {
              "key": "Future Financing Concerns",
              "value": "Management plans additional equity financing and expense reductions, though risks remain regarding the company’s ability to continue as a going concern."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 85,
          "title": "Stockholders' Equity Statement",
          "data": [
            {
              "key": "Balances at December 31, 2020",
              "value": "common_shares: 36804603, stock_amount: 4, paid_in_capital: 492436, other_comprehensive_income: 58, accumulated_deficit: -250441, total_stockholders_equity: 242057"
            },
            {
              "key": "Issuance of common stock through ATM offering",
              "value": "common_shares: 793361, total_stockholders_equity: 4372"
            },
            {
              "key": "Issuance of common stock upon exercise of options",
              "value": "common_shares: 47061, paid_in_capital: 273, total_stockholders_equity: 273"
            },
            {
              "key": "Issuance of common stock under ESPP",
              "value": "common_shares: 113772, paid_in_capital: 837, total_stockholders_equity: 837"
            },
            {
              "key": "Stock-based compensation",
              "value": "paid_in_capital: 16876, total_stockholders_equity: 16876"
            },
            {
              "key": "Unrealized loss on available-for-sale debt securities",
              "value": "other_comprehensive_income: -160, total_stockholders_equity: -160"
            },
            {
              "key": "Net loss",
              "value": "accumulated_deficit: -109326, total_stockholders_equity: -109326"
            },
            {
              "key": "Balances at December 31, 2021",
              "value": "common_shares: 37758797, stock_amount: 4, paid_in_capital: 514794, other_comprehensive_income: -102, accumulated_deficit: -359767, total_stockholders_equity: 154929"
            },
            {
              "key": "summary",
              "value": "This table shows the Statement of Stockholders' Equity for the year ended December 31, 2021. The company's total stockholders' equity decreased from $242,057 to $154,929 during the year. Key activities include stock issuances through ATM offering, stock options, and ESPP, stock-based compensation of $16,876, a significant net loss of $109,326, and an unrealized loss of $160 on available-for-sale debt securities. The total number of common shares increased from 36.8M to 37.8M shares."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 85,
          "title": "Statement of Stockholders' Equity Changes for Year Ended December 31, 2022",
          "data": [
            {
              "key": "Balances at December 31, 2021",
              "value": "shares: 37758797, amount: 4, paid_in_capital: 514794, comprehensive_loss: -102, accumulated_deficit: -359767, stockholders_equity: 154929"
            },
            {
              "key": "Issuance of common stock through ATM offering",
              "value": "shares: 700000, paid_in_capital: 3509, stockholders_equity: 3509"
            },
            {
              "key": "Issuance of common stock under Employee Stock Purchase Plan",
              "value": "shares: 207538, paid_in_capital: 322, stockholders_equity: 322"
            },
            {
              "key": "Vesting of restricted stock units",
              "value": "shares: 384390"
            },
            {
              "key": "Stock-based compensation",
              "value": "paid_in_capital: 16891, stockholders_equity: 16891"
            },
            {
              "key": "Unrealized loss on available-for-sale debt securities",
              "value": "comprehensive_loss: -164, stockholders_equity: -164"
            },
            {
              "key": "Net loss",
              "value": "accumulated_deficit: -97157, stockholders_equity: -97157"
            },
            {
              "key": "Balances at December 31, 2022",
              "value": "shares: 39067391, amount: 4, paid_in_capital: 535592, comprehensive_loss: -266, accumulated_deficit: -456924, stockholders_equity: 78406"
            },
            {
              "key": "summary",
              "value": "This table shows the changes in stockholders' equity for the year ended December 31, 2022. The company's stockholders' equity decreased from $154,929 to $78,406 during the year, primarily due to a net loss of $97,157. Notable activities include stock-based compensation of $16,891, issuance of common stock through ATM offering contributing $3,509, and additional stock issuances through employee programs. The total number of shares increased from 37,758,797 to 39,067,391 over the period."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 173,
          "title": "Stop-Transfer Instructions Enforcement Clause",
          "data": [
            {
              "key": "covenant",
              "value": "order to enforce the foregoing covenant"
            },
            {
              "key": "instruction",
              "value": "the Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such period"
            },
            {
              "key": "closing",
              "value": "Very truly yours, Signature, Print Name, Address of Record: 2"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "mentions_new_risk_factors": {
      "value": true,
      "elements": [
        {
          "type": "risk_factor",
          "page": 2,
          "title": "Table of Contents",
          "data": [
            {
              "key": "description",
              "value": "This page contains the Table of Contents from a Form 10-K (or similar SEC filing). It lists 20 items covering various topics including 'Risk Factors', 'Unresolved Staff Comments', 'Legal Proceedings', 'Executive Compensation', among others. The items reference page numbers ranging from 26 to 111, with an additional entry for 'Form 10-K Summary' on page 115."
            },
            {
              "key": "note",
              "value": "Although the Table of Contents itself does not provide detailed business information, the inclusion of key sections like 'Risk Factors' makes 'risk_factor' the most relevant schema from the available options."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 3,
          "title": "Special Note Regarding Forward-Looking Statements",
          "data": [
            {
              "key": "Document Type",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "Year End Date",
              "value": "December 31, 2022"
            },
            {
              "key": "Risk Factors Section",
              "value": "Part I, Item 1A"
            },
            {
              "key": "Management Discussion Section",
              "value": "Part II, Item 7"
            },
            {
              "key": "Business Section",
              "value": "Part I, Item 1"
            },
            {
              "key": "Regulatory References",
              "value": "Section 27A of the Securities Act of 1933; Section 21E of the Securities Exchange Act of 1934"
            },
            {
              "key": "Forward-Looking Terminology",
              "value": "anticipate, believe, can, continue, could, estimate, expect, intend, may, might, objective, ongoing, plan, potential, predict, project, should, will, or would"
            },
            {
              "key": "R&D and Clinical Programs",
              "value": "Mentions initiation, timing, progress and results of research and development programs, preclinical studies, clinical trials, and IND/regulatory submissions"
            },
            {
              "key": "Industry Focus",
              "value": "Cancer therapies and development of the immuno-oncology industry"
            },
            {
              "key": "Forward-Looking Statement Disclaimer",
              "value": "Statements based on current expectations and subject to risks, uncertainties and other factors detailed in the report"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 4,
          "title": "Table of Contents and Risk Factor Summary",
          "data": [
            {
              "key": "Forward-Looking Statements",
              "value": "The document states that forward-looking statements are based on assumptions and are inherently uncertain. There is no obligation to update these statements to reflect actual results."
            },
            {
              "key": "Risk Factor Summary",
              "value": "A summary of material risks is provided, highlighting factors such as the company’s clinical-stage status, history of losses, dependency on sufficient funding, risks associated with clinical trials (e.g., ATRC-101), potential regulatory approval challenges, impacts of the COVID-19 pandemic, and overall market uncertainty."
            },
            {
              "key": "Business Risks",
              "value": "The document outlines risks related to continuing operations as a going concern, potential delays or failures in drug development, and the limitations of available market data and forecasts."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 5,
          "title": "Risk Factors and Product Candidate Challenges",
          "data": [
            {
              "key": "Revenue and Licensing Risk",
              "value": "Revenue from the sale or licensing of product candidates could be compromised by undesirable side effects from ATRC-101 or future candidates, affecting market acceptance."
            },
            {
              "key": "Funding Risk for Product Development",
              "value": "The company will require substantial additional funds to advance development of product candidates and its discovery platform, risking insufficient resources to develop and commercialize these candidates."
            },
            {
              "key": "Resource Allocation Risk",
              "value": "There is a risk of expending limited resources on a particular product candidate, potentially missing opportunities to capitalize on more profitable candidates."
            },
            {
              "key": "Human Samples Consent Risk",
              "value": "Obtaining rights to use human samples for research and development carries the risk of liability, continuing royalties, or cessation of usage, if appropriate consent is not obtained or the scope is exceeded."
            },
            {
              "key": "Strategic Transactions Risk",
              "value": "Entering into strategic transactions for the development and commercialization of product candidates may prove unsuccessful, negatively affecting market potential, cash position, and increasing expenses."
            },
            {
              "key": "Third-Party Performance Risk",
              "value": "Reliance on third parties for preclinical studies or clinical trials, if they do not perform as required, could delay or derail the development program, impacting business and financial conditions."
            },
            {
              "key": "Supply Chain Disruption Risk",
              "value": "Dependence on third parties for manufacturing and supply, including sole source vendors, raises the risk of limited, interrupted, or substandard material supply."
            },
            {
              "key": "Intellectual Property Risk",
              "value": "Inability to secure or protect intellectual property rights may hinder competitiveness. Failures in compliance or challenges to patent rights could lead to costly litigation and adverse business impacts."
            },
            {
              "key": "Regulatory Approval Risk",
              "value": "The clinical development process is lengthy and uncertain. Failure to obtain regulatory approval, or the burdens of ongoing compliance, could prevent commercialization of product candidates and incur significant additional expenses."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 6,
          "title": "Regulatory and Market Withdrawal Risks; Stock Volatility",
          "data": [
            {
              "key": "Regulatory Compliance",
              "value": "The document discusses regulatory requirements, including adherence to labeling restrictions, accelerated registration pathways, and intense post-marketing obligations, as well as the potential for penalties if regulations are not met."
            },
            {
              "key": "FDA Approval Process",
              "value": "Mentions securing approval from the FDA via accelerated registration pathways, potential need for additional preclinical studies or clinical trials, and risks related to delays or failure if confirmatory trials do not verify clinical benefits."
            },
            {
              "key": "Legal and Compliance Risks",
              "value": "Highlights exposure to U.S. and foreign anti-corruption and anti-money laundering laws, with non-compliance possibly leading to criminal or civil liabilities."
            },
            {
              "key": "Stock Market Risks",
              "value": "Notes risks related to volatility of Class A common stock, including potential dilution effects from future sales or issuances and significant control exerted by principal stockholders."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 13,
          "title": "Competition and Intellectual Property Risk Factors",
          "data": [
            {
              "key": "Competition",
              "value": "The document discusses a competitive landscape in which numerous companies are developing antibodies for the treatment of cancer. It highlights that many competitors are well-capitalized and have extensive clinical, regulatory, and commercial experience. The text also notes that these competitors may attract scientific and managerial talent, potentially impacting the company’s success if competing products, which may be safer, more effective, or less expensive, become available."
            },
            {
              "key": "Intellectual Property",
              "value": "The text emphasizes the importance of obtaining, maintaining, enforcing, and defending patents and other intellectual property rights for novel antibody-based immunotherapeutics. The company’s success depends on its ability to protect its proprietary technology, including its discovery platform and product candidates like ATRC-101. It describes its portfolio of in-licensed and company-owned patents and patent applications across various jurisdictions (U.S., China, Japan, Singapore, Australia, Europe, and through the PCT), as well as the reliance on trademarks, trade secrets, confidentiality agreements, and invention assignment agreements."
            },
            {
              "key": "Risk Factor",
              "value": "The document identifies risks related to intellectual property, including the potential for patents and other protections to be challenged, invalidated, circumvented, infringed, or misappropriated. This could undermine the company’s competitive position and impact its commercial opportunity if competing products or alternative treatments emerge."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 15,
          "title": "Clinical Trials Regulatory Process Overview",
          "data": [
            {
              "key": "Regulatory Requirements",
              "value": "The document outlines that before testing any biological product candidate in humans, it must undergo preclinical testing compliant with GLP, with all data submitted to the FDA as part of an IND."
            },
            {
              "key": "IND Process",
              "value": "An IND request is submitted to the FDA, automatically becoming effective 30 days after receipt unless a clinical hold is imposed, delaying or halting clinical trials."
            },
            {
              "key": "Clinical Trial Operations",
              "value": "Clinical trials are conducted under strict protocols including dosing, subject selection, safety monitoring and require IRB approval and informed consent from participants."
            },
            {
              "key": "Clinical Trial Phases",
              "value": "Details of Phase 1, Phase 2, and Phase 3 trials are provided, discussing the evaluation of safety, dosage, efficacy, and the monitoring of adverse events."
            },
            {
              "key": "FDA Oversight & Risks",
              "value": "The FDA may impose clinical holds if there are safety risks, inadequate information, or design deficiencies, thereby introducing significant risk factors that could delay or suspend the trial process."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 16,
          "title": "Clinical Trials and FDA Regulatory Review Process Overview",
          "data": [
            {
              "key": "Objective",
              "value": "Establish overall risk/benefit ratio of the product for approval and labeling."
            },
            {
              "key": "Post-approval Clinical Trials",
              "value": "Phase 4 trials may be conducted after initial marketing to gather long-term safety data."
            },
            {
              "key": "FDA Monitoring",
              "value": "Extensive monitoring and auditing of clinical activities, data, and investigators is required."
            },
            {
              "key": "IND Safety Reports",
              "value": "Written reports must be submitted promptly for serious and unexpected adverse events; within 15 days for qualifying information and 7 days for fatal or life-threatening events."
            },
            {
              "key": "Clinical Trial Suspension",
              "value": "Trials may be suspended by the FDA, sponsor, or IRB if subjects face unacceptable health risks or if protocols are not followed."
            },
            {
              "key": "Manufacturing Controls",
              "value": "Additional studies and controls, including animal studies and testing for identity, strength, quality, potency, purity, appropriate packaging, and stability are required to ensure quality under cGMP."
            },
            {
              "key": "BLA Submission and Review",
              "value": "After clinical trials, a BLA must be submitted including all study results, manufacturing details, and proposed labeling. The FDA reviews the submission within 60 days and complete review typically takes 12 months, with PDUFA goals of 10 months (standard) or 6 months (priority)."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 21,
          "title": "Healthcare Compliance, Reform and Risk Factors",
          "data": [
            {
              "key": "Compliance Programs",
              "value": "Discussion on implementing compliance programs and marketing codes to ensure adherence to healthcare laws and regulations."
            },
            {
              "key": "Registration Requirements",
              "value": "Mentions that certain states and local jurisdictions require registration of pharmaceutical sales representatives."
            },
            {
              "key": "Penalties",
              "value": "Details potential penalties including civil, criminal, administrative penalties, damages, fines, disgorgement, imprisonment, restructuring of operations, and other serious sanctions for non-compliance."
            },
            {
              "key": "Legal and Financial Risks",
              "value": "Highlights risks such as significant legal expenses, diversion of management attention, and reputational harm due to alleged or suspected violations."
            },
            {
              "key": "U.S. Healthcare Reform",
              "value": "Explores the impact of the Affordable Care Act (ACA), the Inflation Reduction Act (IRA), and various executive orders, legislative proposals and regulatory measures on drug pricing and the broader U.S. healthcare system."
            },
            {
              "key": "Government Oversight",
              "value": "Mentions heightened governmental scrutiny, congressional inquiries, and efforts to reform product pricing and healthcare reimbursement methodologies."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 22,
          "title": "Coverage, Reimbursement Uncertainty and Human Capital Overview",
          "data": [
            {
              "key": "Coverage & Reimbursement Risks",
              "value": "Significant uncertainty exists regarding coverage and reimbursement status for biopharmaceutical products. Third-party payors, including government programs like Medicare and Medicaid, along with commercial insurers, may limit coverage and impose controls that can affect revenue."
            },
            {
              "key": "Pharmacoeconomic Studies Requirement",
              "value": "Manufacturers may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of products in order to secure coverage, impacting return on investment."
            },
            {
              "key": "Government Cost-Containment Measures",
              "value": "Government initiatives, such as price controls and restrictions on reimbursement, could further limit revenue from approved drugs and biological products."
            },
            {
              "key": "Variation in Third-Party Policies",
              "value": "Coverage policies and reimbursement rates vary widely among third-party payors, leading to uncertainty in product pricing and market access."
            },
            {
              "key": "Human Capital Resources",
              "value": "As of December 31, 2022, the company employed 90 full-time employees, with 61 focused on R&D and 26 holding advanced degrees, highlighting a strong investment in human capital without union representation."
            },
            {
              "key": "Corporate Values",
              "value": "Emphasis on Patient-Driven Science, Integrity, Respect, Collaboration, Transparency, and Fun, which underpin the company culture and operational approach."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 25,
          "title": "Risk Factors",
          "data": [
            {
              "key": "Description",
              "value": "Our business and investing in our Class A common stock involves a high degree of risk. The document advises readers to consider and read carefully all the risks and uncertainties described, as well as additional information in the Form 10-K including financial statements, management’s discussion and analysis, and forward-looking statements, before deciding to invest. It warns that any of the listed risk factors or additional unforeseen risks could materially and adversely affect the business, financial condition, results of operations, prospects, and stock price, potentially causing a decline in the market price of the common stock."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 27,
          "title": "Risk Factors and Capital Resources Concerns",
          "data": [
            {
              "key": "Liquidity Risk",
              "value": "If we are unable to obtain adequate additional capital resources, we will not be able to continue operating our business as planned, and may be forced to reduce spending, delay, scale back, or eliminate investments including drug development, regulatory, manufacturing, and R&D efforts."
            },
            {
              "key": "Going Concern Uncertainty",
              "value": "There is substantial doubt about our ability to continue as a going concern, which could adversely affect our stock price, third-party relationships, and ability to attract and retain key personnel."
            },
            {
              "key": "Clinical Development Risk",
              "value": "ATRC-101 is in early clinical development. There are significant risks including failure in development, delays, or regulatory issues that may materially and adversely affect its commercial viability."
            },
            {
              "key": "Regulatory and COVID-19 Impact",
              "value": "Regulatory processes may be delayed due to factors like the COVID-19 pandemic affecting FDA inspections and reviews, which could delay clinical trials and regulatory submissions."
            },
            {
              "key": "Financial Resource Constraints",
              "value": "The company's future development of ATRC-101 and potential future product candidates depends on securing additional financial resources and successful regulatory approvals, which remains uncertain."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 28,
          "title": "Table of Contents - Risk Factors",
          "data": [
            {
              "key": "Preclinical/Clinical Results",
              "value": "Negative or inconclusive outcomes in preclinical studies or clinical trials may require additional studies or program abandonment."
            },
            {
              "key": "Product-related Side Effects",
              "value": "Side effects reported by participants in clinical trials or observed in similar drug candidates."
            },
            {
              "key": "Regulatory Delays",
              "value": "Delays in submitting IND applications or obtaining necessary regulatory approvals, including FDA-imposed conditions affecting trial design and conduct."
            },
            {
              "key": "Clinical Trial Enrollment Challenges",
              "value": "Issues such as delays in enrolling research subjects, high drop-out rates, and difficulties ensuring patient compliance."
            },
            {
              "key": "Supply and Quality Issues",
              "value": "Inadequate supply or quality of components and materials necessary for clinical trials."
            },
            {
              "key": "Cost Overruns",
              "value": "Greater-than-anticipated clinical trial costs may impact program viability."
            },
            {
              "key": "COVID-19 Impact",
              "value": "Disruptions and delays in clinical trial activities for ATRC-101 due to the pandemic, affecting site initiation, patient enrollment, and compliance."
            },
            {
              "key": "Regulatory Approval Uncertainties",
              "value": "Potential limitations on marketing approval, restricted patient populations, required labeling changes, and post-marketing testing obligations."
            },
            {
              "key": "Commercial Viability Risks",
              "value": "Concerns that ATRC-101 or other product candidates may not demonstrate required safety and efficacy, affecting the overall pipeline and business prospects."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 29,
          "title": "Impact of COVID-19 on Business Operations",
          "data": [
            {
              "key": "COVID-19 Impact",
              "value": "The COVID-19 pandemic could materially adversely affect business operations, financial condition, and clinical activities."
            },
            {
              "key": "Clinical Trial Disruption",
              "value": "Disruptions in preclinical and clinical studies including patient recruitment and site operations."
            },
            {
              "key": "Manufacturing Delays",
              "value": "Delays in manufacturing activities and sourcing materials from third-party manufacturers."
            },
            {
              "key": "Collaboration Activities",
              "value": "Delays in collaboration activities with internal and external collaborators."
            },
            {
              "key": "Regulatory Delays",
              "value": "Delays in interactions with FDA and other regulatory authorities affecting clinical trials."
            },
            {
              "key": "Healthcare Resource Diversion",
              "value": "Diversion of hospital resources affecting clinical trial support."
            },
            {
              "key": "Changes in Regulation",
              "value": "Changes in laws due to COVID-19 may alter clinical trial conduct."
            },
            {
              "key": "Transportation Disruptions",
              "value": "Interruptions in commercial transportation affecting clinical trial materials."
            },
            {
              "key": "Staff Productivity Decrease",
              "value": "Decreased staff productivity due to COVID-19 restrictions."
            },
            {
              "key": "Access to Capital",
              "value": "Delays and difficulties in accessing capital due to ongoing pandemic disruptions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 30,
          "title": "Risk Factors: Companion Diagnostics and Product Development Challenges",
          "data": [
            {
              "key": "Companion Diagnostics Approval Risk",
              "value": "Failure to successfully validate, develop and obtain regulatory approval for companion diagnostics could delay or prevent approval and commercialization of product candidates."
            },
            {
              "key": "Regulatory Dependency",
              "value": "Companion diagnostics require separate FDA or equivalent premarket approval, and any delays in approval can adversely impact clinical development timelines."
            },
            {
              "key": "Discovery Platform Uncertainty",
              "value": "The evolving discovery platform is unproven and may not produce viable product candidates, posing a risk to future market revenue."
            },
            {
              "key": "COVID-19 Impact",
              "value": "Disruptions and delays in internal and third-party efforts, attributed to COVID-19, further complicate the development and approval process."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 31,
          "title": "Risk Factors: Product Market Acceptance and Regulatory Issues",
          "data": [
            {
              "key": "Market Acceptance Risk",
              "value": "The market may not be receptive to current or potential future product candidates, which could result in no revenue from sales or licensing."
            },
            {
              "key": "Regulatory Approval Risk",
              "value": "Even if regulatory approval is obtained, there is no assurance that revenue from product sales will be generated or sustained; approvals depend on timing, terms, and geographic scope."
            },
            {
              "key": "Adverse Side Effects",
              "value": "Undesirable side effects from ATRC-101 or other product candidates could lead to clinical trial disruptions, more restrictive labeling, recalls, or denial of approval."
            },
            {
              "key": "Clinical and Commercial Impact",
              "value": "High severity or prevalence of side effects may force suspension or termination of trials, impact patient recruitment and completion, and expose the company to potential liability or regulatory penalties."
            },
            {
              "key": "Overall Business Impact",
              "value": "Any failure in market acceptance or adverse clinical outcomes could materially and adversely affect the company's business, financial condition, and future prospects."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 32,
          "title": "Risk Factors and Capital Requirements",
          "data": [
            {
              "key": "Regulatory Requirements",
              "value": "Regulatory authorities may require additional labeling statements such as a 'black box' warning or contraindications and the creation of a Medication Guide outlining risks of side effects."
            },
            {
              "key": "Litigation Risk",
              "value": "The company could be sued and held liable for harm caused to patients."
            },
            {
              "key": "Competitive Risk",
              "value": "The product may become less competitive which could negatively impact market position."
            },
            {
              "key": "Reputation Risk",
              "value": "There is potential for reputation damage as a result of regulatory and legal issues."
            },
            {
              "key": "Capital Requirements",
              "value": "Substantial additional funds are needed to advance the development of product candidates and the discovery platform, including expansion of development, regulatory, manufacturing, marketing, and sales capabilities."
            },
            {
              "key": "Capital Intensity",
              "value": "The development of biopharmaceutical product candidates is capital-intensive and involves significant expenditures in preclinical studies, clinical trials, and further research and development."
            },
            {
              "key": "Funding Status",
              "value": "As of December 31, 2022, the company had $70.5 million in cash, cash equivalents, and investments, which is expected to fund operations for at least the next 12 months."
            },
            {
              "key": "Future Uncertainties",
              "value": "There are uncertainties related to spending levels, timing of R&D programs, costs for regulatory approvals, manufacturing, potential collaborations, and other corporate activities that could affect operating expenditures."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 33,
          "title": "Risk Factors Discussion and Capital Raising Concerns",
          "data": [
            {
              "key": "Risk Monitoring",
              "value": "Actively monitoring the situation in Ukraine and Russia and assessing its impact on business operations and partnerships."
            },
            {
              "key": "Operational Disruptions",
              "value": "No material interruptions experienced to date, but potential for significant impact due to prolonged conflict, sanctions, and market disruptions."
            },
            {
              "key": "Capital Raising Risk",
              "value": "Inability to obtain adequate financing may delay, reduce, or suspend preclinical studies, clinical trials, research and development programs, and commercialization efforts."
            },
            {
              "key": "Collaboration and Licensing Risk",
              "value": "Raising capital through collaborations, strategic alliances, or licensing could force the relinquishment of valuable rights, revenue streams, or research programs."
            },
            {
              "key": "Debt Financing Risk",
              "value": "Debt financing may come with restrictive covenants that limit actions such as incurring additional debt, capital expenditures, or declaring dividends, potentially affecting stockholder rights."
            },
            {
              "key": "Resource Allocation Risk",
              "value": "Limited financial and managerial resources may result in focusing on specific R&D programs, potentially forgoing more profitable opportunities."
            },
            {
              "key": "Consent and Regulatory Risk",
              "value": "Risks related to obtaining proper consent for using human samples, which could lead to liabilities, continuous royalties, or even cessation of sample usage."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 35,
          "title": "Risk Factors Related to Strategic Transactions and Clinical Development",
          "data": [
            {
              "key": "Risk Factors",
              "value": "Impairment of relationships with key suppliers, manufacturers, or customers due to changes in management and ownership; inability to retain key employees of any acquired business; and risks related to strategic transactions and collaborations."
            },
            {
              "key": "Clinical Development Concerns",
              "value": "Dependence on third-party clinical investigators, CROs, and related organizations for preclinical studies and clinical trials could lead to delays or failures. This may adversely impact the development, commercialization, and competitiveness of product candidates."
            },
            {
              "key": "COVID-19 Impact",
              "value": "Potential significant disruptions or material delays in preclinical studies and clinical trials due to COVID-19 and its variants, which could materially harm the business, financial condition, and operational results."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 36,
          "title": "Clinical Trials Risk Disclosure",
          "data": [
            {
              "key": "Clinical trial costs",
              "value": "Clinical trials are expensive and time-consuming due to extensive research and development, high manufacturing and processing costs, and significant expenses for patient treatment and management of side effects."
            },
            {
              "key": "Patient enrollment challenges",
              "value": "Difficulties in recruiting a sufficient number of eligible patients due to strict eligibility criteria, limited patient populations, competition with other trials, geographic constraints, and reliance on physician referrals."
            },
            {
              "key": "Delays and disruptions",
              "value": "Delays in clinical trials, including enrollment and treatment delays due to COVID-19 protocols, staffing shortages at clinical sites and healthcare facilities, and protocol updates."
            },
            {
              "key": "Impact on product development",
              "value": "Potential material adverse effect on business, financial condition, and prospects, notably in the development of ATRC-101, due to delays and disruptions in clinical trials."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 38,
          "title": "Manufacturing and Commercialization Risk Factors",
          "data": [
            {
              "key": "Reliance on Third-Party Manufacturers",
              "value": "The company depends on third-party manufacturers for the production of product candidates. Failure to secure or maintain these manufacturing relationships, or to comply with regulatory and quality standards, could delay clinical trials, regulatory approvals, and commercialization."
            },
            {
              "key": "cGMP Compliance and Quality Control",
              "value": "Risks related to not meeting current Good Manufacturing Practices (cGMP) could lead to inspections, recalls, or disruption in the production process, adversely affecting the development timeline and business operations."
            },
            {
              "key": "Scale-Up and Capacity Constraints",
              "value": "Inability of existing partners to scale manufacturing efficiently and cost-effectively may hinder the production of large quantities required for clinical trials and commercial launch."
            },
            {
              "key": "Market and Revenue Projections",
              "value": "Uncertainties in the estimated treatable population, potential market size, and reimbursement challenges may negatively impact future product revenues and overall business prospects."
            },
            {
              "key": "Competitive and Regulatory Challenges",
              "value": "Increased competition from other companies developing similar product candidates and rapid technological advancements could affect the company's ability to secure regulatory approvals and successfully commercialize its products."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 40,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Dependence on Key Managers",
              "value": "The document highlights that the relationships cultivated by key managers are critical, and their continued employment is essential for ongoing success."
            },
            {
              "key": "Risk of Employee Turnover",
              "value": "Key employees, including technical personnel, are not contractually bound to stay, which means they could leave at any time without penalty, posing a material risk."
            },
            {
              "key": "Staffing and Hiring Challenges",
              "value": "There is significant emphasis on the challenges of attracting and retaining qualified scientific, technical, and management staff necessary for clinical development and manufacturing."
            },
            {
              "key": "Operational and Commercialization Risks",
              "value": "The text discusses the difficulties in developing internal sales, marketing, and distribution capabilities or in securing acceptable third-party agreements, any of which could affect successful commercialization."
            },
            {
              "key": "Foreign Market and Regulatory Risks",
              "value": "Expansion into foreign markets is noted to present additional regulatory burdens and uncertainties which could materially impact future growth."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 41,
          "title": "Risk Factors: Regulatory and Product Liability Challenges",
          "data": [
            {
              "key": "Regulatory Compliance Risks",
              "value": "Approval in foreign markets requires compliance with diverse regulatory requirements regarding safety, efficacy, clinical trials, commercial sales, pricing, and distribution. Delays and complex negotiations with governmental authorities may adversely impact profitability."
            },
            {
              "key": "Pricing Risks",
              "value": "Price controls and reference pricing in markets such as the European Union can lead to reduced prices and difficulty in negotiating favorable reimbursement levels."
            },
            {
              "key": "Product Liability Risks",
              "value": "The development and commercialization of product candidates expose the company to significant product liability risks. Potential liability claims could result in FDA investigations, recalls, litigation costs, and adverse impacts on reputation and stock price."
            },
            {
              "key": "Insurance and Misconduct Concerns",
              "value": "Increasing costs and difficulties in obtaining sufficient insurance coverage, along with risks of fraud or misconduct by employees, investigators, consultants, or partners, further compound these uncertainties."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 42,
          "title": "Regulatory and Data Protection Risks",
          "data": [
            {
              "key": "Summary",
              "value": "The document outlines risks related to the improper use of clinical trial information, emphasizing potential regulatory sanctions, reputational harm, and financial penalties. Non-compliance with applicable laws such as HIPAA, GDPR, and other data protection regulations is highlighted."
            },
            {
              "key": "Details",
              "value": "It details that individuals conducting non-interventional clinical studies may misuse sensitive data related to antibodies for therapeutic development. The text discusses challenges in preventing misconduct and controlling unknown risks. It also outlines obligations under various data protection laws, including U.S. privacy laws (HIPAA, HITECH, CCPA), EU regulations (GDPR), and considerations arising from Brexit and decisions by the CJEU, which may lead to significant fines, litigation, and operational restructuring if not adhered to."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 43,
          "title": "CCPA Regulatory and Cybersecurity Risk Factors",
          "data": [
            {
              "key": "CCPA Implementation",
              "value": "The CCPA went into effect on January 1, 2020, with enforcement actions by the California Attorney General starting July 1, 2020. It was amended on September 23, 2018."
            },
            {
              "key": "Regulatory Compliance Risks",
              "value": "Compliance with U.S. and international data protection laws (e.g., HIPAA, GDPR) may impose stricter contractual obligations and limitations on data collection, use, and disclosure."
            },
            {
              "key": "Litigation and Enforcement Exposure",
              "value": "Failure to comply could lead to government enforcement actions, civil or criminal penalties, private litigation, and adverse publicity."
            },
            {
              "key": "Data Privacy and Security Breaches",
              "value": "There is a risk of significant liabilities, business disruption, and harm to reputation from potential security breaches or unauthorized access to personal, clinical, or proprietary data."
            },
            {
              "key": "Cyber Attack Vulnerabilities",
              "value": "Reliance on sophisticated IT systems exposes the business to risks from cyber-attacks, which could result in data theft, loss of confidential information, and operational disruption."
            },
            {
              "key": "Third-Party Vendor Risks",
              "value": "Dependence on third-party service providers for data hosting and processing may compound risks in case of breaches or failures to protect data integrity."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 44,
          "title": "Risk Factors: IT Disruptions, Hazardous Materials & Disaster Recovery",
          "data": [
            {
              "key": "IT System Disruptions",
              "value": "Our information technology systems and internal infrastructure face systemic failure risks that could disrupt operations and research and development work."
            },
            {
              "key": "Hazardous Materials Handling",
              "value": "The company uses hazardous, flammable, and toxic chemicals in research, development, and manufacturing, subject to strict environmental and safety regulations."
            },
            {
              "key": "Regulatory Compliance",
              "value": "Compliance with federal, state, and local laws regarding environment, health, and workplace safety is critical; non-compliance could adversely affect the business."
            },
            {
              "key": "Disaster Recovery & Business Continuity",
              "value": "Operations concentrated in one location are vulnerable to unplanned events (e.g., floods, fires, extreme weather, power outages) that may exceed disaster recovery and business continuity measures."
            },
            {
              "key": "Natural Disasters",
              "value": "Operations in the San Francisco Bay Area face risks from earthquakes, wildfires, and other natural disasters, potentially leading to significant financial and operational impacts."
            },
            {
              "key": "Insurance Coverage Limitations",
              "value": "Even with workers' compensation and environmental liability insurance, coverage may be inadequate to fully cover damages or losses from accidents or disasters."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 45,
          "title": "Risks Related to Our Intellectual Property & Patent Protection",
          "data": [
            {
              "key": "Overview",
              "value": "The text outlines several risk factors related to research and development programs and intellectual property rights, emphasizing the potential harm to R&D and adverse effects on the company's business and financial condition."
            },
            {
              "key": "Intellectual Property Risks",
              "value": "Risks include inability to obtain or protect intellectual property rights, challenges in securing patents for technology, and inadequate protection for in-licensed technology."
            },
            {
              "key": "Patent Applications and Prosecution",
              "value": "The document discusses pending patent applications, the uncertainty of patent issuance, and the complex, expensive, and time-consuming process of patent prosecution that could impact competitive advantage."
            },
            {
              "key": "Reliance on Trade Secrets",
              "value": "In addition to patents, the company relies on trade secrets to protect its proprietary technology, though there is no guarantee against infringement or misappropriation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 46,
          "title": "Patent Risk Factors",
          "data": [
            {
              "key": "Publication Delay",
              "value": "Applications in the United States and other jurisdictions are typically not published until 18 months after filing."
            },
            {
              "key": "Amendment Risk",
              "value": "Published pending applications can be amended to cover discovery platforms, product candidates, or the use of technologies, leading to uncertainty."
            },
            {
              "key": "Prior Art Limitations",
              "value": "There is no guarantee that all relevant prior art has been identified, risking invalidation or narrowing of patent rights."
            },
            {
              "key": "Legal Challenges",
              "value": "Patents and patent applications may be challenged through various legal proceedings, which might result in narrowing, invalidation, or unenforceability."
            },
            {
              "key": "Impact on Commercialization",
              "value": "Invalid or unenforceable patent protection may materially harm the business by allowing competitors to enter the market or by limiting exclusive rights."
            },
            {
              "key": "Co-ownership and Licensing Concerns",
              "value": "Co-owned patents and licensing issues may impede obtaining exclusive rights and could lead to third parties licensing competing products."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 47,
          "title": "Intellectual Property License Risks and Government Rights",
          "data": [
            {
              "key": "government_rights",
              "value": "The U.S. government may exercise march-in rights under in-license agreements, which could include disclosing confidential information and using licensed technology for non-commercial purposes."
            },
            {
              "key": "in_license_sources",
              "value": "Patent rights in-licensed from Stanford University, which co-owns rights with a governmental entity, subject to specific reservations of rights."
            },
            {
              "key": "license_obligations",
              "value": "License agreements impose obligations such as development, commercialization, milestone payments, royalties, diligence, and sublicensing, with potential penalties or termination if breached."
            },
            {
              "key": "control_issues",
              "value": "Stanford University retains final approval over patent preparatory actions including filing, prosecution, maintenance, enforcement, and defense, limiting the company's control."
            },
            {
              "key": "risk_impact",
              "value": "Failure to comply with licensing obligations or unauthorized use may result in damages, loss of critical intellectual property rights, and a material adverse effect on the company’s competitive position and business prospects."
            },
            {
              "key": "royalty_obligations",
              "value": "Future royalty payments could be significant, depending on infringement or misappropriation claims related to licensed technology."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 48,
          "title": "Intellectual Property and Patent Risk Factors",
          "data": [
            {
              "key": "issue",
              "value": "Risks related to intellectual property licensing, patent term limitations, and regulatory uncertainties affecting our ability to develop, commercialize products, and achieve profitability."
            },
            {
              "key": "license_agreement_complexity",
              "value": "Complex licensing agreements with third parties can lead to multiple interpretations, potentially narrowing our intellectual property rights or increasing obligations."
            },
            {
              "key": "patent_term_limitations",
              "value": "Patent protection is limited by standard terms (typically 20 years) and may expire before or shortly after product commercialization; extensions are uncertain and may be inadequate."
            },
            {
              "key": "regulatory_and_litigation_risks",
              "value": "Changes in patent law, such as those introduced by the Leahy-Smith America Invents Act, can increase uncertainties, costs, and impact enforcement or defense of patents."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 49,
          "title": "Patent Prosecution and Regulatory Risks",
          "data": [
            {
              "key": "USPTO Proceedings",
              "value": "Additional procedures to challenge the validity of patents through derivation, reexamination, inter partes review, post-grant review and interference proceedings are described."
            },
            {
              "key": "Leahy-Smith Act",
              "value": "Implemented effective March 16, 2013, introducing substantive changes including first-to-file provisions that may increase patent prosecution uncertainty."
            },
            {
              "key": "Patent Protection Uncertainty",
              "value": "Discussion of the uncertainty in obtaining and enforcing patents due to evolving laws, regulations, and judicial interpretations, as well as potential third-party challenges."
            },
            {
              "key": "Impact on Business",
              "value": "Potential material adverse impact on business prospects and financial condition due to increased costs and legal uncertainties surrounding patent prosecution and enforcement."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 50,
          "title": "Intellectual Property Enforcement Risks",
          "data": [
            {
              "key": "Risk Topic",
              "value": "Intellectual Property Protection and Enforcement"
            },
            {
              "key": "Key Concerns",
              "value": "Inability to secure and enforce patents globally, high litigation and prosecution costs, and variable foreign legal protections."
            },
            {
              "key": "Business Impact",
              "value": "Potential material adverse effects on commercialization, product development, and overall business competitiveness."
            },
            {
              "key": "Legal Exposure",
              "value": "Risk of costly legal proceedings, adverse judgments, and compulsory licensing obligations in certain jurisdictions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 54,
          "title": "Intellectual Property Rights Issues and Clinical Development Risks",
          "data": [
            {
              "key": "Concerns Regarding Intellectual Property Rights",
              "value": "Intellectual property rights have limitations and may not adequately protect business interests."
            },
            {
              "key": "Competitors' Potential Activities",
              "value": "Competitors may independently develop similar technologies without infringing on our intellectual property."
            },
            {
              "key": "Uncertainty in Patent Applications",
              "value": "Pending patent applications may not lead to issued patents."
            },
            {
              "key": "Regulatory Approvals Challenges",
              "value": "Obtaining marketing approval for product candidates involves lengthy and uncertain processes."
            },
            {
              "key": "Clinical Trial Risks",
              "value": "Early clinical results may not predict future outcomes, leading to high risks of failure."
            },
            {
              "key": "Possible Delays in Development",
              "value": "Delays may occur in completing preclinical studies and clinical trials."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 55,
          "title": "Risks Related to Clinical Trials and Regulatory Approvals",
          "data": [
            {
              "key": "Clinical Trials Risks",
              "value": "Delays in clinical trials can harm commercial prospects and revenue generation."
            },
            {
              "key": "Regulatory Approval Risks",
              "value": "Regulatory processes are costly, time-consuming and can involve unforeseen delays."
            },
            {
              "key": "Experience and Unpredictability",
              "value": "Limited experience in conducting clinical trials and unpredictable timelines for FDA approvals."
            },
            {
              "key": "Government Regulations Impact",
              "value": "New regulations can alter development timelines and costs."
            },
            {
              "key": "Potential Denial of Approval",
              "value": "Possibility that product candidates may not receive necessary regulatory approvals."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 57,
          "title": "Regulatory and Accelerated Approval Risks",
          "data": [
            {
              "key": "Regulatory Restrictions",
              "value": "The text outlines various regulatory restrictions including limitations on marketing or manufacturing of the product, product withdrawals, recalls (both voluntary and mandatory), fines, warning letters, holds on clinical trials, refusal of FDA approvals, suspension or revocation of licenses, product seizures, import/export restrictions, and injunctions or penalties."
            },
            {
              "key": "Accelerated Approval Pathway",
              "value": "It discusses the use of accelerated approval pathways under the FDCA for products treating serious conditions, including the reliance on surrogate or intermediate clinical endpoints and the requirement for post-approval confirmatory trials to verify clinical benefits."
            },
            {
              "key": "Risk Factors and Implications",
              "value": "The passage emphasizes the uncertainty and risks associated with adapting to changing FDA policies and regulatory requirements. Delays, additional trials, regulatory non-compliance, or failure to confirm clinical benefit could lead to loss of marketing approvals and impact profitability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 58,
          "title": "Risk Factors Related to Healthcare Legislative and Regulatory Reforms",
          "data": [
            {
              "key": "Regulatory Changes",
              "value": "Discussion of the ACA, IRA, and various executive orders and legislation impacting healthcare financing and drug pricing."
            },
            {
              "key": "Approval and Development Risks",
              "value": "Failure to obtain accelerated approval or expedited review for product candidates may delay commercialization and increase development costs."
            },
            {
              "key": "Legislative and Judicial Uncertainty",
              "value": "Ongoing and potential future challenges to the ACA and IRA provisions, as well as broader governmental scrutiny over drug pricing policies."
            },
            {
              "key": "Impact on Competitive Position",
              "value": "Increased cost pressures and changes in reimbursement methodologies could harm the company's competitive position in the market."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 59,
          "title": "Healthcare Regulatory Compliance and Risk Factors",
          "data": [
            {
              "key": "healthcare_reform",
              "value": "Additional state and federal healthcare reform measures may be adopted, potentially limiting government payments for healthcare products and services and reducing demand."
            },
            {
              "key": "compliance_risk",
              "value": "Failure to comply with healthcare laws and regulations such as the Anti-Kickback Statute, HIPAA, and the False Claims Act could lead to enforcement actions, significant penalties, and reputational harm."
            },
            {
              "key": "third_party_arrangements",
              "value": "Arrangements with manufacturers, service providers, and other third parties expose the organization to risks related to fraud, abuse, and misaligned financial relationships under applicable healthcare laws."
            },
            {
              "key": "reporting_requirements",
              "value": "Regulatory obligations, including those imposed by the Physician Payments Sunshine Act and HIPAA (as amended by HITECH), require proper reporting and safeguards for individually identifiable health information."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 60,
          "title": "Regulatory Compliance Risks in Healthcare",
          "data": [
            {
              "key": "Healthcare Regulations",
              "value": "The text outlines the need to comply with local, state, and foreign laws including anti-kickback, false claims, transparency, and privacy regulations, which may impose significant costs."
            },
            {
              "key": "Penalties and Consequences",
              "value": "Non-compliance could lead to severe penalties such as criminal, administrative, and civil fines, reputational harm, injunctions, and even product recalls or market withdrawals."
            },
            {
              "key": "FDA Oversight and Post-Market Requirements",
              "value": "The FDA has extensive post-market authority including mandatory labeling changes, post-market studies, REMS, inspections, and potential withdrawal of product approvals."
            },
            {
              "key": "Third-Party Manufacturing Risks",
              "value": "Reliance on third-party manufacturers reduces direct control over regulatory compliance, heightening risk in manufacturing and supply chain processes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 61,
          "title": "Risks Related to Coverage, Reimbursement, and Regulatory Pricing",
          "data": [
            {
              "key": "Coverage Dependence",
              "value": "The text discusses how the commercialization of product candidates depends on securing coverage and adequate reimbursement from third-party payors such as government programs (Medicare, Medicaid) and private insurers."
            },
            {
              "key": "Pricing Regulations",
              "value": "It highlights the risk of unfavorable pricing regulations and cost-containment measures that could limit reimbursement levels and delay commercial launches."
            },
            {
              "key": "Pharmacoeconomic Requirements",
              "value": "The need for additional clinical evidence and expensive pharmacoeconomic studies to demonstrate cost-effectiveness is emphasized."
            },
            {
              "key": "International Variability",
              "value": "Variations in regulatory approvals, pricing policies, and reimbursement processes from country to country are noted as potential challenges."
            },
            {
              "key": "Legal and Compliance Risks",
              "value": "The document also mentions risks related to adhering to U.S. and foreign anti-corruption and anti-money laundering laws, which could impact business operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 62,
          "title": "Risk Factors Related to Compliance, Tax Reform, and Market Volatility",
          "data": [
            {
              "key": "Anti-Corruption & AML Compliance Risk",
              "value": "Noncompliance with anti-corruption and anti-money laundering laws may result in whistleblower complaints, investigations, sanctions, fines, and reputational harm."
            },
            {
              "key": "Tax Reform Impact",
              "value": "Comprehensive tax legislation, including changes from the Tax Act and IRA provisions, could adversely affect the company’s financial condition through altered corporate tax rates and expense limitations."
            },
            {
              "key": "Legal & Enforcement Risks",
              "value": "Potential enforcement actions, subpoenas, and litigation, including possible appointments of independent compliance monitors, may lead to significant legal, defense, and compliance costs."
            },
            {
              "key": "Operational and Market Risks",
              "value": "Fluctuations in quarterly operating results due to factors such as R&D expenditures, clinical trial outcomes, strategic decisions, and market conditions may impact stock performance and overall business results."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 63,
          "title": "Table of Contents - Risk Factors Overview",
          "data": [
            {
              "key": "Volatility of Stock Price",
              "value": "The document highlights that if quarterly operating results fall below expectations, the price of Class A common stock could decline substantially. It also notes inherent volatility in the stock price due to various factors."
            },
            {
              "key": "Quarterly Operating Results",
              "value": "Emphasizes that quarterly comparisons may not be meaningful indicators of future performance and can lead to substantial fluctuations in stock price."
            },
            {
              "key": "Product Development Risks",
              "value": "Mentions risks related to the advancement of ATRC-101 and potential future product candidates through preclinical studies and clinical trials."
            },
            {
              "key": "Regulatory and Legal Factors",
              "value": "Notes potential impacts from regulatory or legal developments, including changes in laws applicable to products and outcomes of litigation and patent disputes."
            },
            {
              "key": "Market and Competitive Conditions",
              "value": "Includes risks from competitive product introductions, market conditions in the pharmaceutical and biotechnology sectors, and actions by regulatory agencies."
            },
            {
              "key": "Financial and Capital Risks",
              "value": "Highlights risks linked to variations in financial results, difficulties in raising additional capital, and fluctuations in analyst projections and earnings estimates."
            },
            {
              "key": "Broader Economic and Geopolitical Risks",
              "value": "Addresses risks related to political, social, and economic instability abroad, including factors like armed conflicts (e.g. current conflicts such as in Ukraine), natural disasters, and global health epidemics."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 64,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Market Volatility",
              "value": "Stock markets, particularly for pharmaceutical, biopharmaceutical, and biotechnology sectors, have experienced extreme volatility due to the COVID-19 pandemic, government and economic reactions, and regulatory factors."
            },
            {
              "key": "Economic Downturn Impact",
              "value": "A significant downturn in the overall economy or in specific sectors could negatively impact strategic business plans, product development, and growth prospects."
            },
            {
              "key": "Dual Class Structure Risk",
              "value": "The dual class structure, with Class A common stock having one vote per share and non-voting Class B shares convertible into Class A, may limit stockholders' ability to influence corporate matters if conversions occur."
            },
            {
              "key": "Analyst Coverage Concerns",
              "value": "Adverse or misleading research reports and analyst opinions, or a lack of regular coverage, could lead to a decline in the stock price and trading volume."
            },
            {
              "key": "Major Shareholder Influence",
              "value": "Significant ownership by executive officers, directors, and large shareholders, along with agreements (e.g., with Baker Brothers), may allow these parties to exert considerable influence over corporate actions, including board nominations and mergers."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 66,
          "title": "Risks Related to Business and Common Stock Price Volatility",
          "data": [
            {
              "key": "Impact of Class A stock attractiveness on trading market",
              "value": "Less active trading market for Class A common stock and increased volatility in share price."
            },
            {
              "key": "Adoption of new accounting standards",
              "value": "As an emerging growth company, we can delay adoption of new or revised accounting standards."
            },
            {
              "key": "Increased costs of being a public company",
              "value": "Significant legal, accounting, and other expenses incurred as a public company."
            },
            {
              "key": "Uncertainty in compliance with regulations",
              "value": "Potential ongoing uncertainty regarding compliance matters and higher costs due to regulatory changes."
            },
            {
              "key": "Net operating losses utilization limitations",
              "value": "Under Section 382 of the Internal Revenue Code, limitations on utilizing pre-change net operating losses or credits."
            },
            {
              "key": "Impact of stock ownership changes",
              "value": "Future changes in stock ownership could further limit NOLs utilization and recovery."
            },
            {
              "key": "Class action litigation costs",
              "value": "Significant costs expected due to volatility in Class A common stock price, influenced by various operational and market factors."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 67,
          "title": "Risk Factors: Securities Litigation & Anti-Takeover Provisions",
          "data": [
            {
              "key": "Securities Litigation Risk",
              "value": "Volatility in stock price may lead to securities class action litigation, potentially resulting in substantial legal defense costs and management distraction even if the lawsuit lacks merit."
            },
            {
              "key": "Anti-Takeover Provisions",
              "value": "Charter documents include provisions such as prohibition on stockholder actions by written consent, special meeting limitations, staggered board terms, and issuance of preferred stock that may delay or prevent acquisition or management changes."
            },
            {
              "key": "Merger Restrictions under Delaware Law",
              "value": "Section 203 of the Delaware General Corporation Law prohibits a person owning over 15% voting stock from merging with the company for three years, unless approved, which could limit beneficial acquisitions."
            },
            {
              "key": "Exclusive Legal Forums",
              "value": "The company's amended and restated certificate of incorporation designates the Delaware Court of Chancery and certain federal courts as the exclusive forums for disputes, potentially limiting stockholders' options."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 72,
          "title": "Impact of COVID-19 and Financial Operations Overview",
          "data": [
            {
              "key": "COVID-19 Impact",
              "value": "To date, the COVID-19 pandemic has not had a material adverse impact on productivity or business operations as of December 31, 2022. However, future impacts remain uncertain and could materially adversely affect business, financial condition, results of operations, growth prospects, and liquidity."
            },
            {
              "key": "Risk Factors Reference",
              "value": "The report references COVID-19 under the 'Risk Factors' section (Part I, Item 1A) outlining potential disruptions including access to capital and global economic uncertainty."
            },
            {
              "key": "Financial Operations Overview",
              "value": "The document also includes an overview of financial operations, detailing that there is no product revenue, ongoing significant R&D expenses, general and administrative expenses, and interest/other income or expense considerations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 88,
          "title": "Notes to Financial Statements – Business Description and Going Concern",
          "data": [
            {
              "key": "Company",
              "value": "Atreca, Inc."
            },
            {
              "key": "Incorporation Date",
              "value": "June 11, 2010"
            },
            {
              "key": "Location",
              "value": "San Carlos, California"
            },
            {
              "key": "Business Description",
              "value": "Clinical stage biopharmaceutical company utilizing a differentiated platform to discover and develop novel antibody-based immunotherapeutics for solid tumor types."
            },
            {
              "key": "Lead Product Candidate",
              "value": "ATRC-101 – a monoclonal antibody in clinical development with a novel mechanism of action."
            },
            {
              "key": "Primary Activities",
              "value": "Research and development, raising capital, building the management team, and developing its intellectual property portfolio."
            },
            {
              "key": "Going Concern Risk",
              "value": "Substantial doubt exists regarding the company’s ability to continue as a going concern due to expected operating losses, negative cash flows, and the need for additional funding."
            },
            {
              "key": "Planned Mitigation",
              "value": "Management plans additional equity financing and reduction of operating expenses in fiscal 2023 and 2024 to alleviate the going concern risk."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 92,
          "title": "Table of Contents ATRECA, INC. NOTES TO FINANCIAL STATEMENTS",
          "data": [
            {
              "key": "Risks and Uncertainties",
              "value": "The Company is subject to numerous risks including COVID-19 impacts, dependence on key individuals, competition from similar services and larger companies, industry volatility, challenges in obtaining regulatory clearance and adequate financing for growth, difficulties in attracting and retaining qualified personnel, and general economic conditions."
            },
            {
              "key": "Concentration of Credit Risk",
              "value": "Cash and cash equivalents, investments, and other receivables are held at multiple institutions, sometimes exceeding insurance limits. Loss or lack of access to these funds could adversely affect the Company's financial condition, operations, and cash flows."
            },
            {
              "key": "Property and Equipment",
              "value": "Assets are reported at cost less depreciation, with depreciation computed on a straight-line basis over estimated useful lives of two to five years. Leasehold improvements are amortized over the shorter of the asset's useful life or remaining lease term; repairs and maintenance expenses are recognized as incurred."
            },
            {
              "key": "Accounting for Impairment of Long-Lived Assets",
              "value": "Long-lived assets are reviewed for impairment when indicators suggest their carrying amount may not be recoverable. In December 2022, assets no longer used were identified, leading to a $0.4 million impairment expense, while no impairment was recorded in 2021."
            },
            {
              "key": "Intellectual Property",
              "value": "IP-related expenses were $1.1 million for 2022 and $1.2 million for 2021. These costs have not met capitalization criteria."
            },
            {
              "key": "Deferred Rent",
              "value": "Lease agreements for laboratory and office facilities are structured as operating leases. Rent expense is recognized on a straight-line basis, with differences between cash payments and recognized expense recorded as a deferred rent liability."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_guidance_updates": {
      "value": true,
      "elements": [
        {
          "type": "guidance_update",
          "page": 24,
          "title": "Table of Contents and Available Information",
          "data": [
            {
              "key": "Form 10-K",
              "value": "Annual Report"
            },
            {
              "key": "Form 10-Q",
              "value": "Quarterly Reports"
            },
            {
              "key": "Form 8-K",
              "value": "Current Reports"
            },
            {
              "key": "Filed with SEC",
              "value": "U.S. Securities and Exchange Commission"
            },
            {
              "key": "Website for reports",
              "value": "ir.atreca.com"
            },
            {
              "key": "SEC website",
              "value": "www.sec.gov"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 65,
          "title": "Stockholder Approval and Emerging Growth Company Status",
          "data": [
            {
              "key": "context",
              "value": "Management and control over matters requiring stockholder approval, including the annual election of directors and significant corporate transactions."
            },
            {
              "key": "conflicts_of_interest",
              "value": "The interests of stockholders may conflict with the interests of other investors."
            },
            {
              "key": "capital_needs",
              "value": "Significant additional capital may be needed in the future for operations and research."
            },
            {
              "key": "equity_incentive_plan",
              "value": "Includes provisions for stock options and RSUs."
            },
            {
              "key": "stock_dilution",
              "value": "Future sales of Class A or Class B common stock could materially dilute existing stockholders."
            },
            {
              "key": "emerging_growth_company",
              "value": "Status allows for reduced reporting requirements."
            },
            {
              "key": "reporting_exemptions",
              "value": "Exemptions under the JOBS Act may affect stock appeal."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_regulatory_or_litigation_issues": {
      "value": true,
      "elements": [
        {
          "type": "regulatory_litigation",
          "page": 14,
          "title": "Government Regulation and U.S. Biological Products Development Process",
          "data": [
            {
              "key": "Patent Information",
              "value": "Pending patent applications in the U.S. and multiple foreign countries; issued patents in the U.S., Europe, Japan, South Korea, Australia, Mexico, New Zealand, Russia, Hong Kong, South Africa, Israel, and Canada. As of February 15, 2023, the company co-owns pending U.S. and European patent applications related to anti-HIV antibodies, and an issued U.S. patent with a pending European application related to anti-malarial antibodies."
            },
            {
              "key": "Government Regulation",
              "value": "The business is subject to various U.S. and foreign laws, rules, and regulations. Compliance has not materially affected capital expenditures, but future regulatory requirements could have material impacts. Reference is made to the “Risk Factors” and management discussion sections for additional detail."
            },
            {
              "key": "FDA Approval Process",
              "value": "Detailed description of the U.S. biological products development process including compliance with the Federal Food, Drug, and Cosmetic Act and related statutes. The process involves nonclinical laboratory tests, animal studies, IND application and activation, IRB approval, well-controlled human clinical trials (GCPs), submission of a Biologics License Application (BLA), FDA fee payment, review acceptance within 60 days, and cGMP inspection of manufacturing facilities."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 17,
          "title": "FDA Biologics License Application (BLA) Review Process Overview",
          "data": [
            {
              "key": "Submission Clarification",
              "value": "Clarification regarding information provided within the last three months before the PDUFA goal date."
            },
            {
              "key": "FDA Review Initiation",
              "value": "Once accepted for filing, the FDA begins an in-depth substantive review of the BLA to assess safety, potency, effectiveness, and purity."
            },
            {
              "key": "Manufacturing and Compliance",
              "value": "Inspection of manufacturing facilities and clinical sites to ensure compliance with cGMP and GCP requirements."
            },
            {
              "key": "Risk Evaluation and Mitigation Strategy",
              "value": "Determination whether a REMS is necessary to assure the safe use of the product; if required, submission of a proposed REMS is mandatory."
            },
            {
              "key": "Complete Response Letter",
              "value": "If deficiencies are identified, the FDA issues a complete response letter detailing minor or major issues, possibly requiring further actions such as additional clinical trials or labeling changes."
            },
            {
              "key": "Expedited Programs",
              "value": "Mentions of fast track designation, breakthrough therapy designation, accelerated approval, and priority review to expedite drug and biologics review."
            },
            {
              "key": "Regulatory Decisions and Limitations",
              "value": "Approval may come with limitations regarding indications, dosing, or additional restrictions on product distribution."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 18,
          "title": "FDA Regulatory Pathways for Drug and Biologic Approvals",
          "data": [
            {
              "key": "Fast Track Designation",
              "value": "Expedited review process for drugs/biologics intended to treat serious or life-threatening conditions addressing unmet medical needs."
            },
            {
              "key": "Breakthrough Therapy",
              "value": "Designation for products demonstrating substantial improvement on clinically significant endpoints compared to existing therapies, with interactive FDA communications."
            },
            {
              "key": "Priority Review",
              "value": "Regulatory status that aims to review applications within six months, focusing on therapies offering significant improvement over marketed alternatives."
            },
            {
              "key": "Accelerated Approval",
              "value": "Approval based on surrogate or intermediate endpoints with the requirement of post-marketing clinical trials to confirm clinical benefit."
            },
            {
              "key": "Post-Approval Requirements",
              "value": "Ongoing obligations include compliance with cGMP regulations, quality control, record-keeping, reporting adverse effects, and official lot release testing."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 19,
          "title": "Regulatory Compliance and Consequences",
          "data": [
            {
              "key": "FDA Sanctions",
              "value": "Possible sanctions including refusal to approve applications, withdrawal of products, fines."
            },
            {
              "key": "Compliance Requirements",
              "value": "Mandatory compliance with cGMP and periodic inspections by FDA."
            },
            {
              "key": "International Regulation",
              "value": "Requisite approvals must be obtained from regulatory authorities in foreign countries before clinical trials or marketing."
            },
            {
              "key": "Healthcare Laws",
              "value": "Anti-Kickback Statute prohibits inducements related to healthcare items or services."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 20,
          "title": "Overview of Healthcare Fraud and Regulatory Compliance",
          "data": [
            {
              "key": "False Claims Act",
              "value": "Describes federal civil and criminal false claims laws that prohibit knowingly submitting false claims for payment to the government, including for programs like Medicare and Medicaid."
            },
            {
              "key": "Anti-Kickback Statute & ACA Amendments",
              "value": "Explains how the Anti-Kickback Statute, as amended by the ACA, can lead to liability under the False Claims Act, and highlights additional state regulations."
            },
            {
              "key": "Additional Healthcare Fraud Laws",
              "value": "Outlines other statutes such as HIPAA, HITECH, and the Physician Payments Sunshine Act, detailing obligations, penalties, and reporting requirements for healthcare entities."
            },
            {
              "key": "Marketing Practices and Reporting Requirements",
              "value": "Mentions the scrutiny of off-label promotion, inflated drug prices, provision of free products, and state-level requirements for reporting marketing-related expenses and drug pricing."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 51,
          "title": "Risks Related to Patent Litigation and Intellectual Property Disputes",
          "data": [
            {
              "key": "Risk Description",
              "value": "The document outlines significant litigation risks arising from potential third-party infringement claims related to patents. It explains that if a court deems third-party patents valid and enforceable, it may negatively impact the company’s ability to utilize its discovery platform and commercialize its product candidates."
            },
            {
              "key": "Litigation Consequences",
              "value": "Engaging in costly, unpredictable, and time-consuming litigation could force the company to settle claims under unfavorable terms, pay damages including treble damages and attorney’s fees, or face injunctions affecting its technology and product development."
            },
            {
              "key": "Potential Impact",
              "value": "Such legal disputes could result in material adverse effects on revenue generation, delay marketing and R&D efforts, and distract management with litigation proceedings."
            },
            {
              "key": "Intellectual Property Concerns",
              "value": "There is also a risk that if a defendant succeeds in contesting the validity or enforceability of relevant patents, the company could lose valuable patent protection for its product candidates or platform technology."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 53,
          "title": "Potential Legal Risks and Intellectual Property Protection",
          "data": [
            {
              "key": "Involvement in inventorship disputes",
              "value": "We may also become involved in inventorship disputes relating to inventions and patents developed by our employees or consultants under such agreements."
            },
            {
              "key": "Challenges in enforcing trade secret claims",
              "value": "Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming."
            },
            {
              "key": "Effect of trade secret disclosure",
              "value": "If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be materially and adversely harmed."
            },
            {
              "key": "Claims regarding wrongful use of trade secrets",
              "value": "We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets or other proprietary information."
            },
            {
              "key": "Litigation necessity",
              "value": "Litigation or arbitration may be necessary to defend against these claims."
            },
            {
              "key": "Implications of failing to defend claims",
              "value": "If we fail in defending such claims, we may lose valuable intellectual property rights or personnel."
            },
            {
              "key": "Patent protection compliance",
              "value": "Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements."
            },
            {
              "key": "Consequences of patent non-compliance",
              "value": "Non-compliance can result in abandonment or lapse of the patent, resulting in a loss of rights."
            },
            {
              "key": "Protection of trademarks and trade names",
              "value": "If our trademarks and trade names are not adequately protected, it could adversely affect our business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 56,
          "title": "Regulatory Challenges and Approval Process for Product Candidates",
          "data": [
            {
              "key": "Regulatory Challenges",
              "value": "Uncertainty regarding legislative changes and their impact on product candidates."
            },
            {
              "key": "FDA Regulatory Approval Process",
              "value": "FDA has not established definitive policies for certain product candidates."
            },
            {
              "key": "Potential Delays",
              "value": "Delays in clinical development due to anticipated and unanticipated regulatory requirements."
            },
            {
              "key": "Impact on Revenue Generation",
              "value": "Material adverse effect on the ability to generate revenue if regulatory approvals are delayed or failed."
            },
            {
              "key": "Foreign Regulatory Requirements",
              "value": "Varied approval processes and risks associated with obtaining approvals in different countries."
            },
            {
              "key": "Ongoing Regulatory Obligations",
              "value": "Even with approvals, there may be significant ongoing regulatory obligations and reviews."
            },
            {
              "key": "Post-Marketing Testing Requirements",
              "value": "Approval could entail costly post-marketing testing and monitoring of product candidates."
            },
            {
              "key": "Regulatory Compliance",
              "value": "Ongoing compliance with extensive regulatory requirements including production, labeling, and reporting."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 68,
          "title": "Exclusive Forum Provisions and Legal Proceedings",
          "data": [
            {
              "key": "jurisdiction",
              "value": "Federal district courts of the United States are designated as the exclusive forum for securities claims"
            },
            {
              "key": "risk_factor",
              "value": "Potential for significant additional costs and adverse impact on business if claims are litigated in other jurisdictions"
            },
            {
              "key": "enforceability",
              "value": "While Delaware courts find the provisions valid, challenges in alternative venues may arise"
            },
            {
              "key": "litigation",
              "value": "The document discusses potential litigation issues and the strategy to enforce exclusive forum provisions"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 108,
          "title": "Table of Contents Items - Item 9B and 9C",
          "data": [
            {
              "key": "Item 9B. Other Information",
              "value": "None"
            },
            {
              "key": "Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections",
              "value": "Not Applicable"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 125,
          "title": "Dispute Resolution and Arbitration Provisions",
          "data": [
            {
              "key": "Arbitration Procedure",
              "value": "Final, binding, and confidential arbitration conducted by a single arbitrator under JAMS rules for employment disputes."
            },
            {
              "key": "Governing Law",
              "value": "Federal Arbitration Act (9 U.S.C. §§1-16)"
            },
            {
              "key": "Arbitration Location",
              "value": "San Francisco, California"
            },
            {
              "key": "Legal Representation",
              "value": "Executive has the right to be represented by legal counsel at arbitration proceedings."
            },
            {
              "key": "Waiver of Jury Trial",
              "value": "Both Executive and the Company waive the right to trial by jury, judge, or administrative proceeding."
            },
            {
              "key": "Class Action Waiver",
              "value": "Claims must be brought in an individual capacity and not as part of a class or representative proceeding."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 126,
          "title": "General Provisions and Dispute Resolution",
          "data": [
            {
              "key": "Injunctive Relief",
              "value": "The Agreement clarifies that nothing prevents either Executive or the Company from seeking injunctive relief in court to prevent irreparable harm pending arbitration."
            },
            {
              "key": "Notices",
              "value": "Notices must be provided in writing and are effective upon personal delivery (including fax) or the following day if sent via overnight carrier to the respective addresses of the Company and the Executive."
            },
            {
              "key": "Severability",
              "value": "If any provision is found invalid, illegal, or unenforceable, it will not affect the validity of the remaining provisions; the Agreement shall be reformed to reflect the parties' intent under applicable law."
            },
            {
              "key": "Waiver",
              "value": "Any waiver of breach or rights under the Agreement must be in writing and does not operate as a waiver for any past or future breaches."
            },
            {
              "key": "Complete Agreement",
              "value": "The Agreement, along with the Confidentiality Agreement, comprises the entire, final and exclusive understanding between the Executive and the Company, superseding all prior representations."
            },
            {
              "key": "Counterparts and Delivery",
              "value": "The Agreement may be executed in separate counterparts, and electronic delivery (including via PDF or compliant electronic signature methods) is considered valid and effective."
            },
            {
              "key": "Headings",
              "value": "Headings are for convenience only and do not affect the interpretation of the Agreement."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 162,
          "title": "Definitions related to Stock Awards and Rights",
          "data": [
            {
              "key": "Rule 16b-3",
              "value": "Refers to the rule under the Exchange Act regarding securities."
            },
            {
              "key": "Securities Act",
              "value": "The Securities Act of 1933, as amended."
            },
            {
              "key": "Stock Appreciation Right (SAR)",
              "value": "A right to receive appreciation on Common Stock."
            },
            {
              "key": "Stock Appreciation Right Agreement",
              "value": "A written agreement evidencing Stock Appreciation Right terms."
            },
            {
              "key": "Stock Award",
              "value": "Any right to receive Common Stock under the Plan."
            },
            {
              "key": "Stock Award Agreement",
              "value": "A written agreement evidencing Stock Award terms."
            },
            {
              "key": "Subsidiary",
              "value": "A corporation, partnership, or other entity owned or controlled by the Company."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_strategic_restructuring": {
      "value": false,
      "elements": []
    },
    "has_supply_chain_disruptions": {
      "value": true,
      "elements": [
        {
          "type": "supply_chain_disruption",
          "page": 37,
          "title": "Supply Chain Risks and Operational Disruptions",
          "data": [
            {
              "key": "Animal Testing Impact",
              "value": "The document highlights potential future challenges and delays in research and development due to restrictions and controversies around animal testing."
            },
            {
              "key": "Third-Party Manufacturing Reliance",
              "value": "The company relies on third-party contract manufacturers, many of which are sole source vendors, for preclinical, clinical, and commercial product supplies."
            },
            {
              "key": "Supply Chain Vulnerabilities",
              "value": "There is significant risk that supply may become limited or interrupted, impacting product candidate development, especially if manufacturers fail to comply with quality or regulatory standards."
            },
            {
              "key": "COVID-19 Related Disruptions",
              "value": "COVID-19 poses additional risks by potentially causing delays in material supply and complications in negotiating new or redundant manufacturing sources."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_esg_initiatives": {
      "value": true,
      "elements": [
        {
          "type": "esg_initiative",
          "page": 23,
          "title": "Table of Contents - ESG and Corporate Initiatives Overview",
          "data": [
            {
              "key": "Communication and Engagement",
              "value": "The document describes efforts to ensure transparent communication from leadership to employees through multiple channels such as video and written communications, town hall meetings, employee surveys, and the company intranet. It also mentions recognition programs and an ethics and compliance hotline."
            },
            {
              "key": "Diversity and Inclusion",
              "value": "It emphasizes the company’s commitment to diversity, recognizing differences in gender, race, sexuality, and other backgrounds, and actively promotes employee participation in diversity and inclusion initiatives."
            },
            {
              "key": "Talent Acquisition",
              "value": "The section underlines the importance of hiring the right people through innovative tools and structured processes, highlighting company branding and sourcing efforts to attract a diverse and highly qualified candidate pool."
            },
            {
              "key": "Health and Wellness",
              "value": "The report details a comprehensive compensation and benefits program that supports employee health, work/life balance, and financial needs. It includes market competitive pay, stock grants, bonuses, healthcare, retirement plans, paid time off, family leave, flexible work, onsite health services, preventative care, and employee assistance programs."
            },
            {
              "key": "COVID-19 Response",
              "value": "In response to the pandemic, the company has implemented health and safety protocols, a flexible work policy for remote work, ergonomic assessments, COVID-19 testing coverage for onsite employees, enhanced mental health offerings, and support for dynamic work schedules."
            },
            {
              "key": "Corporate Information",
              "value": "This section provides corporate details including incorporation information in Delaware, the principal executive office address in San Carlos, CA, contact telephone, website address, and trademark notices."
            }
          ],
          "currency": "N/A"
        }
      ]
    }
  },
  "currency": {
    "USD": 9,
    "EUR": 13,
    "AUD": 10,
    "ZAR": 4
  },
  "sha1": "5f226fe96206888930e3baaf0bff70d4b0a1db40"
}